Appendix P

Colorado Medical Assistance Program
Prior Authorization Procedures, Coverage Policies and Drug Utilization Criteria
Health First Colorado Pharmacy Benefit
For Physicians and Pharmacists

Drug products requiring a prior authorization for the Health First Colorado pharmacy benefit are listed in this document. Prior authorization criteria are based on FDA product labeling, CMS approved compendia, clinical practice guidelines, and peer-reviewed medical literature.

Prior Authorization Procedures:

- Prior authorizations may be submitted to the helpdesk by:
  - Phone: 1-800-424-5725
  - Fax: 1-888-424-5881
  - Electronic Prior Authorization Requests (ePA) are supported by CoverMyMeds and may be submitted via Electronic Health Record (EHR) systems or through the CoverMyMeds provider portal.
- Products qualify for a 3-day emergency supply in an emergency situation. In this case, call the helpdesk for an override.
- Prior authorization (PA) forms are available by visiting https://www.colorado.gov/hcpf/pharmacy-resources .
- PA forms can be signed by anyone who has authority under Colorado law to prescribe the medication. Assistants of authorized persons cannot sign the PA form.
- Physicians or assistants who are acting as the agents of the physicians may request a PA by phone.
- Pharmacists from long-term-care pharmacies and infusion pharmacy must obtain a signature from someone who is authorized to prescribe drugs before they submit PA forms.
- Pharmacists from long-term-care pharmacies and infusion pharmacies can request a PA by phone if specified in the criteria.
- Please note that initiating therapy with a requested drug product, including non-preferred drugs, prior to a PA request being reviewed and approved does not necessitate approval of the PA request. This includes initiating therapy by administration in the inpatient setting, by using office samples, or by any other means.
- All PA requests are coded online into the PA system.
- A provider may request a step therapy exception for the treatment of a serious or complex medical condition pursuant to section 25.5-4-428, C.R.S. Serious or complex medical condition means the following medical conditions: serious mental illness, cancer, epilepsy, multiple sclerosis, or human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS), or a condition requiring medical treatment to avoid death, hospitalization, or a worsening or advancing of disease progression resulting in significant harm or disability. The step therapy exception request form is available by visiting https://hcpf.colorado.gov/pharmacy-resources .

Early Refill Limitations:

- Non-controlled prescriptions may be refilled after 75% of previous fill is used. Controlled substance prescriptions (DEA Schedule 2 through 5) may be refilled after 85% of the previous fill is used. Synagis may be refilled after 92.5% of the previous fill is used.

Medical Supply Products and Medications:

- All supplies, including insulin needles, food supplements and diabetic supplies are not covered under the pharmacy benefit, but are covered as medical supply items through the Durable Medical Equipment (DME) benefit.
- If a medical benefit requires a PA, the PA request can be submitted through the provider application available at http://www.coloradopar.com/
- Contact information for DME questions can be found on the Provider Contacts web page at https://hcpf.colorado.gov/provider-help.

Physician Administered Drugs and Medical Billing:

- Physician administered drugs (PADs) include any medication or medication formulation that is administered intravenously or requires administration by a healthcare professional (including cases where FDA package labeling for a medication specifies that

administration should be performed by or under the direct supervision of a healthcare professional). PAD criteria listed on Appendix P apply specifically to drug products when billed through the Health First Colorado pharmacy benefit. Only PADs administered by a healthcare professional in the member's home or in a long-term care facility should be billed through the Health First Colorado pharmacy benefit (see "Physician Administered Drugs" section below). PADs administered by a healthcare professional in the office, clinic, dialysis unit, or outpatient hospital settings should be billed through the Health First Colorado medical benefit using the standard buy-and-bill process and following procedures outlined in the PAD Billing Manual (found on the PAD Resources Page at https://www.colorado.gov/hcpf/physician-administered-drugs).

Prescription Drug Monitoring Program (PDMP):

- Effective October 1, 2021, Medicaid providers permitted to prescribe controlled substances must query the Colorado Prescription Drug Monitoring Program (PDMP) before prescribing controlled substances to Medicaid members, in accordance with Section 5042 of the "Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act." The requirement to check the PDMP does not apply when a member:
  - Is receiving the controlled substance in a hospital, skilled nursing facility, residential facility, or correctional facility
  - Has been diagnosed with cancer and is experiencing cancer-related pain
  - Is undergoing palliative care or hospice care
  - Is experiencing post-surgical pain that, because of the nature of the procedure, is expected to last more than 14 days
  - Is receiving treatment during a natural disaster or during an incident where mass casualties have taken place
  - Has received only a single dose to relieve pain for a single test or procedure
  - In the case that a provider is not able to check the PDMP before prescribing a controlled substance, despite a good faith effort, the State shall require the provider to document the effort, including the reasons why the provider was not able to conduct the check (the State may require the provider to submit, upon request, such documentation to the State).
- Additional information about the Colorado PDMP is available by visiting https://dpo.colorado.gov/PDMP

Drug Product(s)	Criteria	PA Approval Length
ACETAMINOPHEN CONTAINING PRODUCT MAXIMUM DOSING	A prior authorization is required for dosages of acetaminophen exceeding 4000mg/day. Doses over 4000mg/day are not qualified for emergency 3-day supply approval	

ACTHAR (corticotropin)	**Acthar** (corticotropin) may be approved for members that meet the following criteria:
	• Member has a diagnosis of Infantile Spasms (West Syndrome) and meets all the criteria below:
	  ○ Member is < 2 years of age
	  ○ Member has electroencephalogram documenting diagnosis
	  ○ Acthar is being used as monotherapy
	  ○ Member does not have suspected congenital infection
	  ○ Prescribed by or in consultation with a neurologist or epileptologist
	OR
	• Member has diagnosis of multiple sclerosis and is experiencing an acute exacerbation **AND**
	• Member does not have concomitant primary adrenocortical insufficiency or adrenocortical hyperfunction **AND**
	• Member has trialed and failed corticosteroid therapy prescribed to treat acute exacerbation due to multiple sclerosis. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction **AND**
	• Member is not receiving concomitant live or live attenuated vaccines **AND**
	• Member does not have one of the following concomitant diagnoses:
	  ○ Scleroderma, osteoporosis, systemic fungal infections, ocular, herpes simplex, recent surgery, history of peptic ulcer disease, heart failure,
		4 week supply

<table>
<tr><th>Drug Product(s)</th><th>Criteria</th><th>PA Approval Length</th></tr>
<tr><td></td><td>uncontrolled hypertension, or sensitivity to proteins of porcine origin.
AND
• Acthar (corticotropin) will be approved based on the following FDA recommended doses. (see Table 1)

Table 1: FDA Recommended Dosing
<table><tr><th>Diagnosis</th><th>Dose</th></tr><tr><td>Infantile Spasms
(under age of 2 years)</td><td>75 units/m^2 IM twice daily for two weeks; After two weeks, dose should be tapered according to the following schedule: 30 U/m^2 IM in the morning for 3 days; 15 units/m^2 IM in the morning for 3 days; 10 units/m^2 IM in the morning for 3 days; and 10 units/m^2 IM every other morning for 6 days (3 doses).</td></tr><tr><td>Acute Exacerbation of Multiple Sclerosis</td><td>80-120 units IM or SQ daily for 2-3 weeks</td></tr></table>
Quantity Limits: 4 week supply</td><td></td></tr>
<tr><td>ADAKVEO (crizanlizumab-tmca)</td><td>Adakveo (crizanlizumab-tmca) may be approved for members meeting the following criteria:
• Medication is being administered in the member’s home or in a long-term care facility by a healthcare professional AND
• Medication is being used to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

Maximum dose: Adakveo 5mg/kg every 2 weeks (IV Infusion)</td><td>One year</td></tr>
<tr><td>ADUHELM (aducanumab-avwa)</td><td>Aduhelm (aducanumab-avwa) may be approved if the following criteria are met:
• For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member’s home or in a long-term care facility AND
• Member has documented diagnosis of mild cognitive impairment or mild dementia stage of Alzheimer’s disease, the population in which treatment was initiated in clinical trials, as evidenced by all of the following:
o Positron Emission Tomography (PET) scan OR lumbar puncture positive for amyloid beta plaque AND
o Clinical Dementia Rating global score (CDR-GS) of 0.5 or 1 (available at https://otm.wustl.edu/cdr-terms-agreement/) AND
o Mini-Mental State Examination (MMSE) score of 24-30 OR Montreal Cognitive Assessment (moCA) Test score of 19-25
AND
• Member is ≥ 50 years of age AND</td><td>See criteria</td></tr>
</table>

Drug Product(s)	Criteria	PA Approval Length
	• The prescriber attests that member has been counseled on the approval and safety status of Aduhelm (aducanumab-avwa) being approved under accelerated approval based on reduction in amyloid beta plaques AND • Prior to initiation of Aduhelm (aducanumab-avwa), the prescriber attests that the member meets both of the following: o Member has had a brain MRI within the prior one year to treatment initiation, showing no signs or history of localized superficial siderosis, ≥ 10 brain microhemorrhages, and/or brain hemorrhage > 1 cm AND o Attestation that MRI will be completed prior to the 7th (1st dose at 10 mg/kg) and 12th (6th dose at 10 mg/kg) infusion AND • Member <u>does not</u> have any of the following: o Any medical or neurological condition other than Alzheimer's Disease that might be a contributing cause of the subject's cognitive impairment including (but not limited to) stroke/vascular dementia, tumor, dementia with Lewy bodies [DLB], frontotemporal dementia [FTD] or normal pressure hydrocephalus o Contraindications to PET, CT scan, or MRI o History of or increased risk of amyloid related imaging abnormalities ARIA-edema (ARIA-E) or ARIA-hemosiderin deposition (ARIA-H) o History of unstable angina, myocardial infarction, chronic heart failure, or clinically significant conduction abnormalities, stroke, transient ischemic attack (TIA), or unexplained loss of consciousness within 1 year prior to initiation of Aduhelm (aducanumab-avwa) o History of bleeding abnormalities or taking any form of anticoagulation therapy AND • The requested medication is being prescribed by or in consultation with a neurologist AND • The prescribed regimen meets FDA-approved labeled dosing: a. <u>Infusion 1 and 2</u>: 1 mg/kg over approximately 1 hour every 4 weeks b. <u>Infusion 3 and 4</u>: 3 mg/kg over approximately 1 hour every 4 weeks c. <u>Infusion 5 and 6</u>: 6 mg/kg over approximately 1 hour every 4 weeks d. <u>Infusion 7 and beyond</u>: 10 mg/kg over approximately 1 hour every 4 weeks. <u>Initial approval period</u>: 6 months <u>Second prior authorization</u>: an additional 6 months of Aduhelm (aducanumab-avwa) therapy may be approved with provider attestation that a follow-up MRI will be (or has been) completed prior to the 7th infusion <u>Subsequent approval</u>: an additional 6 months of Aduhelm (aducanumab-avwa) therapy may be approved with provider attestation that a follow-up MRI will be (or has been) completed prior to the 12th infusion <u>Maximum dose</u>: 10 mg/kg IV every 4 weeks The above coverage standards will continue to be reviewed and evaluated for any applicable changes due to the evolving nature of factors including disease course, available treatment options and available peer-reviewed medical literature and clinical evidence. If request is for	

Drug Product(s)	Criteria	PA Approval Length
	use outside of stated coverage standards, support with peer reviewed medical literature and/or subsequent clinical rationale shall be provided and will be evaluated at the time of request. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).	
ADZYNMA (apadamtase alfa)	**Adzynma** (apadamtase alfa) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND • Member is ≥ 2 years of age AND • Member has a diagnosis of congenital thrombotic thrombocytopenic purpura (cTTP) confirmed by genetic testing indicating severe deficiency of ADAMTS13 protease and/or based on clinical judgment, AND • The requested medication is being prescribed by or in consultation with a hematologist. Maximum dose: Prophylactic therapy: 40 IU/kg weekly On-demand therapy: 40 IU/kg/day	One year
AEMCOLO (rifamycin)	**Aemcolo** (rifamycin) may be approved if the following criteria are met: • The member is ≥ 18 years of age AND • The member has a diagnosis of travelers' diarrhea caused by a non-invasive strain of E. Coli, without fever and without bloody stool AND • The member has trialed and failed† treatment with oral azithromycin AND • The member is not allergic to the rifamycin drug class (such as rifamycin, rifaximin, rifampin). Maximum Dose: 4 tablets/day Quantity Limit: 12 tablets (3 day supply) †Failure is defined as: lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction.	Six months
AFINITOR DISPERZ (everolimus)	**Afinitor Disperz** (everolimus) tablet for suspension may be approved if the following criteria are met: • The member is ≥ 1 year of age and Afinitor Disperz (everolimus) is being prescribed for Tuberous Sclerosis Complex (TSC) for treatment of Subependymal Giant Cell Astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected OR • The member is ≥ 2 year of age and Afinitor Disperz (everolimus) is being prescribed for adjunctive treatment of TSC-associated partial-onset seizures.	One year
AGAMREE (vamorolone)	**Agamree** (vamorolone) may be approved when the following criteria are met: • Member is ≥ 2 years of age AND • Member has a diagnosis of Duchenne Muscular Dystrophy (DMD) and is ambulatory AND • A baseline assessment of ambulatory function using the Time to Stand Test (TTSTAND) has been documented prior to initiating Agamree (vamorolone) therapy AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Medication is prescribed by or in consultation with a neurologist or a provider who specializes in treatment of DMD (such as a cardiologist, pulmonologist, or physical medicine and rehabilitation physician AND • Member requires use of long-term corticosteroid therapy with Agamree (vamorolone) due to an inability to tolerate therapy with traditional corticosteroids AND • Member has received all appropriate immunizations according to current ACIP guidelines at least two weeks prior to (at least 4 to 6 weeks prior for live-attenuated or live vaccines) Agamree (vamorolone) initiation AND • Provider attests that member will be monitored for corticosteroid-related effects (such as Cushing's syndrome, hyperglycemia, behavioral/mood disturbances, or adrenal insufficiency after Agamree (vamorolone) therapy is withdrawn) AND • Provider attests that the dose of Agamree (vamorolone) will be appropriately reduced per product labeling for members who are concurrently taking strong CYP3A4 inhibitors (such as itraconazole, ketoconazole, diltiazem, ritonavir). Maximum dose: 7.5ml (300mg) per day <u>Reauthorization</u>: After one year of treatment with Agamree (vamorolone), the member may receive approval to continue therapy for one year if the following criteria are met: • Member has shown no clinically significant or intolerable adverse effects related to vamorolone treatment AND • Member demonstrates response to vamorolone treatment with clinical improvement in trajectory from baseline assessment in ambulatory function as measured by the Time to Stand Test (TTSTAND).	
ALBUMIN	Albumin products may be approved if meeting the following criteria: • Medication is given in the member's home or in a long-term care facility AND • Administration is for one of the following FDA-approved indications: o Hypoproteinemia o Burns o Shock due to: ▪ Burns ▪ Trauma ▪ Surgery ▪ Infection o Erythrocyte resuspension o Acute nephrosis o Renal dialysis o Hyperbilirubinemia o Erythroblastosis fetalis	One year
ALDURAZYME (laronidase)	**Aldurazyme** (laronidase) may be approved for members meeting the following criteria: • Aldurazyme (laronidase) is being administered in a long-term care facility or in a member's home by a healthcare professional AND • Member is 6 months of age or older AND • Member does not have acute febrile or respiratory illness AND • Member does not have progressive/irreversible severe cognitive impairment AND	One year

<table>
<tr><th>Drug Product(s)</th><th>Criteria</th><th>PA Approval Length</th></tr>
<tr><td></td><td>

Member has a diagnosis of Mucopolysaccharidosis, Type 1 confirmed by one of the following:

Detection of pathogenic mutations in the IDUA gene by molecular genetic testing OR
Detection of deficient activity of the α-L-iduronidase lysosomal enzyme

AND
Member has a diagnosis of one of the following subtypes:

Diagnosis of Hurler (severe) or Hurler-Scheie (attenuated) forms of disease OR
Diagnosis of Scheie (attenuated) form of disease with moderate to severe symptoms

AND
Alurazyme (laronidase) is being prescribed by or in consultation with a provider who specializes in inherited metabolic disorders AND
Member has a documented baseline value for urinary glycosaminoglycan (uGAG) AND
Member has a documented baseline value for one of the following based on age:

Members ≥ 6 years of age: percent predicted forced vital capacity (FVC) and/or 6- minute walk test OR
Members 6 months to 6 years of age: cardiac status, upper airway obstruction during sleep, growth velocity, mental development, FVC, and/or 6-minute walk test

<u>Reauthorization Criteria:</u>
After one year, member may receive approval to continue therapy if meeting the following:

Has documented reduction in uGAG levels AND
Has demonstrated stability or improvement in one of the following based on age:

Members ≥ 6 years of age: stability or improvement in percent predicted FVC and/or 6-minute walk test OR
Members 6 months to less than 6 years of age: stability or improvement in cardiac status, upper airway obstruction during sleep, growth velocity, mental development, FVC and/or 6-minute walk test

Max dose: 0.58 mg/kg as a 3 to 4-hour infusion weekly.
</td><td></td></tr>
<tr><td>ALINIA (nitazoxanide)</td><td>
Alinia (nitazoxanide) may be approved if meeting the following criteria:

ALINIA is being prescribed for diarrhea caused by Giardia lamblia or Cryptosporidium parvum AND
Member is 1 year of age or older AND
If treating diarrhea due to C. parvum in members with Human Immunodeficiency Virus (HIV) infection, the member is receiving antiretroviral therapy AND
Prescription meets the following FDA-labeled dosing:

<table>
<tr><th>Age (years)</th><th>Dosage of Nitazoxanide</th><th>Duration</th></tr>
<tr><td>1-3</td><td>5 mL (100mg) oral suspension every 12 hours with food</td><td></td></tr>
<tr><td>4-11</td><td>10 mL (200mg) oral suspension every 12 hours with food</td><td>3 days</td></tr>
<tr><td>>11</td><td>500mg orally every 12 hours with food</td><td></td></tr>
</table>
</td><td></td></tr>
</table>

Drug Product(s)	Criteria	PA Approval Length
ALKINDI SPRINKLE (hydrocortisone)	**Alkindi Sprinkle** (hydrocortisone) may be approved if the following criteria are met: • Member has a diagnosis of adrenocortical insufficiency AND • Prescriber confirms that member is unable to use an alternative generic glucocorticoid therapy AND • Prescriber confirms that member cannot take a solid oral dosage form AND • Member does not have a nasogastric or gastric tube AND • Member has received counseling that Alkindi Sprinkle (hydrocortisone) capsules: o Cannot be swallowed whole AND o The granules with each capsule cannot be crushed or chewed AND o Each dose of granules should be followed with fluid to ensure that all granules are swallowed. Maximum Quantity: Three 50 capsule packages/30 days	One year
ALLERGY EXTRACT PRODUCTS (Oral)	**Grastek** (timothy grass pollen allergen extract): Must be between 5 and 65 years old. Must not be pregnant or nursing. Must be prescribed by an allergist. Must have a documented diagnosis to ONLY timothy grass pollen allergen extract or the Pooideae family (meadow fescue, orchard, perennial rye, Kentucky blue, and red top grasses) confirmed by positive skin test or IgE antibodies. Must have tried and failed allergy shots for reasons other than needle phobia. Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. Must be willing to administer epinephrine in case of severe allergic reaction. Must take first dose in physician's office. Must be started 12 weeks prior to the season if giving only seasonally. May be taken daily for up to 3 consecutive years. Must NOT have: • Severe, unstable or uncontrolled asthma • Had an allergic reaction in the past that included trouble breathing, dizziness or fainting, rapid or weak heartbeat • Ever had difficulty with breathing due to swelling of the throat or upper airway after using any sublingual immunotherapy before • Been diagnosed with eosinophilic esophagitis • Allergic to any of the inactive ingredients contained in Grastek which include gelatin, mannitol, and sodium hydroxide • A medical condition that may reduce the ability to survive a serious allergic reaction including but not limited to: markedly compromised lung function, unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension. • Taking medications that can potentiate or inhibit the effect of epinephrine including but not limited to: beta-adrenergic blockers, alpha-adrenergic blockers, ergot alkaloids, tricyclic antidepressants, levothyroxine, monoamine oxidase inhibitors, certain antihistamines, cardiac glycosides, and diuretics. • Be taken with other immunotherapy (oral or injectable) **Odactra** (dermatophagoides pteronyssinus and dermatophagoides farinae):	One year

Drug Product(s)	Criteria	PA Approval Length
	Must be between 5 and 65 years old. Must not be pregnant or nursing. Must be prescribed by an allergist. Must have a documented diagnosis to ONLY house dust mite induced allergic rhinitis confirmed by positive IgE antibody testing or positive skin testing to licensed house dust mite allergen extracts Must have tried and failed allergy shots for reasons other than needle phobia. Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. Must be willing to administer epinephrine in case of severe allergic reaction. Must take first dose in physician's office. Must be started 12 weeks prior to the season if giving only seasonally. May be taken daily for up to 3 consecutive years. Must NOT have: • Severe, unstable or uncontrolled asthma • Had an allergic reaction in the past that included trouble breathing, dizziness or fainting, rapid or weak heartbeat • Ever had difficulty with breathing due to swelling of the throat or upper airway after using any sublingual immunotherapy before • Been diagnosed with eosinophilic esophagitis • Allergic to any of the inactive ingredients contained in Grastek which include gelatin, mannitol, and sodium hydroxide • A medical condition that may reduce the ability to survive a serious allergic reaction including but not limited to: markedly compromised lung function, unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension. • Taking medications that can potentiate or inhibit the effect of epinephrine including but not limited to: beta-adrenergic blockers, alpha-adrenergic blockers, ergot alkaloids, tricyclic antidepressants, levothyroxine, monoamine oxidase inhibitors, certain antihistamines, cardiac glycosides, and diuretics. • Be taken with other immunotherapy (oral or injectable) **Oralair** (sweet vernal, orchard, perennial rye, timothy, Kentucky blue grass mixed pollens allergen extract): Must be between 5 and 65 years old. Must not be pregnant or nursing. Must be prescribed by an allergist. Must have a documented diagnosis to ONLY Sweet Vernal, Orchard, Perennial Rye, Timothy, or Kentucky Blue Grass allergen extract confirmed by positive skin test or IgE antibodies. Must have tried and failed allergy shots for reasons other than needle phobia. Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. Must be willing to administer epinephrine in case of severe allergic reaction. Must take first dose in physician's office. Must NOT have: • Severe, unstable or uncontrolled asthma • Had an allergic reaction in the past that included trouble breathing, dizziness or fainting, rapid or weak heartbeat	

Drug Product(s)	Criteria	PA Approval Length
	• Ever had difficulty with breathing due to swelling of the throat or upper airway after using any sublingual immunotherapy before • Been diagnosed with eosinophilic esophagitis • Allergic to any of the inactive ingredients contained in Oralair which include mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate, and lactose monohydrate. • A medical condition that may reduce the ability to survive a serious allergic reaction including but not limited to: markedly compromised lung function, unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension. • Taking medications that can potentiate or inhibit the effect of epinephrine including but not limited to: beta-adrenergic blockers, alpha-adrenergic blockers, ergot alkaloids, tricyclic antidepressants, levothyroxine, monoamine oxidase inhibitors, certain antihistamines, cardiac glycosides, and diuretics. • Be taken with other immunotherapy (oral or injectable) **Ragwitek** *(short ragweed pollen allergen extract):* Must be between 5 and 65 years old. Must be started 12 weeks prior to the season and only prescribed seasonally. Must not be pregnant or nursing. Must be prescribed by an allergist. Must have a documented diagnosis to ONLY short ragweed pollen allergen extract or the Ambrosia family (giant, false, and western ragweed) confirmed by positive skin test or IgE antibodies. Must have tried and failed allergy shots for reasons other than needle phobia. Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. Must be willing to administer epinephrine in case of a severe allergic reaction. Must take first dose in physician's office. Must NOT have: • Severe, unstable or uncontrolled asthma • Had an allergic reaction in the past that included trouble breathing, dizziness or fainting, rapid or weak heartbeat • Ever had difficulty with breathing due to swelling of the throat or upper airway after using any sublingual immunotherapy before • Been diagnosed with eosinophilic esophagitis • Allergic to any of the inactive ingredients contained in Ragwitek which include gelatin, mannitol, and sodium hydroxide • A medical condition that may reduce the ability to survive a serious allergic reaction including but not limited to: markedly compromised lung function, unstable angina, recent myocardial infarction, significant arrhythmia, and uncontrolled hypertension. • Taking medications that can potentiate or inhibit the effect of epinephrine including but not limited to: beta-adrenergic blockers, alpha-adrenergic blockers, ergot alkaloids, tricyclic antidepressants, levothyroxine, monoamine oxidase inhibitors, certain antihistamines, cardiac glycosides, and diuretics. • Be taken with other immunotherapy (oral or injectable)	
ALPHA–1 PROTEINASE INHIBITORS	FDA approved indication if given in the member's home or in a long-term care facility: • **Aralast**: Chronic augmentation therapy in members having congenital deficiency of Alpha –1 Proteinase Inhibitor with clinically evident emphysema	Lifetime

Drug Product(s)	Criteria	PA Approval Length
	• **Prolastin**: Emphysema associated with Alpha-1 Antitrypsin Deficiency • **Zemaira**: Chronic augmentation and maintenance therapy in members with Alpha- 1 Proteinase Inhibitor deficiency with clinically evident emphysema	
ALVAIZ (eltrombopag choline)	**Alvaiz** (eltrombopag choline) may be approved if the following criteria are met: For ALL Indications: • Eltrombopag choline is not substitutable with other eltrombopag products on a mg-per-mg basis AND • Prescriber is aware that Alvaiz (eltrombopag choline) may increase the risk of severe and potentially life-threatening hepatotoxicity, and that hepatic function must be monitored before and during therapy AND • Prescriber is aware that member will undergo ocular exams prior to initiation of therapy, during therapy, and will be regularly monitored for signs and symptoms of cataracts AND • Member has been counseled to take Alvaiz (eltrombopag choline) at least 2 hours before or 4 hours after any products containing polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, zinc, dairy products, and supplements containing minerals) to avoid a significant reduction in eltrombopag absorption, AND • Member is not breastfeeding AND • Alvaiz (eltrombopag choline) tablets should not be split, chewed, or crushed. Pediatric patients must be able to swallow tablets whole AND • Meets additional criteria for prescribed indication below. Persistent or Chronic Immune Thrombocytopenia: • Member is ≥ 6 years of age AND • Member has a confirmed diagnosis of persistent or chronic (> 3 months) immune thrombocytopenia AND • Member's degree of thrombocytopenia and clinical condition increase the risk (documented) of bleeding as demonstrated by the following lab values: o Platelet count less than 20,000/mm3 OR o Platelet count less than 30,000/mm3 accompanied by signs and symptoms of bleeding AND • Requested medication is being prescribed by a hematologist AND • Member has tried and failed‡ at least one of the following: o Systemic corticosteroid therapy within the past 6 months (such as prednisone 1-2 mg/kg for 2 to 4 weeks, or pulsed dexamethasone 40 mg daily for 4 days) o Immunoglobulin replacement o Splenectomy Thrombocytopenia Associated with Hepatitis C: • Member has a confirmed diagnosis of chronic hepatitis C associated thrombocytopenia AND • Member is ≥ 18 years of age AND • Requested medication is being prescribed by a gastroenterologist, infectious disease specialist, transplant specialist, or hematologist AND • Member has clinically documented thrombocytopenia (defined as platelets < 60,000 microL) AND	See criteria

Drug Product(s)	Criteria	PA Approval Length
	• Prescriber acknowledges that safety and efficacy have not been established for the use of Alvaiz (eltrombopag choline) in combination with direct-acting antiviral agents used without interferon for the treatment of chronic hepatitis C infection AND • Prescriber is aware that in patients with chronic hepatitis C, Alvaiz (eltrombopag choline) used in combination with interferon and ribavirin may increase the risk of hepatic decompensation. Severe Aplastic Anemia: • Member has a confirmed diagnosis of severe aplastic anemia AND • Member is ≥ 18 years of age AND • Requested medication is being prescribed by a hematologist AND • Member must have had a documented insufficient response to immunosuppressive therapy [antithymocyte globulin (ATG)], alone or in combination with cyclosporine and/or a corticosteroid. Maximum dose: • Persistent or chronic immune thrombocytopenia: 54 mg/day • Thrombocytopenia associated with hepatitis C: 72 mg/day • Severe aplastic anemia: 108 mg/day Initial approval: Initial prior authorization approval will be granted for 12 months. Reauthorization: Reauthorization approval for a maximum of 6 months will require documentation both of lab results and efficacy of treatment with Alvaiz (eltrombopag choline). ‡Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions.	
ALYFTREK (vanzacaftor/tezacaftor/ deutivacaftor)	**Alyftrek** (vanzacaftor/tezacaftor/deutivacaftor) may be approved if ALL of the following criteria are met: • Member is ≥ 6 years of age AND • Member has a diagnosis of cystic fibrosis (CF) confirmed by genetic tests indicating at least one F508del mutation or another responsive mutation in the CFTR gene as outlined in FDA product labeling AND • Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is being prescribed by or in consultation with a pulmonologist AND • Baseline Forced Expiratory Volume (FEV1) must be collected AND • Provider attests that member has documented serum transaminase and bilirubin results from within the 3 months prior to initiation of Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) therapy AND • Liver function tests will be monitored every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter AND • Member does not have moderate or severe hepatic impairment (Child-Pugh Classes B or C) AND • Member continues to receive standard of care CF therapies (such as bronchodilators, inhaled antibiotics, dornase alfa, and hypertonic saline) AND • Member has been counseled to avoid food or drink containing grapefruit during treatment with Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Member is not concurrently taking a strong CYP3A inhibitor (such as ketoconazole, itraconazole, posaconazole, ritonavir, indinavir, saquinavir, clarithromycin, erythromycin, diltiazem, verapamil, fluvoxamine) and other significant drug interactions have been reviewed according to product labeling AND • Due to the risk of developing lens opacities/cataracts in patients with CF who are ≤ 18 years, provider attests that baseline and follow-up eye exams will be performed. Maximum dose: Three Alyftrek 4 mg/ 20 mg/ 50 mg tablets per day Two Alyftrek 10 mg/ 50 mg/ 125 mg tablets per day Quantity limits: 84 Alyftrek 4 mg/ 20 mg/ 50 mg tablets per 28 days 56 Alyftrek 10 mg/ 50 mg/ 125 mg tablets per 28 days Continuation of therapy: Members with a current prior authorization approval on file for Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) may receive approval for continuation of therapy. Members are limited to one prior authorization on file for Trikafta (elexacaftor/tezacaftor/ivacaftor) OR Alyftrek (vanzacaftor/tezacaftor/deutivacaftor).	
AMONDYS 45 (casimersen)	**Amondys 45** (casimersen) may be approved for members meeting the following criteria: • Medication is being administered in the member's home or in a long-term care facility by a healthcare professional AND • Member has a diagnosis of Duchenne Muscular Dystrophy (DMD) AND • Member must have genetic testing confirming mutation of the DMD gene that is amenable to exon 45 skipping AND • Medication is prescribed by or in consultation with a neurologist or a provider who specializes in treatment of DMD (such as a cardiologist, pulmonologist, or physical medicine and rehabilitation physician or pulmonary specialist) AND • Provider attests that serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR) will be measured prior to initiation of and that the member will be monitored periodically for kidney toxicity during treatment AND • The member must be on corticosteroids at baseline or prescriber provides clinical rationale for not using corticosteroids AND • If the member is ambulatory, functional level determination of baseline assessment of ambulatory function is required OR if not ambulatory, member must have a baseline Brooke Upper Extremity Function Scale or Forced Vital Capacity (FVC) documented AND • Provider and patient or caregiver are aware that continued US FDA approval of Amondys 45 (casimersen) for Duchenne muscular dystrophy (DMD) may be contingent upon verification and description of clinical benefit in a confirmatory trial. Reauthorization: After one year of treatment with Amondys 45 (casimersen), the member may receive approval to continue therapy for one year if the following criteria are met: • Member has shown no intolerable adverse effects related to Amondys 45 (casimersen) treatment at a dose of 30mg/kg IV once a week AND	Initial: One year Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	• Member has normal renal function or stable renal function if known impairment AND • Member demonstrates response to Amondys 45 (casimersen) treatment with clinical improvement in trajectory from baseline assessment in ambulatory function OR if not ambulatory, member demonstrates improvement from baseline on the Brooke Upper Extremity Function Scale or in Forced Vital Capacity (FVC). Above coverage standards will continue to be reviewed and evaluated for any applicable changes due to the evolving nature of factors including disease course, available treatment options, and available peer-reviewed medical literature and clinical evidence. Maximum Dose: 30 mg/kg per week	
ANOREXIANTS	Medications prescribed for use for weight loss are not a covered benefit. **Adipex P** (phentermine) **Belviq** (lorcaserin) **Contrave** (naltrexone/bupropion) **Lomaira** (phentermine) **Phentermine** **Qsymia** (phentermine/topiramate ER) **Saxenda** (liraglutide) **Xenical** (Orlistat)	
ANTI-ANEMIA MEDICATIONS	Oral prescription iron products may be approved for members with a diagnosis of iron deficient anemia (applies to products available by prescription only) Injectable anti-anemia agents (such as **Infed®**, **Ferrlecit®**, **Venofer®, Dexferrum®**) may be approved for members meeting the following criteria: • Member has a diagnosis of iron deficient anemia **AND** • Oral preparations are ineffective or cannot be used **AND** • Medication is being administered in a long-term care facility or in the member's home by a home healthcare provider Note: For coverage criteria for OTC **f**errous sulfate and ferrous gluconate, refer to "OTC Products" section.	Lifetime
ANTIPSYCHOTIC LONG-ACTING INJECTABLE PRODUCTS	Effective October 1, 2024, coverage information and criteria for long-acting injectable antipsychotic medications is located on the Preferred Drug List (PDL).	
AQNEURSA (levacetylleucine)	**Aqneursa** (levacetylleucine) may be approved if the following criteria are met: • Member weighs ≥ 15 kg AND • Member has a documented diagnosis of Niemann-Pick disease type C, molecularly confirmed by genetic testing AND • Requested medication is being prescribed by a neurologist or other provider specializing in the treatment of Niemann-Pick disease type C AND • A baseline assessment of disability has been documented using a version of the NPC Clinical Severity Scale (NPCCSS) prior to initiating Aqneursa (levacetylleucine) therapy AND • Member is not pregnant AND • If member is breastfeeding, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Aqneursa	6 months

Drug Product(s)	Criteria	PA Approval Length
	(levacetylleucine) and any potential adverse effects on the breastfed infant or from the underlying maternal condition AND • Members of childbearing potential been counseled that Aqneursa (levacetylleucine) may cause fetal harm and to use effective contraception during treatment and for 7 days after the last dose of Aqneursa, if therapy is discontinued AND • Members are limited to one prior authorization approval on file for Miplyffa (arimoclomol citrate) OR Aqneursa (levacetylleucine). Maximum Dose: 4 grams/day Maximum Quantity: 112 unit dose 1-gram packets/28 days Initial Approval: 6 months Reauthorization Approval: Continuation of therapy for 6 months may be approved if all of the following criteria are met: • Based on ongoing response to treatment, the provider attests there is medical necessity justifying continuation of drug therapy AND • Member has demonstrated response to treatment based on quantitative scores using the same scale(s) previously used to assess Aqneursa treatment (see bullet point 4 of the initial authorization criteria), AND • A brief explanation, including the provider name, must be submitted if a provider other than the one who initially performed the neurologic exam completes any follow-up exam(s) AND • A brief explanation must be submitted if an exam scale other than the scale used for initial authorization is used for reassessment.	
ATTRUBY (acoramidis)	**Attruby** (acoramidis) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) AND • Requested medication is being prescribed by or in consultation with a cardiologist AND • Member does not have polyneuropathy associated with ATTR AND • Member has a documented history of heart failure with NYHA functional class I to III. Maximum dose: 1,424 mg/day Maximum quantity: four 356 mg tablets/day	One year
AVEED (testosterone undecanoate)	Claims for medications administered in a clinic or medical office are billed through the Health First Colorado medical benefit.	Product not eligible for pharmacy billing.
BACTROBAN (mupirocin) Cream and Nasal Ointment	Effective 4/10/2025, no prior authorization is required for Bactroban (mupirocin) cream and nasal ointment products.	
BARBITURATES **Coverage for Medicare dual-eligible members**	Dual-eligible Medicare-Medicaid Beneficiaries:	

Drug Product(s)	Criteria	PA Approval Length
	Effective 01/01/2013, barbiturates are no longer covered under the Health First Colorado pharmacy benefit for Medicare-Medicaid dual-eligible members.	
BENLYSTA (belimumab)	**Benlysta** (belimumab) may be approved if the following criteria are met: • For requests for the IV formulation, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility **AND** • Member is age ≥ 5 years and has active, autoantibody-positive systemic lupus erythematosus (SLE) and receiving standard therapy OR has active lupus nephritis and is receiving standard therapy **AND** • Member has incomplete response to standard therapy from at least two of the following therapeutic classes: antimalarials, immunosuppressants and glucocorticoids; **AND** • Member maintains use of standard therapy while on Benlysta (belimumab) **AND** • Member is not receiving other biologics or intravenous cyclophosphamide **AND** • The product is NOT being prescribed for severe active lupus nephritis or severe active central nervous system lupus. Maximum dose: IV formulation: 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter. Subcutaneous formulation: 200 mg once weekly. If initiating therapy for active lupus nephritis, 400-mg dose (two 200 mg injections) once weekly for 4 doses followed by 200mg once weekly thereafter.	One year
BENZODIAZEPINES Coverage for Medicare dual-eligible members	Dual-eligible Medicare-Medicaid Beneficiaries: Benzodiazepines will no longer be a Medicaid benefit for Medicare-Medicaid enrollees (dual-eligible members). The claims are no longer excluded from Medicare part D coverage and therefore must be billed to Medicare part D. Colorado Medicaid will no longer cover these medications for these members beginning on January 1, 2013.	
BESREMI (ropeginterferon alfa-2b)	**Besrimi** (ropeginterferon alfa-2b) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • The requested medication is being prescribed for the treatment of polycythemia vera AND • The requested medication is being prescribed by a hematologist AND • Member does NOT meet any of the following: o History of, or presence of, severe psychiatric disorders, particularly severe depression, suicidal ideation, or history of suicide attempt o Moderate or severe hepatic impairment o History of, or presence of, active serious or untreated autoimmune disease o The member is an immunosuppressed transplant recipient AND • Prescriber attests that complete blood count (CBC) will be checked at least every 2 weeks during the titration phase and at least every 3 to 6 months during the maintenance phase after the patient's optimal dose is established AND • Prescriber attests that a pre-treatment pregnancy test will be performed, and that members of reproductive potential will be advised to use effective contraception during treatment and for at least 8 weeks after the final dose AND • Provider attests that assessments of psychiatric well-being will be performed at baseline and monitored periodically. Maximum Dose: 500 mcg every two weeks Quantity Limit: Four 500 mcg/mL prefilled syringes/30 days	One year

Drug Product(s)	Criteria	PA Approval Length
	Reauthorization: If hematological stability has been achieved after at least 1 year of therapy on a two week dosing interval of BESREMi (ropeginterferon alfa-2b), provider attests to considering an expanded dosing interval of every 4 weeks.	
BLOOD PRODUCTS	FDA approved indications if given in the member's home or in a long-term care facility: Plasma protein fraction; shock due to burns, trauma, surgery; hypoproteinemia; adult respiratory distress syndrome; cardiopulmonary bypass; liver failure; renal dialysis; or hemophilia.	Lifetime
BLUJEPA (gepotidacin)	**Blujepa** (gepotidacin) may be approved if the following criteria are met: • Member is female and ≥12 years of age AND • Member weighs at least 40 kg AND • Member has a diagnosis of uncomplicated UTI proven or strongly suspected to be caused by E. coli, K. pneumoniae, Citrobacter freundii complex (CFC), S. saprophyticus or E. faecalis AND • Member does not have severe renal impairment (eGFR <30 mL/min) and is not receiving dialysis AND • Member does not have severe hepatic impairment (Child-Pugh Class C) AND • Member has tried and failed‡ treatment with three of the following: o Ciprofloxacin o Fosfomycin o Levofloxacin o Nitrofurantoin o Sulfamethoxazole-trimethoprim AND • Medication is being prescribed by or in consultation with an infectious disease specialist AND • Member has received counseling to take Blujepa (gepotidacin) tablets after a meal to reduce stomach upset. Maximum dose: 3,000 mg/day Maximum quantity: One 5-day treatment course (twenty 750 mg tablets) for per 30 days ‡Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction.	One year
BONE RESORPTION SUPPRESSION AND RELATED AGENTS (Injectable Formulations) Aredia, Denosumab Biosimilars, Ganite, Hectorol, Ibandronate, Miacalcin, Pamidronate, Prolia, Reclast, Zemplar, Zometa	**Prolia** (denosumab) or denosumab-containing biosimilar agents may be approved if the following criteria are met: • Member is in a long-term care facility or home health (this medication is required to be administered by a healthcare professional) AND • Member has one of the following diagnoses: o Postmenopausal osteoporosis with high fracture risk o Osteoporosis o Bone loss in men receiving androgen deprivation therapy in prostate cancer o Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer AND • Member has serum calcium greater than 8.5mg/dL AND • Member is taking calcium 1000 mg daily and at least 400 IU vitamin D daily AND	One year

Drug Product(s)	Criteria	PA Approval Length

	• Has trial and failure of preferred bisphosphonate for one year AND (Failure is defined as: lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction)
	• Member meets ANY of the following criteria:
	  ○ has a history of an osteoporotic vertebral or hip fracture
	  ○ has a pre-treatment T-score of < -2.5
	  ○ has a pre-treatment T-score of < -1 but > -2.5 AND either of the following:
	  • Pre-treatment FRAX score of > 20% for any major fracture
	  • Pre-treatment FRAX score of > 3% for hip fracture
	
	Maximum dose of Prolia is 60mg every 6 months
	
	For all other injectable Bone Resorption Suppression and Related Agents, prior authorization will only be approved as a pharmacy benefit when the medication is administered in a long-term care facility or in a member's home.	

BOTULINUM TOXIN AGENTS (Botox, Daxxify, Dysport, Myobloc, Xeomin)	Botulinum toxin agents may receive approval if meeting the following criteria: • Medication is being administered in a long-term care facility or the member's home by a healthcare professional AND • Member has a treatment diagnosis of cervical or facial dystonia (limited to agents with FDA-labeled indication for this prescribed use). **Prior authorization for botulinum toxin agents prescribed for use for cosmetic purposes will not be approved.**	One year
BOWEL PREPERATION AGENTS	For the following Bowel Preparation Agents, members will require a prior authorization for quantities exceeding 2 units in 30 days. • Colyte • Gavilyte-C • Gavilyte-H • Gavilyte-N • Gialax • Golytely • Moviprep • Peg-Prep • Suprep • Sutab • Trilyte	30 days
BRAND FAVORED MEDICATIONS	See "Brand Favored Product List" on the Pharmacy Resources webpage at https://www.colorado.gov/pacific/hcpf/pharmacy-resources .	
BREXAFEMME (ibrexafungerp)	**Brexafemme** (ibrexafungerp) may be approved if the following criteria are met: • The member is post-menarchal and ≥ 17 years of age AND • Brexafemme (ibrexafungerp) is being prescribed to treat vulvovaginal candidiasis AND • The member has trialed and failed† two azole antifungal products (oral and/or topical) AND • The member is not pregnant or breastfeeding Maximum Dose: 600 mg/day Quantity Limit: 120 tablets/30 days	One year

Drug Product(s)	Criteria	PA Approval Length
	†Failure is defined as: lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction.	
BRINSUPRI (brensocatib)	**Brinsupri** (brensocatib) may be approved if the following criteria are met: • Member is ≥12 years of age AND • Member has a diagnosis of bronchiectasis AND • Member does not have cystic fibrosis AND • Member will be monitored for dermatologic adverse reactions, including rash, dry skin, and hyperkeratosis AND • Member will be monitored for gingival and periodontal adverse reactions and referred to dental care services while taking Brinsupri (brensocatib) AND • Member has received counseling to not receive any live attenuated vaccines while receiving Brinsupri (brensocatib) and for two weeks after Brinsupri (brensocatib) therapy is discontinued AND • Requested medication is being prescribed by or in consultation with a pulmonologist or infectious disease specialist AND • Member meets one of the following: o Member is 12 to 17 years of age with at least one pulmonary exacerbation in the last 12 months that resulted in the prescription of an antibiotic agent OR o Member is ≥ 18 years of age and has had at least two pulmonary exacerbations in the last 12 months that resulted in the prescription of an antibiotic agent. Maximum dose: 25 mg/day Maximum quantity: 30 tablets/30 days	One year
BRIUMVI (ublituximab-xiiy)	**Briumvi** (ublituximab-xiiy) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND • Member is ≥ 18 years of age AND • Member has a relapsing form of multiple sclerosis (MS) AND • Member has experienced at least one relapse in the prior year or two relapses in the prior two years AND • Member has had trial and failure with any two high efficacy disease modifying therapies (such as ofatumumab, fingolimod, rituximab, ocrelizumab, alemtuzumab). Failure is defined as allergy, intolerable side effects, significant drug-drug interaction, or lack of efficacy. Lack of efficacy is defined as one of the following: o On MRI, presence of any new spinal lesions, cerebellar or brainstem lesions, or change in brain atrophy OR o Signs and symptoms on clinical exam consistent with functional limitations that last one month or longer AND • Member does not have active hepatitis B virus (HBV) infection AND • The requested medication is prescribed by or in consultation with a neurologist or a physician that specializes in the treatment of multiple sclerosis AND	One year

Drug Product(s)	Criteria	PA Approval Length

	• Member does not have low serum immunoglobulins, based on quantitative tests performed before initiating treatment, AND
	• Prescriber attests that appropriate premedication (such as a corticosteroid and antihistamine) will be administered prior to each Briumvi (ublituximab-xiiy) infusion AND
	• For members of childbearing potential:
	  o Member is not pregnant and prescriber acknowledges that pregnancy testing is recommended for members of reproductive potential prior to each infusion AND
	  o Member has been counseled regarding the use of highly effective contraceptive methods while receiving treatment with Briumvi (ublituximab-xiiy) and for at least 6 months after stopping therapy.
	
	Quantity limit: Four 150 mg/6 mL single-dose vials for the first 2 weeks (initial dose), and three 150 mg/6 mL single-dose vials every 24 weeks thereafter.
	
	Exemption: If member is currently receiving and stabilized on Briumvi (ublituximab-xiiy), they may receive prior authorization approval to continue therapy.	

BRONCHITOL (mannitol)	**Bronchitol** (mannitol) may be approved for members meeting the following criteria: • Bronchitol (mannitol) is being prescribed as an add-on therapy for cystic fibrosis (CF) AND • Member is an adult (≥ 18 years of age) with a confirmed diagnosis of cystic fibrosis AND • Member has severe lung disease as documented by bronchoscopy or CT scan AND • Member has an FEV1 between 40% and 89% of predicted value AND • Member is receiving other appropriate standard therapies for management of cystic fibrosis (such as inhaled antibiotic, airway clearance physiotherapy, inhaled beta2 receptor agonist) AND • Member has had an adequate trial and failure of nebulized hypertonic saline, or is currently using nebulized hypertonic saline on a regular basis AND • Member has trialed and failed twice-daily treatment with recombinant human deoxyribonuclease (dornase alfa, rhDNase). Failure is defined as allergy, intolerable side effects or inadequate response AND • Member has successfully passed the Bronchitol Tolerance Test (BTT) under the supervision of a healthcare practitioner AND • Member has been prescribed a short-acting bronchodilator to use 5 to 15 minutes before each dose of Bronchitol (mannitol). Maximum dose: 400mg twice a day by oral inhalation Quantity limit: One 4-week Treatment Pack (4 inhalers, 560 capsules) per 28 days	One year
BUPRENORPHINE-CONTAINING PRODUCTS - ORAL (indicated for opioid use disorder/opioid dependency)*	**Bunavail** (buprenorphine/naloxone) buccal film may be approved for members who meet all of the following criteria: • The member has a diagnosis of opioid dependence AND • The member is 16 years of age or older AND • No claims data show concomitant use of opioids in the preceding 30 days unless the physician attests the member is no longer using opioids AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• The member must have tried and failed, intolerant to, or has contraindication to buprenorphine/naloxone SL tablets or films. **Buprenorphine/Naloxone** sublingual film: • Effective 07/01/2023, prior authorization is not required for generic buprenorphine/naloxone sublingual film. • Maximum dose is 32mg of buprenorphine/day *(updated 2/28/25).* **Buprenorphine/Naloxone** sublingual tablet: • Effective 04/12/2023, prior authorization is not required for buprenorphine/naloxone sublingual tablet. • Maximum dose is 24mg of buprenorphine/day. **Suboxone (brand name)** sublingual film: • Effective 07/01/2023, prior authorization is not required for generic buprenorphine/naloxone sublingual film. Requests for use of the brand product formulation are subject to meeting criteria outlined in the "Generic Mandate" section. • Maximum dose is 32mg of buprenorphine/day *(updated 2/28/25).* **Subutex** (buprenorphine) sublingual tablet will be approved if all of the following criteria are met: • The member has an opioid dependency AND • The member is pregnant OR the member is unable to take naloxone due to allergy or intolerable side effects AND • Subutex (buprenorphine) sublingual tablet will not be approved for the treatment of pain* AND • Maximum dose is 32mg of buprenorphine/day *(updated 2/28/25).* **Zubsolv** (buprenorphine/naloxone) sublingual tablet will be approved if all of the following criteria are met: • The member has a diagnosis of opioid dependence AND • The member is 16 years of age or older AND • No PDMP data shows concomitant use of prescription opioids for pain in the last 30 days unless the prescriber attests the member is no longer using prescription opioids for pain AND • The member must have tried and failed, intolerant to, or has a contraindication to generic buprenorphine/naloxone SL tablets or Suboxone films. **Buprenorphine products indicated for treating pain are located on the preferred drug list (PDL). Long-Acting injectable buprenorphine products indicated for treating OUD are included on the PDL.* *Note: Opioid claims submitted for members currently receiving oral buprenorphine-containing SUD treatment medications will require entry of point-of-sale DUR service codes (Reason for Service, Professional Service, Result of Service) for override of drug-drug interaction (DD) with use of this drug combination (see "Opioid and Buprenorphine-Containing substance use disorder (SUD) Product Combination Effective 06/01/21" section on the PDL).*	

Drug Product(s)	Criteria	PA Approval Length
BUTALBITAL-CONTAINING PRODUCTS WITHOUT CODEINE	Butalbital-containing combination products that do not contain codeine may be approved for the following (requests for all other uses will require manual clinical review): • Members with a diagnosis of epilepsy, cancer, or chronic mental health disorder OR • For the treatment of insomnia, tension headache, muscle contraction headache, or raised intracranial pressure OR • For use for sedation. *Note: Coverage information for barbiturate-containing medications that are labeled for use for the treatment of epilepsy, and multi-ingredient barbiturate-containing medications that contain codeine, can be found on the Health First Colorado Preferred Drug List (PDL).*	One year
BYNFEZIA (octreotide acetate)	**Bynfezia** (octreotide acetate) may be approved if all of the following criteria are met: • Member is an adult (≥ 18 years of age) with a confirmed diagnosis of acromegaly OR severe diarrhea and flushing episodes associated with metastatic carcinoid tumors OR vasoactive intestinal peptide tumors (VIPomas) AND • Bynfezia (octreotide acetate) is prescribed by, or in consultation with, an endocrinologist or oncologist AND • Member has trialed and failed octreotide acetate injection solution (vial). Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction AND • Provider confirms that member has had a baseline thyroid function test drawn prior to the initiation of Bynfezia (octreotide) and plans to monitor periodically during treatment AND • For treatment indication acromegaly, the following criteria are met: o The member has trialed and failed bromocriptine mesylate at maximally tolerated doses. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction AND o The member cannot be treated with surgical resection or pituitary irradiation Maximum Dose: • Acromegaly: 1500 mcg/day (doses > 300 mcg/day may not result in additional benefit) • Carcinoid Tumors: 750 mcg/day • VIPomas: 750 mcg/day (doses > 450 mcg/day are generally not required)	One year
CABLIVI (caplacizumab)	**Cablivi** (caplacizumab) may be approved if all the following criteria have been met: • Member is 18 years or older **AND** • Member has a diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) **AND** • Member is undergoing plasma exchange and is receiving immunosuppressive therapy **AND** • Cablivi (caplacizumab) is being prescribed by or in consultation with a hematologist **AND** • Prescriber is aware that concomitant use of CABLIVI with any anticoagulant or underlying coagulopathy may increase the risk of severe bleeding, including epistaxis and gingival hemorrhage **AND**	One year

Drug Product(s)	Criteria	PA Approval Length
	• Member has not experienced more than 2 recurrences of aTTP while on Cablivi (caplacizumab) **AND** • To bill for Cablivi (caplacizumab) under the pharmacy benefit, the medication must be administered in the member's home or in a long-term care facility. Maximum dose: • First day of treatment: 11 mg prior to plasma exchange, followed by 11 mg after plasma exchange • Subsequent days during treatment period: 11 mg once daily	
CAMZYOS (mavacamten)	**Camzyos** (mavacamten) may be approved if the following criteria are met: • Member is ≥ 18 years of age **AND** • Member is able to swallow capsules **AND** • Member is being treated for symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy AND has a left ventricular ejection fraction of ≥ 55% **AND** • The requested medication is being prescribed by, or in consultation with, a cardiologist **AND** • Echocardiogram assessment of LVEF has been performed prior to initiation of CAMZYOS (mavacamten) therapy and will be repeated periodically during treatment **AND** • Member has tried and failed **ALL** of the following, up to maximally indicated doses. (Failure is defined as contraindication, lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction): o Non-vasodilating beta blocker (any beta blocker except carvedilol or nebivolol) o Non-dihydropyridine calcium channel blocker (such as verapamil, diltiazem) **AND** • Due to increased risk of systolic heart failure, member's medication profile has been reviewed for potential drug interactions with CYP2C19 or CYP3A4 inhibitors (such as fluoxetine, omeprazole, esomeprazole, cimetidine, itraconazole, ketoconazole, fluconazole, ritonavir, diltiazem, verapamil) according to product labeling **AND** • Member does not have severe hepatic impairment (Child-Pugh C) **AND** • Members of reproductive potential have been counseled to use effective contraception during treatment with CAMZYOS (mavacamten) and for 4 months after the last dose. Maximum Dose: 25 mg/day (unless on certain interacting medications) Quantity Limit: 30 capsules/30 days Reauthorization: Approval for CAMZYOS may be reauthorized for 1 year if LVEF > 50% and member's clinical status is stable or improved.	Initial: 6 months Continued: One year
CERDELGA (eliglustat)	**Cerdelga** (eliglustat) may be approved if all of the following criteria are met: • Member has a diagnosis of Gaucher disease type 1 **AND** • Documentation has been provided to the Department that the member is a CYP2D6 extensive, intermediate, or poor metabolizer as detected by an FDA cleared test **AND**	One year

Drug Product(s)	Criteria	PA Approval Length
	• The member has been counseled regarding the potential for drug interactions with treatment and concomitant medications have been evaluated **AND** • The following criteria are met based on the member's CYP2D6 metabolizer status verified by FDA-cleared testing: CYP2D6 Poor Metabolizer (PM): o Member is not taking a strong CYP3A inhibitor (such as indinavir, nelfinavir, ritonavir, saquinavir, suboxone, erythromycin, clarithromycin, telithromycin, posaconazole, itraconazole, ketoconazole, nefazodone) CYP2D6 Intermediate Metabolizer (IM): o Member is not taking a strong CYP3A inhibitor (such as indinavir, nelfinavir, ritonavir, saquinavir, suboxone, erythromycin, clarithromycin, telithromycin, posaconazole, itraconazole, ketoconazole, nefazodone) **AND** o Member is not taking a moderate CYP3A inhibitor in combination with a moderate or strong CYP2D6 inhibitor CYP2D6 Extensive Metabolizer (EM): o Member is not taking a strong CYP3A inhibitor in combination with a moderate or strong CYP2D6 inhibitor **AND** o Member is not taking a moderate CYP3A inhibitor in combination with a moderate or strong CYP2D6 inhibitor Quantity Limits: Max 60 tablets/30 days	
CHLOROQUINE	Effective 05/16/2023, prior authorization is no longer required for chloroquine.	
CLEMASTINE ORAL SYRUP	**Clemastine** oral syrup may be approved when the following criteria are met: • Member is ≥ 6 years of age AND • Member is unable to take the solid oral dosage form of clemastine AND • Member has tried and failed at least three of the following (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions): o Cetirizine o Cyproheptadine o Diphenhydramine o Fexofenadine o Levocetirizine o Loratadine	One year
CLEMSZA *(IPG Pharmaceuticals, Inc. clemastine)*	**Clemsza** (*IPG Pharmaceuticals, Inc. clemastine*) oral tablets may be approved if the following criteria are met: • Member is ≥12 years of age AND • Member is not breastfeeding AND • Member is not being treated for lower respiratory tract symptoms, including asthma AND • Member is not taking a monoamine oxidase inhibitor (MAOI) AND • Prescriber attests that member is unable to use an alternative generic clemastine product (other than IPG Pharmaceuticals Clemsza) and clinical justification is provided supporting that no alternative generic clemastine product can be used AND	One year

Drug Product(s)	Criteria	PA Approval Length

	• Member has tried and failed at least three of the following (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions):
	  ○ Cetirizine
	  ○ Cyproheptadine
	  ○ Diphenhydramine
	  ○ Fexofenadine
	  ○ Levocetirizine
	  ○ Loratadine
	
	Maximum dose: 8.04 mg/day
	
	Maximum quantity: 90 tablets/30 days	

CLIENT OVERUTILIZATION PROGRAM (COUP)	Effective 9/14/19, pharmacy claims for members enrolled in Health First Colorado's COUP (Client Overutilization Program) program may deny for these members when filling prescriptions at a pharmacy that is not their designated COUP lock-in pharmacy or filling a medication prescribed by a provider that is not their designated COUP lock-in prescriber. Health First Colorado Reginal Accountable Entity (RAE) organizations work with members enrolled in COUP to assist with coordinating care and improving services provided to these members. Members and providers should contact the member's RAE organization for questions regarding the COUP program.* Contact information for Health First Colorado RAE regions can be found at https://www.colorado.gov/pacific/hcpf/accphase2. Additional information regarding the COUP program and enrollment criteria can be accessed at https://www.colorado.gov/pacific/hcpf/client-overutilization-program. **For questions regarding pharmacy claims denials that are unable to be addressed during normal RAE organizational business hours (M-F 8:00 AM – 4:00 PM Mountain Standard Time), members and providers may contact the Prime Therapeutics Helpdesk at 1-800-424-5725.*	
COUGH AND COLD (Prescription Products)	Prescription cough and cold medications may be approved if meeting the following criteria: • For members < 21 years of age, no prior authorization is required OR for members ≥ 21 years of age, prior authorization may be approved with diagnosis of a chronic condition (such as COPD or asthma) AND • For members with dual Medicare eligibility, pharmacy claims for prescription cough and cold medications prescribed for chronic conditions should be billed to Medicare. Prescription cough and cold medications prescribed for dual Medicare eligible members for acute conditions are covered through the Health First Colorado pharmacy benefit with completion of prior authorization verifying use for acute illness. **Promethazine DM and Codeine/Hydrocodone-containing cough and cold liquid preparations** are subject to meeting the following* *(Effective 5/12/23)*: • Subject to meeting quantity limits for products listed below OR diagnosis and clinical rationale is provided supporting the need for use of the requested product at doses exceeding quantity limitation AND • For requests for codeine-containing preparations for members < 18 years of age: ○ Member is 12 years to 17 years of age AND	One year

Drug Product(s)	Criteria	PA Approval Length
	○ Member does not have obstructive sleep apnea or severe lung disease AND ○ Member is not pregnant or breastfeeding AND ○ Renal function is not impaired (GFR > 50 mL/min) AND ○ Member is not receiving strong inhibitors of CYP3A4 AND ○ Request meets one of the following: ▪ Member has trialed codeine or codeine-containing products in the past with no history of allergy or adverse drug reaction to codeine OR ▪ Member has not trialed codeine or codeine-containing products in the past and the prescriber acknowledges reading the following statement: "Approximately 1-2% of the population metabolizes codeine in a manner that exposes them to a much higher potential for toxicity. Another notable proportion of the population may not clinically respond to codeine. We ask that you please have close follow-up with members newly starting codeine and codeine-containing products to monitor for safety and efficacy." Quantity Limits: Guaifenesin and codeine syrup – 180 mL/30 days Promethazine and codeine syrup – 180 mL/30 days Promethazine and dextromethorphan syrup – 180 mL/30 days Promethazine, phenylephrine and codeine syrup – 180 mL/30 days Hydrocodone polistirex/chlorpheniramine polistirex ER suspension – 120 mL/30 days Hydrocodone bitartrate and homatropine methylbromide syrup - 180mL/30 days *Note: For OTC cough and cold product coverage, see "OTC Products" section.*	
CRENESSITY (crinecerfont)	**Crenessity** (crinecerfont) may be approved if the following criteria are met: • Member is ≥ 4 years of age AND • Member has a diagnosis of 21-hydroxylase deficiency classic congenital adrenal hyperplasia confirmed by ONE of the following: ○ Elevated 17-hydroxyprogesterone level ○ Confirmed CYP21A2 genotype ○ Positive newborn screening with confirmatory second-tier testing ○ Diagnostic results after cosyntropin stimulation AND • The requested medication is being prescribed by or in consultation with an endocrinologist, urologist, genetics/metabolic physician, or a physician who specializes in the treatment of adrenal hyperplasia AND • Crenessity (crinecerfont) will be taken in combination with adequate systemic glucocorticoid replacement therapy AND • Member does not have severe renal impairment or end-stage renal disease AND • Member has been counseled to take each dose of Crenessity (crinecerfont) with a meal AND • The dose of Crenessity (crinecerfont) will be adjusted appropriately according to product labeling for members who are concurrently taking a strong or moderate CYP3A4 inducer. Maximum dose: 400 mg/day	One year

Drug Product(s)	Criteria	PA Approval Length
	Maximum quantity: 25 mg capsules: two capsules/day 50 mg capsules: two capsules/day 100 mg capsules: four capsules/day Oral solution 50 mg/mL: 4 mL twice daily	
CRYSVITA (burosumab)	**Crysvita** (burosumab) may be approved if the following criteria are met: • Crysvita (burosumab) is being administered by a healthcare professional in the member's home or in a long-term care facility AND • The member is ≥ 6 months of age and has a diagnosis of X-linked hypophosphatemia (XLH) OR the member is ≥ 2 years of age and has a diagnosis of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized AND • The member has an estimated GFR of ≥ 30 mL/min AND • The member is not taking an oral phosphate product and/or an active vitamin D analog (such as calcitriol, paricalcitol, doxercalciferol or calcifediol). . Maximum Dose: 180 mg every two weeks Quantity Limit: Six 30 mg/mL single dose vials per 14 days	One year
CTEXLI (chenodiol)	**Ctexli** (chenodiol) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of cerebrotendinous xanthomatosis confirmed by genetic tests showing pathogenic variants in the CYP27A1 gene AND • The request medication is being prescribed by a gastroenterologist, hepatologist, neurologist, or cardiologist AND • Baseline ALT, AST, and total bilirubin levels have been assessed prior to initiation of therapy AND • Member has trial and failure with Chenodal (chenodiol) 250 mg. Failure is defined as lack of efficacy, allergy, or intolerable side effects AND • Member will be monitored for signs and symptoms of hepatotoxicity during therapy and if signs and symptoms consistent with hepatotoxicity occur, Ctexli (chenodiol) will be immediately discontinued AND • If member is concurrently taking a bile acid sequestering agent (such as cholestyramine or colestipol) or aluminum-based antacids, the member has been counseled to take Ctexli (chenodiol) doses at least 4 hours prior to taking those interacting drugs AND • If member is concurrently taking anticoagulant therapy (such as warfarin), the member has been counseled about the increased risk of bleeding while taking Ctexli (chenodiol). Maximum dose: 750 mg/day Quantity limit: 90 tablets/30 days	One year
CUVRIOR (trientine tetrahydrochloride)	**Cuvrior** (trientine tetrahydrochloride) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of stable Wilson's Disease meeting at least one of the following criteria: o Hepatic parenchymal copper content of ≥250 mcg/g dry weight	One year

Drug Product(s)	Criteria	PA Approval Length
	○ Presence of Kayser-Fleischer ring in cornea ○ Serum ceruloplasmin level <50 mg/L ○ Basal 24-hour urinary excretion of copper > 100 mcg (1.6 micromoles) ○ Genetic testing results indicating mutation in ATP7B gene AND • Requested product is being prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant specialist AND • Member has failed a three-month trial of penicillamine. Failure is defined as a lack of efficacy, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions AND • Member has failed a three-month trial of trientine. Failure is defined as a lack of efficacy, allergy, intolerable side effect or significant drug-drug interaction. Maximum dose: 3,000 mg/day Quantity limit: 300 tablets/30 days	
CYSTADROPS (cysteamine hydrochloride)	**Cystadrops** (cysteamine hydrochloride) may be approved if the following criteria are met: • The member has a diagnosis of corneal cystine crystal deposits associated with cystinosis, AND • Cystadrops (cysteamine hydrochloride) are being prescribed by a physician experienced in the management of cystinosis AND • The member has been counseled to store unopened bottles in the refrigerator in the original carton (avoid freezing) AND • The member has been counseled to store the bottle of Cystadrops (cysteamine hydrochloride) currently in use in the original carton, tightly closed and at room temperature AND • The member has been counseled that each bottle of Cystadrops (cysteamine hydrochloride) should be discarded 7 days after first opening, even if there is medication left in the bottle AND • The member has been counseled to remove soft contact lenses prior to use of Cystadrops (cysteamine hydrochloride) and wait at least 15 minutes to reinsert lenses after use Maximum Dose: 1 drop in each eye 4 times a day (8 drops total/day) Quantity Limit: Four 5 mL bottles per 28 days	One year
DARAPRIM (pyrimethamine)	**Daraprim** (pyrimethamine) may be approved if all the following criteria are met: • Member is prescribed Daraprim (pyrimethamine) for use for one of the following: ○ Treatment of toxoplasmic encephalitis or congenital toxoplasmosis **OR** ○ Prophylaxis for congenital toxoplasmosis **OR** ○ Treatment of acute malaria due to susceptible strains of plasmodia **OR** **AND** • Daraprim (pyrimethamine) is prescribed by or in consultation with an infectious disease specialist **AND** • Member does not have megaloblastic anemia due to folate deficiency **AND** • If prescribed for prophylaxis for congenital toxoplasmosis or for the treatment of acute malaria due to susceptible strains of plasmodia, the request meets the following based on the prescribed use: Prophylaxis for Congenital Toxoplasmosis:	8 weeks

Drug Product(s)	Criteria	PA Approval Length
	• Member has experienced intolerance to prior treatment with trimethoprim-sulfamethoxazole (TMP-SMX) based on meeting one of the following: o Member has been re-challenged with trimethoprim-sulfamethoxazole (TMP-SMX) using a desensitization protocol and is still unable to tolerate **OR** o Member has evidence of life threatening-reaction to trimethoprim-sulfamethoxazole (TMP-SMX) in the past (such as toxic epidermal necrolysis or Stevens-Johnson syndrome). Treatment of Acute Malaria Due to Susceptible Strains of Plasmodia: • Member has tried and had an inadequate response or is intolerant to two other malaria treatment regimens (such as, but not limited to, atovaquone/proguanil, Coartem, chloroquine, hydroxychloroquine, chloroquine plus Primaquine, quinine plus clindamycin, quinidine plus doxycycline) **AND** • Daraprim is prescribed in consultation with an infectious disease specialist with travel/tropical medicine expertise. *Note: The Center for Disease Control does not recommend Daraprim (pyrimethamine) for the prevention or the treatment of malaria.*	
DARTISLA (glycopyrrolate)	**Dartisla** (glycopyrrolate) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of peptic ulcer disease AND • Member has been tested for *H. pylori* and received eradication therapy if appropriate, AND • Member has had an adequate trial of a generic glycopyrrolate tablet regimen at maximally tolerated recommended doses and has failed to achieve a clinically significant response AND • The requested medication will be used as an adjunct treatment with a proton pump inhibitor (or H2 antagonist) and not as monotherapy Initial approval: 6 months Reauthorization: Prescriber attests that the member has experienced positive clinical response to therapy Maximum dose: 6.8 mg/day Quantity limit: 120 orally disintegrating tablets/30 days	Initial Approval: 6 months Continuation Approval: One year
DAYBUE (trofinetide) **DAYBUE STIX (trofinetide)**	**Daybue** (trofinetide) or **Daybue Stix** (trofinetide) may be approved if the following criteria are met: • Member is ≥ 2 years of age AND • Member has been diagnosed with Rett syndrome with a documented mutation in the MECP2 gene AND • Member does not have moderate to severe renal impairment AND • Requested medication is being prescribed by or in consultation with a neurologist or developmental pediatrician AND • Member or parent/caregiver has been counseled regarding the potential risks of diarrhea and dehydration associated with trofinetide therapy and to avoid pre-treatment laxative use AND	Initial Approval: 3 months Continued Approval: One year

<table>
<tr><th>Drug Product(s)</th><th>Criteria</th><th>PA Approval Length</th></tr>
<tr><td></td><td>

Prescriber has performed baseline symptom assessment AND
Based on limited available clinical evidence for the use of trofinetide, the prescriber has engaged in shared decision making with the member/parent/caregiver prior to prescribing this medication.

Initial approval: 3 months

Reauthorization: Reauthorization approval may be received for 1 year with provider attestation that:

A follow-up symptom assessment has been performed, AND
The member's clinical status is stable or improved and also free of persistent severe diarrhea, episodes of severe dehydration, or significant weight loss.

Quantity limit: four 450 mL bottles/14 days (1,800 mL/14 days)

Dosing limitations:
<table>
<tr><th>Weight</th><th>Dosage*</th><th>Daybue Solution Volume</th><th>Daybue Stix Number of Packets</th></tr>
<tr><td>9 kg to < 12 kg</td><td>5,000 mg twice daily</td><td>25 mL twice daily</td><td>One 5,000 mg packet twice daily</td></tr>
<tr><td>12 kg to < 20 kg</td><td>6,000 mg twice daily</td><td>30 mL twice daily</td><td>One 6,000 mg packet twice daily</td></tr>
<tr><td>20 kg to < 35 kg</td><td>8,000 mg twice daily</td><td>40 mL twice daily</td><td>One 8,000 mg packet twice daily</td></tr>
<tr><td>35 kg to < 50 kg</td><td>10,000 mg twice daily</td><td>50 mL twice daily</td><td>Two 5,000 mg packets twice daily</td></tr>
<tr><td>≥ 50 kg</td><td>12,000 mg twice daily</td><td>60 mL twice daily</td><td>Two 6,000 mg packets twice daily</td></tr>
<tr><td colspan="4">*See FDA product labeling for dose adjustments in patients with renal impairment.</td></tr>
</table>
Members currently stabilized on the requested medication may receive approval to continue treatment on that medication if the criteria for reauthorization are met.
</td><td></td></tr>
<tr><td>DESI DRUGS</td><td>DESI drugs (Drugs designated by the Food and Drug Administration as Less Than Effective Drug Efficacy Study Implementation medications) are not a covered benefit.</td><td></td></tr>
<tr><td>DIFICID (fidoxomicin)</td><td>Dificid (fidoxomicin) may be approved if all the following criteria are met:

Member is age ≥ 6 months AND
Member has a documented diagnosis (including any applicable labs and/or tests) for Clostridium difficile-associated diarrhea AND
Prescribed by or in conjunction with a gastroenterologist or an infectious disease specialist AND
Member has failed at least a 10 day treatment course of oral vancomycin. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.

Maximum quantity:
20 tablets per 30 days
136 mL per 10 days</td><td>1 month</td></tr>
<tr><td>DOJOLVI (triheptanoin)</td><td>Dojolvi (triheptanoin) may be approved if the following criteria are met:</td><td>One year</td></tr>
</table>

Drug Product(s)	Criteria	PA Approval Length
	• Member has a molecularly-confirmed diagnosis of long-chain fatty acid oxidation disorder (LC-FAOD) AND • The requested drug is being prescribed by an endocrinologist, geneticist, metabolic physician, medical nutrition physician, or LC-FAOD expert, AND • Member is experiencing symptoms of deficiency exhibited by the presence of <u>at least one</u> of the following: o Severe neonatal hypoglycemia o Hepatomegaly o Cardiomyopathy o Exercise intolerance o Frequent episodes of myalgia o Recurrent rhabdomyolysis induced by exercise, fasting or illness **AND** • Member is not currently taking a pancreatic lipase inhibitor (such as orlistat) AND • Member does not have a diagnosis of pancreatic insufficiency AND • The requested drug will not be administered through a feeding tube made of PVC.	
DOPTELET (avatrombopag) **DOPTELET SPRINKLE (avatrombopag)**	**Doptelet** (avatrombopag) may be approved if meeting the following criteria for the prescribed indication: <u>Treatment of Thrombocytopenia with Chronic Liver Disease (CLD):</u> • Member is prescribed Doptelet tablet formulation and is 18 years of age or older AND • Member has a confirmed diagnosis of thrombocytopenia with chronic liver disease and is scheduled to undergo an elective procedure AND • Member has trial and failure of Mulpleta (lusutrombopag). Failure is defined as a lack of efficacy, allergy, intolerable side effects, or significant drug-drug interactions AND • Prescribed dosing does not exceed 5 day supply per procedure. <u>Treatment of Thrombocytopenia with Persistent or Chronic Immune Thrombocytopenia (ITP):</u> • Member is an adult ≥ 18 years of age with a documented diagnosis of chronic immune thrombocytopenia or a pediatric patient 1 to 17 years of age with a documented diagnosis of persistent or chronic immune thrombocytopenia AND • The request meets one of the following: o For members ≥ 6 years of age, the prescribed medication is Doptelet tablet formulation OR o For members 1 to 6 years of age, the prescribed medication is Doptelet Sprinkle granule formulation. AND • Member has trial and failure of Promacta (eltrombopag). Failure is defined as a lack of efficacy, allergy, intolerable side effects, or significant drug-drug interactions. <u>Quantity Limits</u>: Doptelet (avatrombopag) tablet: 40mg daily Doptelet Sprinkle (avatrombopag) granules: 20mg daily	One year

Drug Product(s)	Criteria	PA Approval Length
	Age Limits: Doptelet (avatrombopag) tablet: ≥ 6 years of age Doptelet Sprinkle (avatrombopag) granules: 1 to 6 years of age	
DOXEPIN TOPICAL PRODUCTS	**Prudoxin** and generic doxepin 5% cream may be approved if the member meets the following criteria: • Member is 18 years of age or older AND • Member has a diagnosis of moderate pruritis with atopic dermatitis or lichen simplex chronicus AND • Member has trial and failure‡ of one prescription-strength topical corticosteroid AND one topical immunomodulator product (see PDL for preferred products) **Zonalon** may be approved if member has trial and failed‡ either doxepin 5% cream or Prudoxin® and meets all of the following criteria. • Member has a diagnosis of moderate pruritis with atopic dermatitis or lichen simplex chronicus AND • Member has trial and failure‡ of one prescription-strength topical corticosteroid AND one topical immunomodulator product (see PDL for preferred products) Quantity Limit for Topical Doxepin Products: 8 day supply per 30-day period ‡Failure is defined as: lack of efficacy of a three-month trial, allergy, intolerable side effects or significant drug-drug interaction.	One year
DUVYZAT (givinostat)	**Duvyzat** (givinostat) may be approved if the following criteria are met: • Member is ≥ 6 years of age AND • Member has a diagnosis of Duchenne Muscular Dystrophy (DMD) and is ambulatory AND • Member is on a stable dose of corticosteroids AND • Requested medication is being prescribed by or in consultation with a neurologist or a provider who specializes in treatment of DMD (such as a cardiologist, pulmonologist, or physical medicine and rehabilitation physician) AND • Prescriber confirms that prior to initiating Duvyzat (givinostat) therapy, ambulatory function has been assessed and documented based on the 4-step Climb Test (4SC) or similar motor function test used for DMD AND • Prescriber confirms that a baseline triglyceride level has been drawn prior to initiation of Duvyzat (givinostat) and that triglycerides will be monitored at 1 month, 3 months, 6 months, and then every 6 months thereafter following initiation of therapy AND • Prescriber confirms that a baseline platelet count of >150 x 109/L has been confirmed prior to initiation of Duvyzat (givinostat) and that blood counts will be monitored every 2 weeks for the first 2 months of treatment, then monthly for the first 3 months, and every 3 months thereafter AND • Prescriber confirms that a baseline ECG has been performed if member has underlying cardiac disease OR if member is taking concurrently taking medication(s) that cause QT prolongation AND • Prescriber acknowledges that Duvyzat (givinostat) should be discontinued if the following clinical situations arise:	Initial: 6 months Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	○ Hematological abnormalities worsen despite Duvyzat (givinostat) dose modification(s) per product labeling OR ○ Triglycerides remain elevated despite adequate dietary intervention and Duvyzat (givinostat) dose modification(s) per product labeling OR ○ Moderate or severe diarrhea persists despite Duvyzat (givinostat) dose modification(s) per product labeling OR ○ QTc interval is > 500 ms OR the QTc change from pre-treatment baseline is > 60 ms Maximum Dose: 53.2 mg (6 mL) twice daily Initial Approval: 6 months Reauthorization: The member may receive approval for one year for continuation of therapy if the following criteria are met: • Member has shown no clinically significant or intolerable adverse effects related to Duvyzat (givinostat) treatment AND • Member demonstrates response to Duvyzat (givinostat) treatment with clinical improvement in trajectory from the baseline assessment in ambulatory function conducted prior to initiation of Duvyzat (givinostat) therapy (see bullet point 5 of the initial authorization criteria).	
EGRIFTA (tesamorelin acetate)	**Egrifta** or **Egrifta SV** will be approved if all the following criteria is met: • Must be prescribed in consultation with a physician who specializes in HIV/AIDS AND • Member is 18 years of age or older AND • Member has a diagnosis of HIV-related lipodystrophy with excess abdominal fat meeting the following criteria: ○ Male member must have a waist circumference of at least 95cm (37.4in) and a waist to hip ratio of at least 0.94 OR ○ Female member must have a waist circumference of at least 94cm (37in) and a waist to hip ratio of at least 0.88 AND ○ Baseline waist circumference and waist to hip ratio must be provided • Member is currently receiving highly active antiretroviral therapy including protease inhibitors, nucleoside reverse transcriptase inhibitor, or non-nucleoside reverse transcriptase inhibitors AND • Member does not have a diagnosis of hypophysectomy, hypopituitarism, pituitary surgery, head irradiation or head trauma AND • Member does not have any active malignancy or history of malignancy AND • For women of childbearing potential, member must have a negative pregnancy test within one month of therapy initiation	6 months
ELESTRIN GEL (estradiol)	A prior authorization will only be approved if a member has tried and failed on generic oral estradiol therapy and diagnosed with moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause. Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions. Members currently stabilized on Elestrin (estradiol) gel may receive approval to continue treatment with that medication.	One year
ELFABRIO (pegunigalsidase alfa)	**Elfabrio** (pegunigalsidase alfa) may be approved if the following criteria are met: • For billing under the pharmacy benefit, medication is being administered in the member's home or in a long-term care facility (LTCF) by a healthcare professional AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Member is ≥ 18 years of age AND • Member has a confirmed diagnosis of Fabry disease AND • The medication is being prescribed by or in consultation with a neurologist or metabolic disease provider AND • Member has an eGFR ≥ 30 mL/min AND • Member has been counseled regarding use of highly effective contraceptive method(s) while receiving treatment. Maximum dose: 1 mg/kg every two weeks, based on actual body weight	
EMFLAZA (deflazacort)	**Emflaza** (deflazacort) may be approved if all the following criteria are met: • Member is at least 2 years of age or older AND • Member has diagnosis of Duchenne muscular dystrophy and a documented mutation in the dystrophin gene AND • Member must have documented (per claims history or provider notes) adequate trial and/or failure to prednisone therapy, adequate trial duration is at least three month. (Failure is defined as a lack of efficacy, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions) AND • The medication is prescribed by or in consultation with a physician who specializes in the treatment of Duchenne muscular dystrophy and/or neuromuscular disorders. AND • Serum creatinine kinase activity at least 10 times the upper limit of normal at some stage in their illness AND • Absence of active infection including tuberculosis and hepatitis B virus Maximum dose: 0.9mg/kg daily for tablets and suspension (may be rounded up to nearest ml)	One year
EMPAVELI (pegcetacoplan)	**Empaveli** (pegcetacoplan) may be approved if all of the following criteria are met: • Member is 18 years of age or older AND • Medication is being administered in the member's home or in a long-term care facility by a healthcare professional OR the member has received proper training for administration of subcutaneous infusion AND • Member is not pregnant AND • Member has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) confirmed by high-sensitivity flow cytometry AND • Member has received vaccination against encapsulated bacteria (such as *Streptococcus pneumoniae, Neisseria meningitidis*, and *Haemophilus influenzae* type b) at least 2 weeks prior to initiation of Empaveli therapy, unless treatment cannot be delayed OR if the vaccines were administered within the last 2 weeks, member has received 2 weeks of antibacterial drug prophylaxis AND • Member does not have any active infections caused by encapsulated bacteria (such as *Streptococcus pneumoniae*, *Neisseria meningitidis* types A, C, W, Y, and B, and *Haemophilus influenzae* type b) AND • Member has a baseline lactate dehydrogenase result available and is being monitored by prescriber AND • Empaveli is not being used in combination with Soliris (eculizumab), Ultomiris (ravulizumab-cwvz), or other medications to treat PNH (with exception of combination used during interval for switching between products) AND	One year

<table>
<tr><th>Drug Product(s)</th><th>Criteria</th><th>PA Approval Length</th></tr>
<tr><td></td><td>

Empaveli is being prescribed by, or in consultation with, a hematologist, immunologist, or nephrologist AND
Prescriber is enrolled in the Empaveli Risk Evaluation and Mitigation Strategy (REMS) program.

Maximum dose: 1,080 mg (1 single-dose vial) every three days
</td><td></td></tr>
<tr><td>EMVERM (mebendazole)</td><td>
Table 1: Emverm FDA Approved Dosing and Duration in Adults and Children
<table>
<tr><th>Diagnosis</th><th>Dose</th><th>Duration</th><th>Quantity Limits</th></tr>
<tr><td>Ancylostoma duodenale or Necator americanus (hookworm)</td><td>100 mg twice daily</td><td>3 consecutive days, may be repeated in 3 weeks in needed.</td><td>6 tablets/member</td></tr>
<tr><td>Ascariasis (roundworm)</td><td>100 mg twice daily</td><td>3 consecutive days, may be repeated in 3 weeks if needed.</td><td>6 tablets/member</td></tr>
<tr><td>Enterobiasis (pinworm)</td><td>100 mg once</td><td>May give second dose in three weeks if needed.</td><td>2 tablets/member</td></tr>
<tr><td>Trichuriasis (whipworm)</td><td>100 mg twice daily</td><td>3 consecutive days, may be repeated in 3 weeks in needed.</td><td>6 tablets/member</td></tr>
</table>
Emverm (mebendazole) will be approved for members that meet the following criteria:

Member is 2 years or older AND
Member has a diagnosis of one of the following: Ancylostoma duodenale or Necator americanus (hookworm), Ascariasis (roundworm), Enterobiasis (pinworm), or Trichuriasis (whipworm) AND
Member has failed a trial of albendazole for FDA approved indication and duration (Table 1) (Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) AND
For diagnoses other than pinworm, Emverm is being prescribed by an infectious disease specialist AND
Female members have a negative pregnancy test AND
Emverm® Is being prescribed in accordance to FDA dosing and duration (Table 1)

Quantity limits: Based on indication (Table 1)
</td><td>See Table</td></tr>
<tr><td>ENSPRYNG (satralizumab-mwge)</td><td>
Enspryng (satralizumab-mwge) may be approved if meeting the following criteria:

Member is an adult (≥ 18 years of age) AND
Member has a documented diagnosis of neuromyelitis optica spectrum disorder (NMOSD) that includes a positive serologic test for anti-aquaporin-4 (AQP4) antibodies AND
Member has a past medical history of at least one of the following:

Optic neuritis

</td><td>Initial: 6 months

Continued: One year</td></tr>
</table>

Drug Product(s)	Criteria	PA Approval Length
	○ Acute myelitis ○ Area postrema syndrome; episode of otherwise unexplained hiccups or nausea and vomiting ○ Acute brainstem syndrome ○ Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions ○ Symptomatic cerebral syndrome with NMOSD-typical brain lesions **AND** • Member does not have any active infections, including localized infections **AND** • Member does not have active Hepatitis B infection, as confirmed by negative surface antigen [HBsAg] and anti-HBV tests **AND** • Member does not have active or untreated latent tuberculosis **AND** • Provider confirms that member has a baseline Liver Function Panel drawn prior to initiation of ENGSPYNG treatment and member does not has an AST or ALT level greater than 1.5 times the upper limit of normal **AND** • Provider confirms that neutrophil counts will be checked 4 to 8 weeks after initiation of ENSPRYNG therapy, and thereafter at regular clinically determined intervals to monitor for decreased neutrophil counts **AND** • Provider has screened for immunizations the member is due to receive according to immunization guidelines **AND** • Any live or live-attenuated vaccines will be administered at least 4 weeks prior to initiation of ENSPRYNG **AND** • Any non-live vaccines will be administered at least 2 weeks prior to initiation of ENSPRYNG (whenever possible) **AND** • ENSPRYNG is prescribed by or in conjunction with a neurologist. Reauthorization: After receiving initial six month approval, EYNSPRYNG (satralizumab-mwge) may be approved for one year if the following criteria: • Member has shown no adverse effects to ENGSPYNG treatment at a maintenance dose of 120 mg subcutaneously every 4 weeks **AND** • Member does not have any active infections (including localized infections) **AND** • Member does not have an AST or ALT level greater than 1.5 times the upper limit of normal **AND** • Provider confirms that neutrophil counts are currently within normal limits and will continue to be monitored at clinically determined intervals during ENSPRYNG therapy. Maximum dose: 120 mg subcutaneously every 2 weeks for three doses, followed by 120 mg subcutaneously every 4 weeks maintenance dose.	
EOHILIA (budesonide)	**Eohilia** (budesonide) oral suspension may be approved if the following criteria are met: • Member is ≥ 11 years of age AND • Member has a documented diagnosis of eosinophilic esophagitis (EoE), AND • Member is following appropriate dietary therapy interventions AND • Medication is being prescribed by or in consultation with a gastroenterologist, allergist or immunologist AND • Because the use of corticosteroids may cause a reduction of growth velocity, the growth of pediatric patients who are taking Eohilia (budesonide) will be monitored AND • Member (or parent/caregiver) has been counseled regarding the following:	One year (one 12-week treatment course)

Drug Product(s)	Criteria	PA Approval Length
	○ Eohilia (budesonide) should not be given along with food or liquid AND ○ The member should not eat or drink for at least 30 minutes after each dose AND ○ After each dose, to rinse mouth with water and spit out contents without swallowing AND ○ To avoid consumption of grapefruit juice for the duration of therapy. Maximum dose: 4 mg (20 mL)/day Maximum quantity: 60 unit-dose packets/30 days Approval will be limited to one 12-week treatment course per year	
ERECTILE DYSFUNCTION OR SEXUAL DYSFUNCTION PRODUCTS Caverject, Cialis, Edex, Imvexxy, Levitra, Muse, Viagra, Addyi, Osphena, Premarin Cream, Sildenafil, Tadalafil (generic Cialis), Staxyn, Stendra, Xiaflex, Yohimbine	Medications prescribed for use for erectile dysfunction or other sexual dysfunction diagnoses are not covered (these medications may be eligible for approval only when prescribed for other FDA-labeled or medically accepted indications). **Yohimbine** prior authorization may be approved for use as a mydriatic agent or a vasodilator (not related to erectile dysfunction). Prior authorizations for use of yohimbine for erectile dysfunction will not be approved. **Sildenafil** prior authorization may be approved for off-label use for Raynaud's disease.	See criteria Do not qualify for emergency 3 day supply
ERTACZO (sertaconazole nitrate)	**Ertaczo** (sertaconazole nitrate) cream may be approved if the following criteria are met: • Member is ≥ 12 years of age AND • Member is immunocompetent AND • Member has a diagnosis of interdigital tinea pedis caused by Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum AND • Medication is being prescribed by or in consultation with a dermatologist or infectious disease specialist AND • Member has trialed and failed‡ at least three of the following ○ Clotrimazole ○ Miconazole ○ Terbinafine ○ Tolnaftate ○ Ketoconazole ○ Itraconazole ○ Fluconazole AND • Member has been counseled to dry the affected area(s) thoroughly before application of Ertaczo (sertaconazole) cream after bathing. Quantity limit: one 60 gram tube per 30 days	6 months

Drug Product(s)	Criteria	PA Approval Length
	‡Failure is defined as lack of efficacy with a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction.	
ESBRIET (pirenidone)	**Esbriet** (pirenidone) may be approved if the following criteria are met: • Member has been diagnosed with idiopathic pulmonary fibrosis AND • Is being prescribed by or in conjunction with a pulmonologist AND • Member is 18 years or older AND • Member has baseline ALT, AST, and bilirubin prior to starting therapy AND • Member does not have severe (Child Pugh C) hepatic impairment, severe renal impairment (Crcl<30 ml/min), or end stage renal disease requiring dialysis AND • Female members of reproductive potential must have been counseled regarding risk to the fetus AND • Member is not receiving a strong CYP1A2 inducer (such as carbamazepine, phenytoin, rifampin).	One year
EVKEEZA (evinacumab)	**Evkeeza** (evinacumab) may be approved if the following criteria are met: • For billing under the pharmacy benefit, the requested medication is being administered in the member's home or in a long-term care facility (LTCF) by a healthcare professional AND • Member is ≥ 5 years of age AND • Member has a diagnosis of homozygous familial hypercholesterolemia (HoFH) AND • The requested drug is being prescribed by, or in consultation with a cardiologist, Certified Lipid Specialist (CLS) or an endocrinologist AND • Member has failed to achieve desired LDL-C with three months of maximally tolerated therapy with one high-potency statin (atorvastatin or rosuvastatin) in combination with ezetimibe. Failure is defined as lack of efficacy (member with ASCVD and LDL-C >55 mg/dL or member with HoFH and LDL-C >100 mg/dL), allergy, intolerable side effects, contraindication, or significant drug-drug interaction. For members with past or current incidence of rhabdomyolysis, trial and failure of statin therapy is not required AND • Member has trialed and failed therapy with a PCSK9 inhibitor (alirocumab or evolocumab). Failure is defined as lack of efficacy after a 3-month trial, allergy, intolerable side effects, contraindication, or significant drug-drug interaction AND • Member is not pregnant and members of reproductive potential have been counseled regarding use of effective contraception during and for 5 months following treatment. Note: The safety and effectiveness of Evkeeza (evinacumab) have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH). <u>Reauthorization</u>: Reauthorization may be approved for 1 year with provider attestation confirming efficacy in lowering LDL-C.	One year
EVRYSDI (risdiplam)	**Evrysdi** (risdiplam) may be approved if the following criteria are met: • Member has documented diagnosis of 5q-autosomal recessive spinal muscular atrophy (SMA) by genetic testing and SMN1 mutation (two or more SMN2 gene copies must be specified) **AND**	15 months

<table>
<tr><th>Drug Product(s)</th><th>Criteria</th><th>PA Approval Length</th></tr>
<tr><td></td><td>

Treating and prescribing provider(s) is a neurologist or pediatrician experienced in treatment of SMA AND
The prescriber attests that the member will be assessed by <u>at least one</u> of the following exam scales at baseline and during subsequent office visits:

Hammersmith Infant Neurological Examination Module 2 (HINE2)
Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
Hammersmith Functional Motor Scale Expanded (HFMSE)
Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III)
Motor Function Measure (MFM-32)
Revised Upper Limb Module (RULM)

AND
Prior to the start of EVRYSDI treatment, the provider attests that the member meets all of the following:

Female members of childbearing potential have a documented negative pregnancy test within 2 weeks of initiating EVRYSDI therapy AND
Female members of childbearing potential have been instructed to use effective contraception during treatment with EVRYSDI and for at least 1 month after discontinuing treatment AND
Male members have been advised prior to initiation of therapy that their fertility may be compromised while being treated with EVRYSDI AND
Baseline liver function panel has been drawn and does not indicate hepatic impairment (EVRYSDI is extensively metabolized by the liver) AND
Drug-drug interactions including (but not limited to) MATE substrates such as metformin, cimetidine, and acyclovir, have been screened for, addressed if needed, and will be continually monitored

AND
The following criteria are met:

The member is not on a treatment plan that includes concomitant or previous treatment with ZOLGENSMA (onasemnogene abeparvovec-xioi) AND
The member is not receiving concomitant treatment with SPINRAZA (nusinersen) OR the member was treated with SPINRAZA previously and had to discontinue use due to lack of efficacy, allergy, intolerable side effects, or a contraindication to receiving intrathecal injections AND
The member’s weight is provided and meets recommended daily dosing:

<table>
<tr><th>Age and Body Weight</th><th>Recommended Daily Dosage</th></tr>
<tr><td>2 months to less than 2 years of age</td><td>0.2 mg/kg</td></tr>
<tr><td>2 years and older, weighing less than 20 kg</td><td>0.25 mg/kg</td></tr>
<tr><td>2 years and older, weighing 20 kg or more</td><td>5 mg</td></tr>
</table>
Reauthorization criteria: After 15 months, members may receive approval to continue therapy if the following criteria are met:

The member has shown no adverse events to EVRYSDI treatment AND
The member has demonstrated response to treatment by showing significant clinical improvement or no decline documented using quantitative scores using the same exam scale(s) used prior to initiating EVRYSDI treatment (please see number 4 of initial authorization criteria). Improvement of SMA-related symptoms must be compared to

</td><td></td></tr>
</table>

<table>
<tr><th>Drug Product(s)</th><th>Criteria</th><th>PA Approval Length</th></tr>
<tr><td></td><td>the baseline assessment and motor function must be measured against the degenerative effects of SMA AND
• The prescriber provides the following information:
o A brief explanation, including the provider name, must be submitted if a provider other than the one who initially performed the motor exam completes any follow-up exam(s) AND
o A brief explanation must be submitted if an exam scale other than the scale used for initial authorization is used for reassessment AND
o The member does not have hepatic impairment AND
o Member weight is provided and meets recommended daily dosing:

<table><tr><th>Age and Body Weight</th><th>Recommended Daily Dosage</th></tr><tr><td>2 months to less than 2 years of age</td><td>0.2 mg/kg</td></tr><tr><td>2 years and older, weighing less than 20 kg</td><td>0.25 mg/kg</td></tr><tr><td>2 years and older, weighing 20 kg or more</td><td>5 mg</td></tr></table>
Maximum dose: 5mg/day

Above coverage standards will continue to be reviewed and evaluated for any applicable changes due to the evolving nature of factors including disease course, available treatment options, and available peer-reviewed medical literature and clinical evidence.</td><td></td></tr>
<tr><td>EXJADE (deferasirox)</td><td>Please see “Jadenu and Exjade”</td><td></td></tr>
<tr><td>EXONDYS 51 (eteplirsen)</td><td>Exondys 51 (eteplirsen) may be approved if the following criteria are met:
• For billing under the pharmacy benefit, medication is being administered in the member’s home or in a long-term care facility by a healthcare professional AND
• Member must have genetic testing confirming mutation of the Duchenne Muscular Dystrophy (DMD) gene that is amenable to exon 51 skipping AND
• Medication is prescribed by or in consultation with a neurologist or a provider who specializes in treatment of DMD (i.e. neurologist, cardiologist, pulmonologist, or physical medicine and rehabilitation physician) AND
• The member must be on corticosteroids at baseline or has a contraindication to corticosteroids AND
• If the member is ambulatory, functional level determination of baseline assessment of ambulatory function is required OR if not ambulatory, member must have a Brooke Upper Extremity Function Scale of five or less documented OR a Forced Vital Capacity (FVC) of 30% or more.

<u>Reauthorization</u>:
Provider attests that treatment with Exondys 51 (eteplirsen) is necessary to help member improve or maintain functional capacity based on assessment of trajectory from baseline for ambulatory or upper extremity function or Forced Vital Capacity (FVC).

<u>Maximum Dose</u>: 30 mg/kg per week (documentation of patient’s current weight with the date the weight was obtained)</td><td>Initial:
One year

Continued:
One year</td></tr>
</table>

Drug Product(s)	Criteria	PA Approval Length
	Above coverage standards will continue to be reviewed and evaluated for any applicable changes due to the evolving nature of factors including disease course, available treatment options, and available peer-reviewed medical literature and clinical evidence.	
EXTENCILLINE (benzathine benzylpenicillin)	Effective 5/9/24, the FDA-authorized imported drug due to shortage, Extencilline (benzathine benzylpenicillin), is eligible for coverage for Health First Colorado members. Claims submitted under the pharmacy benefit are eligible for coverage when administered by a healthcare professional in the member's home or in a long-term care facility.	.
FABHALTA (iptacopan)	**Fabhalta** (iptacopan) may be approved if the following criteria are met: • Member is ≥18 years of age AND • Member has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) confirmed by high-sensitivity flow cytometry AND • Member has an eGFR ≥30 mL/min AND • Member does not have severe hepatic disease (Child-Pugh Class C) AND • Member does not have any active infections caused by an encapsulated bacteria (such as Streptococcus pneumoniae and Neisseria meningitidis) AND • Member has received vaccination against encapsulated bacteria (such as Streptococcus pneumoniae and Neisseria meningitidis) at least 2 weeks prior to initiation of Fabhalta (iptacopan) therapy. If urgent iptacopan therapy is indicated in a patient who is not up to date with vaccines, or the vaccines were administered within the last 2 weeks, prescriber attests that the member will receive appropriate antibacterial drug prophylaxis and the vaccines will be administered as soon as possible AND • Requested product is being prescribed by or in consultation with a hematologist, immunologist or nephrologist AND • Member has residual anemia (hemoglobin < 10 g/dL) at baseline AND • Fabhalta (iptacopan) is not being used in combination with an anti-C5 complement inhibitor that is used to treat PNH AND • Member's medication profile does not indicate any clinically significant interactions with CYP2C8 inducers (such as rifampin, phenobarbital, phenytoin) or strong CYP2C8 inhibitors (such as gemfibrozil, clopidogrel, fluticasone) AND • Prescriber is enrolled in the Fabhalta Risk Evaluation and Mitigation Strategy (REMS) program. Quantity limit: 60 capsules/30 days Maximum dose: 400 mg/day <u>Reauthorization</u>: Reauthorization may be approved for 1 year with prescriber attestation that member's hemoglobin has increased by ≥2 g/dL from baseline while on Fabhalta (iptacopan) therapy.	Initial: 6 months Continued: One year
FERRIPROX (deferiprone)	**Ferriprox** (deferiprone) may be approved if the following criteria are met: • Must be prescribed in conjunction with a hematologist or oncologist AND • Member's weight must be provided AND • Ferriprox (deferiprone) is being prescribed for one of the following indications: o Treatment of transfusion-related iron overload in patients with thalassemia syndromes OR o Treatment of transfusion-related iron overload in patients with sickle cell disease or other anemias	One year

Drug Product(s)	Criteria	PA Approval Length
	AND • Member has an absolute neutrophil count > 1.5 x 109 AND • Member has failed or has had an inadequate response to Desferal (deferoxamine) AND Exjade (deferasirox) as defined by serum ferritin >2,500mcg/L before treatment with Ferriprox OR member has been intolerant to or experienced clinically significant adverse effects to Desferal (deferoxamine) or Exjade (deferasirox) such as evidence of cardiac iron overload or iron-induced cardiac dysfunction. Maximum dose: 99mg/kg/day	
FILSPARI (sparsentan)	**Filspari** (sparsentan) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of primary immunoglobulin A nephropathy (IgAN) and is at risk of rapid disease progression, AND • Member has a urine protein-to-creatinine ratio of ≥1.5 g/g AND • Member is not pregnant AND • Member does not have heart failure AND • Member has tried and failed† maximally tolerated dose of an immunosuppressant (such as corticosteroids, mycophenolate, tacrolimus, cyclosporine, leflunomide, cyclophosphamide, and azathioprine) AND • Member has tried and failed† maximally tolerated doses of an ACE inhibitor, angiotensin receptor blocker (ARB) or angiotensin receptor/neprilysin inhibitor (ARNI) AND • Member is not concurrently taking any of the following medications: o ACE inhibitor o Angiotensin receptor blocker (ARB) o Endothelin receptor antagonist (such as ambrisentan, atrasentan, bosentan) o Direct renin inhibitor (such as aliskiren) o Angiotensin receptor/neprilysin inhibitor (ARNI) AND • Provider attests that member's medication profile has been reviewed for drug interactions between Filspari (sparsentan) and strong/moderate CYP3A inhibitors, strong CYP3A inducers, CYP2B6 substrates, and other agents that may result in clinically significant interacting drugs, according to product labeling AND • Prior to initiation of Filspari (sparsentan) therapy, the member's hepatic aminotransferases (ALT, AST) are not greater than 3 times the upper limit of normal AND • Requested medication is being prescribed by or in consultation with a nephrologist or immunologist AND • Provider and patient or caregiver are aware that continued US FDA approval of Filspari (sparsentan) to slow kidney function decline in patients with IgAN may be contingent upon verification and description of clinical benefit in confirmatory trial(s). † Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. Maximum dose: 400 mg daily Quantity limits:	One year

Drug Product(s)	Criteria	PA Approval Length
	200mg: 14-day supply per fill maximum 400mg: 30 tablets per 30 days Continuation of Therapy: Members who are currently stabilized on the requested medication may receive approval to continue treatment on that medication.	
FILSUVEZ (birch triterpenes)	**Filsuvez** (birch triterpenes) may be approved if the following criteria are met: • Member is ≥ 6 months of age, AND • Member must have undergone testing confirming one of the following diagnoses and genetic mutations: o Dystrophic epidermolysis bullosa (DEB), based on mutation(s) in the collagen type VII alpha 1 chain (*COL7A1*) gene OR o Junctional epidermolysis bullosa (JEB), based on mutation(s) in the collagen type XVII gene (*COL17A1*), laminin 332 genes (*LAMA3, LAMB3 and LAMC2*), integrin α6β4 genes (*ITGA6 and ITGB4*) or the integrin α3 subunit (*IGTA3*) AND • The requested medication is being prescribed by or in consultation with a provider who has expertise in treating epidermolysis bullosa. Initial approval: Approval will be limited to one 90-day treatment course per one year. Reauthorization: Reauthorization requests for an additional treatment course of Filsuvez (birch triterpenes) will undergo clinical review by a call center pharmacist on a case-by-case basis and require provider submission of clinical information (such as documentation from medical chart notes) demonstrating re-epithelialization without drainage or complete closure of the treated wounds(s) has been observed during the prior treatment course with Filsuvez. Claims limitation: 15-day supply per fill, up to one tube daily	See criteria
FIRDAPSE (amifampridine)	**Firdapse** (amifampridine) may be approved for members meeting the following criteria: • Member is an adult ≥ 6 years of age AND • Member has a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) Maximum Dose: 80mg daily	One year
FLUORIDE PRODUCTS	Prescription fluoride products: • Prescription fluoride products will be approved for members less than 21 years of age without a prior authorization. • For members 21 years of age or older approval will be granted if using well water or living in an under-fluoridated area designated by the CDC*. • Approval for members not meeting these criteria will require a letter of necessity and will be individually reviewed. OTC fluoride products: • The following OTC fluoride products are eligible for prior authorization approval for all members using well water or living in an under-fluoridated area designated by the CDC*: fluoride chewable tablets, ludent fluoride chewable tablets, sodium fluoride 0.5mg/mL drops • Approval for members not meeting these criteria will require a letter of necessity and will be individually reviewed.	One year

Drug Product(s)	Criteria	PA Approval Length
	*Information and reports regarding water fluoridation can be found on the CDC website at: https://nccd.cdc.gov/DOH_MWF/Default/CountyList.aspx?state=Coloradateid=8&stateabbr=CO&reportLevel=2.	
FORZINITY (elamipretide)	**Forzinity** (elamipretide) may be approved if the following criteria are met: • Member is ≥ 12 years of age AND • Member weighs at least 30 kg AND • Member has a documented diagnosis of Barth Syndrome AND • Forzinity (elamipretide) is being prescribed by a cardiologist, pediatric cardiologist or genetics/metabolic physician AND • Provider has documented results at baseline of a 6-minute Walk Test (6MWT) and a Total Fatigue Score on the Barth Syndrome Symptom Assessment AND • Forzinity (elamipretide) dosing will be reduced according for product labeling for adults who have severe renal impairment (eGFR less than 30 mL/min) who are not on dialysis AND • Member or caregiver has received proper training for administration of Forzinity (elamipretide) subcutaneous injections AND • Member or caregiver has been instructed to store Forzinity (elamipretide) vials in the refrigerator. Maximum Dose: 40 mg/day Quantity Limit: One carton of four 280 mg vials/28 days Initial approval: Six months Reauthorization: Reauthorization may be approved for one year with provider attestation to improvement in both of the following assessments: • 6-minute Walk Test (6MWT) • Total Fatigue Score on the Barth Syndrome Symptom Assessment	Initial: 6 months Continued: One year
FUROSEMIDE CARTRIDGE for ON-BODY INFUSOR	Furosemide Cartridge for On-Body Infusor (Furoscix or Lasix ONYU) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a documented diagnosis of NYHA Class II/III chronic heart failure AND • Member has tried and failed† at least one of the following oral therapies: o furosemide ≥ 160 mg daily o torsemide 40 mg daily o bumetanide 4 mg daily AND • Member has tried and failed† the addition of oral metolazone to oral loop diuretic therapy AND • Prescriber confirms that the member has a history of at least one prior hospitalization or emergency department visit due to heart failure exacerbation and/or fluid overload AND • The requested medication is being prescribed by or in consultation with a cardiologist AND • Prescriber acknowledges that the requested medication is intended for short-term use in the outpatient setting AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Provider attests that member will be educated on proper infusor placement on the body, instructions for starting the infusion, and safe disposal of the used infusor device. Quantity limit: 7 pre-filled 80 mg cartridges plus infusors per 30 days †Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction.	
FUZEON (enfuvirtide)	If administered in the physician's office or delivered to physician's office, physician must bill as a medical claim on the 1500 claim form **(no PA required).** If administered in the member's home or in a long-term care facility, a prior authorization is required and must meet the criteria below for approval. Based on clinical trial data, ENF should be used as part of an *optimized* background regimen for treatment-experienced members: • For treatment-experienced members with evidence of HIV-1 replication, treatment should include at least one antiretroviral agent with demonstrated HIV-1 susceptibility on the basis of genotypic/phenotypic *resistance* assays, and *two* "active" antiretroviral agents. o Members must have limited treatment options among currently commercially available agents. • Members must be 18 years of age or older with advanced HIV-1 infection, and not responding to approved antiretroviral therapy. • Members must have a CD4 lymphocyte count less than 100 cells/mm3 and a viral load greater than 10,000 copies/ml (measurement within the last 90 days). Past adherence must be demonstrated based on: • Attendance at scheduled appointments, and/or • Prior antiretroviral regimen adherence, and/or • Utilization data from pharmacy showing member's use of medications as prescribed • Ability to reconstitute and self-administer ENF therapy. At 24 weeks, members must experience at least ≥ 1 $\log_{10}$ decrease in HIV RNA or have HIV RNA below quantifiable limits to continue treatment with ENF. Members are not eligible if antiretroviral treatment-naive and/or infected with HIV-2. Pre-approval is necessary Practitioner must either be Board Certified in Infectious Disease, or be an HIV experienced practitioner. Verification must be produced with the prior approval documents. **These guidelines may be modified on the basis of other payer formularies and/or the emergence of new data.**	Six months
GALAFOLD (migalastat hydrochloride)	**Galafold** (migalastat hydrochloride) prior authorization may be approved for members meeting the following criteria: ▪ Member is ≥ 12 years of age **AND** ▪ The medication is being prescribed by or in consultation with a neurologist **AND**	One year

Drug Product(s)	Criteria	PA Approval Length
	▪ Member has a confirmed diagnosis of Fabry's disease with an amenable galactose alpha gene (GLA) variant per in vitro assay data. (Amenable GLA variants are those determined by a clinical genetics professional as pathologic or likely pathologic) **AND** ▪ Member does not have severe renal impairment or end-stage renal disease requiring dialysis. Maximum dose: 123 mg once every other day	
GAMASTAN (immune globulin)	Pharmacy benefit prior authorization may be approved for FDA-labeled indications, dose, age, and role in therapy as outlined in package labeling for administration of the medication in the member's home or in a long-term care facility by a healthcare professional. Administration in a doctor's office, clinic, outpatient hospital, or dialysis unit are to be billed through the Health First Colorado medical benefit using the standard buy-and-bill process.	One year
GATTEX (teduglutide)	**Gattex** (teduglutide) may be approved if all of the following criteria are met: • Member is one year of age or older AND • Member has documented short bowel syndrome AND • Member is dependent on parenteral nutrition/intravenous support for twelve consecutive months AND • The prescribing physician is a gastroenterologist AND • Medical necessity documentation has been submitted for review and approval by pharmacy call center clinical staff (Phone: 1-800-424-5725; Fax: 1-888-424-5881) AND • The initial prior authorization will be limited to a two-month supply.	Two months initially; may be approved for up to one year
GENERIC MANDATE	<u>Brand Name Medications and Generic Mandate:</u> • Brand name drug products that have a therapeutically equivalent generic drug product (as determined by the FDA) will require prior authorization for brand product coverage and will be covered without a prior authorization if meeting one of the following exceptions: o The brand name drug is prescribed for the treatment of (and the prescriber has indicated dispense as written on the brand name prescription): ▪ Biologically based mental illness defined in 10-16-104 (5.5) C.R.S. ▪ Cancer ▪ Epilepsy ▪ HIV/AIDS o The Department has determined that the brand name product is lower cost than the therapeutically equivalent generic • Prior authorization for use of a brand name drug product that has a therapeutically equivalent generic (and does not meet exceptions above) may also be approved if: o The prescriber is of the opinion that a transition to the generic equivalent of the brand name drug would be unacceptably disruptive to the patient's stabilized drug regimen o The patient is started on the generic equivalent drug but is unable to continue treatment on the generic drug as determined by the prescriber	
GIMOTI (metoclopramide)	**Gimoti** (metoclopramide) may be approved for members meeting the following criteria: • Member is an adult (≥ 18 years of age) AND • Member has a confirmed diagnosis of acute or recurrent diabetic gastroparesis AND • Member has failed an adequate trial of metoclopramide solution. Failure is defined as allergy to inactive ingredients, inability to administer the solution through an	One year

Drug Product(s)	Criteria	PA Approval Length
	enteral route (such as nasogastric or percutaneous endoscopic gastrostomy routes), or intolerable side effects AND • Member does not have a history of tardive dyskinesia AND • Member has not been diagnosed with a parkinsonian syndrome (such as Parkinson's disease, progressive supranuclear palsy, multiple system atrophy, or corticobasal degeneration) AND • Member does not have moderate to severe liver disease (Child Pugh B or C) AND • Member does not have moderate or severe renal impairment (creatinine clearance less than 60 mL/min) AND • Member is not a known poor metabolizer of CYP2D6, which may contribute to a higher potential for metoclopramide toxicity, including dystonias AND • For members ≥ 65 years of age, the following additional criteria are met: o Gimoti (metoclopramide) is not being prescribed as initial therapy for diabetic gastroparesis AND o Member has been stabilized on treatment with an oral metoclopramide dose of 10mg four times a day for at least 30 days prior to switching to Gimoti (metoclopramide) AND o Prescriber acknowledges that exceeding 12 weeks of <u>total</u> metoclopramide therapy (from all dosage forms and routes of administration) should be avoided in members who are ≥ 65 years of age due to risk of developing tardive dyskinesia. Maximum dose: One spray (15 mg) four times daily Duration limit (for members ≥ 65 years of age): Limited to 12-week supply per year	
GLYCATE (glycopyrrolate)	**Glycate** (glycopyrrolate) may be approved for members meeting the following criteria: • Member is 18 years of age or older AND • Member has a diagnosis of peptic ulcer disease AND • Member <u>does not</u> have any of the following conditions: o Glaucoma o Obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy) o Obstructive disease of the gastrointestinal tract (such as achalasia, pyloroduodenal stenosis, etc.) o Paralytic ileus o Intestinal atony of the elderly or debilitated patient o Unstable cardiovascular status in acute hemorrhage o Severe ulcerative colitis o Toxic megacolon complicating ulcerative colitis o Myasthenia gravis AND • Member has tried and failed at least two proton pump inhibitors (failure is defined as lack of efficacy with 4 week trial, allergy, intolerable side effects, or significant drug-drug interaction) AND • Glycate (glycopyrrolate) is being used as adjunctive therapy AND • Glycate (glycopyrrolate) is being prescribed by or in consultation by a gastroenterologist	One year

Drug Product(s)	Criteria	PA Approval Length
HAIR GROWTH MEDICATIONS	Medications prescribed solely for use for hair growth, including when prescribed as treatment for alopecia areata, are excluded from coverage under the Health First Colorado pharmacy benefit.	
HEMADY (dexamethasone)	**Hemady** (dexamethasone) may be approved for members meeting the following criteria: • Member is an adult (≥18 years of age) AND • Member has a confirmed diagnosis of multiple myeloma (MM) AND • Hemady (dexamethasone) is being prescribed in combination with other anti-myeloma treatment agents AND • Member does not have pheochromocytoma AND • Members of childbearing potential have been advised to use effective contraception during treatment and for at least one month after the last dose AND • Member has trialed and failed generic dexamethasone tablets. Failure is defined as allergy or intolerable side effects. Maximum dose: 40 mg/day	One year
HIGH COST CLAIMS	Effective 5/1/2023, pharmacy claims exceeding $9,999.00 require prior authorization and are subject to meeting the following per FDA product package labeling for approval with pharmacist review of requests: • Diagnosis/use for FDA-labeled indication AND • Based on prescribed indication, prescription meets the following per label: o Dosing o Strength o Dosage form o Quantity o Days supply AND • If product is an IV formulation or product labeling indicates that the medication should be administered by a healthcare professional, must meet approval criteria for physician administered drugs (see "Physician Administered Drugs" section). The following drug categories are <u>not</u> subject (are exceptions) to the $9,999.00 claim limitation: • Products/drug classes listed on the Preferred Drug List (PDL) • Products/drug categories with PA criteria listed on the Appendix P • Oncology medications • Actimmune • Fabry disease treatments • Hemophilia treatments • Long-acting injectable antipsychotic medications • Medication-Assisted-Treatment (MAT) medications • Naloxone or Naltrexone • Medications used for the treatment or prevention of HIV	
Homozygous Familial Hypercholesterolemia (HoFH)	**Juxtapid** (lomitapide) may be approved if all of the following criteria are met: • Member is 18 years of age or older; • Member has documented diagnosis of homozygous familial hypercholesterolemia (HoFH); • Member has failed therapy with high dose statin therapy (e.g. atorvastatin 40mg or higher, Crestor 20mg or higher)	One year

Drug Product(s)	Criteria	PA Approval Length
	• The prescribing physician is enrolled in the Juxtapid REMS program. **Kynamro** (mipomersen) may be approved for members meeting all of the following criteria: • Confirmed diagnosis of homozygous familial hypercholesterolemia (HoFH) as determined by either a or b a. Laboratory tests confirming diagnosis of HoFH: LDLR DNA Sequence Analysis OR LDLR Deletion/Duplication Analysis for large gene rearrangement testing---only if the Sequence Analysis is negative OR APOB and dPCSK9 testing if both of the above tests are negative but a strong clinical picture exists. b. Documentation is received confirming a clinical or laboratory diagnosis of HoFH • Has a history of therapeutic failure, contraindication, or intolerance to high dose statin therapy or cholesterol absorption inhibitor (ezetimibe or bile acid resin) AND • Is being prescribed by a physician specializing in metabolic lipid disorders AND • The prescriber is enrolled in the REMS program AND • Is not being used as monotherapy AND • Has baseline liver function (AST, ALT, ALK, and total bilirubin) AND • Does not have moderate or severe hepatic impairment or active liver disease.	
HORMONE THERAPY	**Depo Provera** (medroxyprogesterone) **intramuscular** injectable suspension may be approved if meeting the following criteria: • The requested medication is being administered by a healthcare professional in the member's home or in a long-term care facility (claims for medications administered in a clinic or medical office are billed through the Health First Colorado medical benefit) AND • Prescribed use is for FDA-labeled indications or indications supported by or included in certain compendia described in section 1927(g)(1)(B)(i) of the Social Security Act. **Depo Provera** (medroxyprogesterone) **subcutaneous** injectable suspension does not require prior authorization and pharmacy claims are eligible for 12-month supply coverage *(effective 07/01/22).* **Implanon (etonogestrel)** See PHYSICIAN ADMINISTERED DRUGS. Not a covered pharmacy benefit when implanted in the clinic or hospital outpatient center. **Nexplanon (etonogestrel)** See PHYSICIAN ADMINISTERED DRUGS. Not a covered pharmacy benefit when implanted in the clinic or hospital outpatient center.	One year
ILUMYA (tildrakizumab-asmn)	**Ilumya** (tildrakizumab-asmn) prior authorization may be approved for members meeting all of the following criteria: • Medication is being administered in the member's home or in a long-term care facility by a healthcare professional AND • Member is 18 years of age or older and has diagnosis of moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy AND • Member does not have guttate, erythrodermic, or pustular psoriasis AND • Provider attests to:	Initial: 12 weeks Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	• Baseline Provider Global Assessment (PGA) score for plaque psoriasis severity of at least 3 (Scored 0-4, 4 being most severe) OR • Baseline Psoriasis Area and Severity Index (PASI) score of 12 or greater AND • Medication is being prescribed by or in conjunction with a rheumatologist, allergist, or dermatologist AND • Member has tried and failed‡ ALL preferred agents in the "Targeted Immune Modulators" PDL drug class that are FDA-labeled for use for the same prescribed indication AND • Initial authorization will be for 12 weeks Continued authorization for 12 months will require prescriber attestation to PGA score reduction of 2 or more points OR PASI score reduction of 75% OR prescriber attestation to clinically meaningful improvement with Ilumya® regimen. *Claims for medications administered in a clinic or medical office are billed through the Health First Colorado medical benefit.*	
IMAAVY (nipocalimab)	**Imaavy** (nipocalimab) may be approved if the following criteria are met: • For billing under the pharmacy benefit, medication is being administered in the member's home or in a long-term care facility (LTCF) by a healthcare professional AND • Prescriber acknowledges that doses administered by a healthcare provider in the doctor's office or clinic are to be billed through the Health First Colorado medical benefit through the standard buy-and-bill process AND • Member is ≥ 12 years of age AND • Member has a diagnosis of generalized myasthenia gravis that falls within Myasthenia Gravis Foundation of America (MGFA) Class II to IV disease AND • Member has a positive serologic test for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies AND • Requested product is being prescribed by or in consultation with a neurologist AND • A baseline Quantitative Myasthenia Gravis (QMG) assessment has been documented AND • Patient has a MG-Activities of Daily Living (MG-ADL) total score of ≥6 AND • Member has failed† treatment with one of the following: o Two concomitant immunosuppressive therapies for at least 1 year OR o Immunosuppressive therapy in combination with plasmapheresis or plasma exchange or IVIG AND • As a precaution, prescriber has considered discontinuation of Imaavy (nipocalimab) and using alternative therapies in members receiving long-term therapy with medications that bind to the human Fc receptor (such as IVIG, other immunoglobulins, or other C5 complement inhibitors). <u>Reauthorization</u>: Reauthorization for one year may be approved if meeting all of the following: • Member has increase from baseline in Quantitative Myasthenia Gravis (QMG) assessment and/or MG-Activities of Daily Living (MG-ADL) score AND • Member has demonstrated improvement in muscle strength with fatigue maneuvers from baseline AND • Member has not experienced any treatment restricting adverse effects.	Initial: 6 months Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	† Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.	
INZIRQO (hydrochlorothiazide)	**Inzirqo** (hydrochlorothiazide) powder for oral suspension may be approved if the following criteria are met: • Member is ≥ 6 months of age AND • Prescriber attests that the member cannot take a solid oral hydrochlorothiazide dosage form. Maximum dose: < 2 years of age: 37.5 mg/day 2 years of age and older: 100 mg/day Maximum quantity: 4 bottles of 800 mg oral powder for reconstitution/ month	One year
IQIRVO (elabranor)	**Iqirvo** (elafibranor) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of primary biliary cholangitis and meets one of the following: o Combined therapy: Requested medication will be used in combination with ursodiol (ursodeoxycholic acid) if the member had an inadequate response (lack of efficacy) following at least one year of treatment with ursodiol (ursodeoxycholic acid) alone OR o Monotherapy: Requested medication will be used as monotherapy in members who have trialed and failed ursodiol (ursodeoxycholic acid) therapy. Failure is defined as allergy, intolerable side effects, or significant drug-drug interaction AND • Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant provider AND • Laboratory tests to evaluate ALT, AST, alkaline phosphatase and total bilirubin will be performed at baseline and during treatment with Iqirvo (elafibranor), according to product labeling AND • Prior to initiating therapy, the member does NOT have an elevated creatine phosphokinase (CPK) and/or signs/symptoms of muscle pain or myopathy, and prescriber attests that these parameters will be monitored throughout treatment with Iqirvo (elafibranor) AND • Member does not have complete biliary obstruction, cirrhosis, or other types of liver disease AND • Members without serologic evidence of immunity have received hepatitis A and hepatitis B vaccinations AND • Prescriber has considered the risk of fracture in members treated with Iqirvo (elafibranor) AND • Prescriber has counseled member to abstain from alcohol or avoid heavy alcohol use AND • Prescriber attests that a pre-treatment pregnancy test will be performed, and that members of reproductive potential will be advised to switch to effective non-hormonal contraceptives OR add a barrier method when using hormonal contraceptives and for at least 3 weeks after last dose of Iqirvo (elafibranor) AND	Initial: 6 months Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	• Prescriber attests that members of reproductive potential will be advised to avoid breastfeeding during treatment and for 3 weeks after last dose of Iqirvo (elafibranor) AND • Prescriber attests the member has been counseled that the approval and safety status of Iqirvo (elafibranor) is based on reduction of alkaline phosphatase. Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Maximum Dose: 80 mg/day Maximum Quantity: 30 tablets/30 days Initial Approval: 6 months Reauthorization: Member may receive approval for one year with provider attestation that a biochemical response (such as an alkaline phosphatase level less than 1.67-times the upper limit of normal) has been observed after 6 months of therapy.	
ISTURISA (osilodrostat)	**Isturisa** (osilodrostat) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of Cushing's disease AND • Pituitary surgery is not an option or the member had surgery and it was not curative AND • The requested drug is being prescribed by, or in consultation with, an endocrinologist AND • For initial dose titrations, one of the following are met: o If the member has moderate hepatic impairment, the starting dose is 1 mg twice daily OR o If the member has severe hepatic impairment, the starting dose is 1 mg once daily in the evening. Maximum Dose: 60 mg/day	One year
JADENU and EXJADE (deferasirox)	**Jadenu** (deferasirox) or **Exjade** (deferasirox) may be approved for members that meet the following criteria: • Must be prescribed in conjunction with a hematologist or oncologist AND • Member's weight must be provided AND • Member has a diagnosis for chronic iron overload due to blood transfusion AND • Member is 2 years of age or older AND • Member has consistently high serum ferritin levels > 1000 mcg/L (demonstrated by at least 2 values in the prior three months OR • Member has a diagnosis for chronic iron overload due to non-transfusion dependent thalassemia syndromes AND • Member is 10 years of age or older AND • Member has liver iron levels > 5 mg iron per gram of dry weight and serum ferritin levels > 300 mcg/L document in the prior three months	One year

Drug Product(s)	Criteria	PA Approval Length
	Members must also meet the following additional criteria for all Jadenu and Exjade approvals: • Member does not have advanced malignancies and/or high-risk myelodysplastic syndromes AND • Member has a creatinine clearance > 40 ml/min AND • Member has a platelet count > 50 x 10^9/L Maximum Dosing: Maximum dose of Jadenu (deferasirox): 28mg/kg/day Maximum dose of Exjade (deferasirox): 40mg/kg/day	
JASCAYD (nerandomilast)	**Jascayd** (nerandomilast) may be approved if the following criteria are met: • Member is ≥18 years of age AND • Member has been diagnosed with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis AND • The requested medication is being prescribed by or in conjunction with a pulmonologist AND • Member has trialed and failed treatment with nintedanib or pirfenidone. Failure is defined as defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND • Baseline ALT, AST, and bilirubin tests have been performed prior to starting therapy AND • Member does not have severe (Child Pugh C) hepatic impairment AND • Members of reproductive potential must have been counseled regarding risk to the fetus and to avoid becoming pregnant while receiving treatment with Jascayd (nerandomilast) AND • If member is breastfeeding, potential adverse effects on the breastfed infant have been considered along with the mother's clinical need for with Jascayd (nerandomilast) therapy AND • Member is not concurrently taking a strong CYP3A4 inducer (such as carbamazepine, phenytoin, rifampin) AND • Member is not concurrently taking a strong CYP3A4 inhibitor (such as clarithromycin, itraconazole, ketoconazole, posaconazole, ritonavir, voriconazole) AND • Provider attests that the dose of Jascayd (nerandomilast) will be appropriately reduced per product labeling for members who are concurrently taking a moderate CYP3A4 inhibitor (such as diltiazem, erythromycin, fluconazole, grapefruit, verapamil). Quantity Limit: 60 tablets/30 days Continuation of Therapy: Members who are currently stabilized on Jascayd (nerandomilast) may receive approval for continuation of therapy with that agent.	One year
JESDUVROQ (daprodustat)	**Jesduvroq** (daprodustat) may be approved if meeting the following criteria: • Member is 18 years of age or older AND • Member has chronic kidney disease (CKD) and has been receiving dialysis for at least four months AND • Member is not taking a strong CYP2C8 inhibitor (such as gemfibrozil) AND • Member does not have uncontrolled hypertension, AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Laboratory tests to evaluate ALT, AST, alkaline phosphatase, total bilirubin, hemoglobin and iron status will be performed at baseline and during treatment with Jesduvroq (daprodustat), according to product labeling, AND • The requested medication is not being prescribed as a substitute for red blood cell transfusions in patients who require immediate correction of anemia AND • The requested medication is not being prescribed for treatment of anemia of chronic kidney disease in patients who are not on dialysis AND • For members NOT being treated with an erythropoiesis stimulating agent (ESA), initial dosing will be based on the baseline hemoglobin level (g/dL) per product labeling AND • For members being switched from an ESA to Jesduvroq (daprodustat) therapy, the starting dose will be based on the dose of the ESA at the time of the switch. Maximum dose: 24 mg/day	
JOENJA (leniolisib)	**Joenja** (leniolisib) may be approved if the following criteria are met: • Member is ≥ 12 years of age and weighs at least 45 kg AND • Member has been diagnosed with activated phosphoinositide 3-kinase delta (PI3K-delta) syndrome (APDS) with a documented variant in either PIK3CD or PIK3R1 AND • Requested product is being prescribed by or in consultation with an immunologist AND • Member does not have moderate to severe hepatic impairment AND • Member is not pregnant AND • Member has not received a B-cell depleting medication within 6 months of starting leniolisib therapy AND • Member has not received an immunosuppressive medication or another PI3K-delta inhibitor within 6 weeks of starting leniolisib therapy AND • Members of reproductive potential have been advised to avoid breastfeeding and to use effective contraception during and after treatment with Joenja (leniolisib) in accordance with FDA product labeling. Maximum dose: 140 mg/day Quantity limit: 60 tablets/30 days	One year
JYNARQUE (tolvaptan)	**Jynarque** (tolvaptan) may be approved if the following criteria are met: • Member is an adult (≥ 18 years of age) AND • Member has a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) and is at risk for rapid disease progression AND • Medication is being prescribed by a nephrologist AND • Member does not have a history or sign/symptoms of significant liver impairment or injury (uncomplicated polycystic liver disease is not a contraindication for therapy) AND • Member is not taking a strong Cytochrome 3A inhibitor (such as erythromycin, clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, fluconazole, voriconazole, lopinavir/ritonavir, indinavir/ritonavir, ritonavir, conivaptan, delavirdine and milk thistle) AND • Member is not using desmopressin (dDAVP) AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• If member is taking a moderate Cytochrome 3A inhibitor (such as erythromycin, fluconazole, or verapamil) JYNARQUE (tolvaptan) will be prescribed at a reduced dose AND • Member has normal blood sodium concentrations, is able to sense or respond to thirst, and has a normal blood volume AND • Member does not have urinary outflow obstruction or anuria Maximum Dosing: 120mg per day	
KALYDECO (ivacaftor)	**Kalydeco** (ivacaftor) may be approved if all of the following criteria are met: • Member has been diagnosed with cystic fibrosis AND • Member is an adult or pediatric patient 1 month of age or older AND • Documentation has been provided to indicate one of the following gene mutation: in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, R117H, S549R or another FDA approved gene mutation.* AND • Documentation has been provided that baseline ALT and AST have been accessed and are within 2x normal limits (AST and ALT should be examined every 3 months for the first year and annually after that). * If the member's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. The requested medication will only be approved at doses no more than 150 mg twice daily. Prior Authorizations need to be obtained yearly. The requested medication will not be approved for members who are concurrently receiving rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, or St. John's Wort.	One year
KERENDIA (finerenone)	**Kerendia** (finerenone) may be approved if the following criteria are met: • Member meets the following criteria based on prescribed indication: Chronic Kidney Disease with T2DM: o Member is ≥ 18 years of age AND o Member has a diagnosis of chronic kidney disease associated with type 2 diabetes and both of the following: ▪ Urinary albumin-to-creatinine ratio > 30 mg/day ▪ eGFR ≥ 25 mL/min/1.73m2 AND o Member is receiving concomitant therapy with either a maximally tolerated ACE inhibitor or ARB unless member has trialed and failed at least 30 days of an ACE inhibitor or ARB therapy or has an allergy, intolerance, or contraindication AND o Members with an eGFR >20 mL/min/1.73m2 are receiving concomitant therapy with a SGLT2 Inhibitor, unless member has an allergy, intolerance, or contraindication to a SGLT2 inhibitor AND o Provider attests that serum potassium is <5 mEq/L prior to initiation of therapy AND that serum potassium will be monitored. Heart Failure with Preserved or Mid-Range Ejection Fraction:	One year

Drug Product(s)	Criteria	PA Approval Length
	○ Member is 18 years of age or older AND ○ Member has a diagnosis of heart failure with preserved or mid-range ejection fraction (LVEF ≥ 40%) with NYHA class II-IV and meets all of the following: ▪ Member has trialed and failed spironolactone or eplerenone. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction AND ▪ Members with an eGFR >20 mL/min/1.73m2 are receiving therapy with a preferred SGLT2 inhibitor, unless member has an allergy, intolerance, or contraindication AND ▪ Member has had at least one prior hospitalization for worsening heart failure. Maximum dose: 40 mg/day Maximum quantity: 30 tablets/month Continuation of therapy: Members who have been previously stabilized on Kerendia (finerenone) may receive approval to continue the medication.	
KHINDIVI (hydrocortisone)	**Khindivi** (hydrocortisone) oral solution may be approved if the following criteria are met: • Member is ≥ 5 years of age AND • Member has a diagnosis of adrenocortical insufficiency AND • Prescriber confirms that member is unable to use an alternative generic glucocorticoid therapy AND • Prescriber confirms that member cannot take a solid oral dosage form AND • Member will be counseled that Khindivi (hydrocortisone) oral solution must be stored in a refrigerator and protected from light. Maximum Quantity: Two 16-ounce bottles per 30 days	One year
KISUNLA (donanemab-azbt)	**Kisunla** (donanemab-azbt) may be approved if the member meets ALL the following criteria: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND • Member has documented diagnosis of mild cognitive impairment or mild dementia stage of Alzheimer's disease, the population in which treatment was initiated in clinical trials, as evidenced by ALL the following: ○ Positron Emission Tomography (PET) scan OR lumbar puncture positive for amyloid beta plaque ○ Mini-Mental State Examination (MMSE) score of 20-28 OR Montreal Cognitive Assessment (MoCA) Test score of 19-25 ○ Progressive change in memory function for at least 6 months AND • Member is 60 years of age or older AND • Medication is prescribed by or in consultation with a neurologist AND • Prior to initiation of medication, the prescriber attests that the member meets ALL the following:	See criteria

Drug Product(s)	Criteria	PA Approval Length
	○ Member has had a baseline brain MRI within the prior one year to treatment initiation, showing no signs or history of microhemorrhages and/or superficial siderosis ○ Attestation that MRI will be completed prior to the 2nd, 3rd, 4th, and 7th infusions ○ Member is negative for apolipoprotein E ε4 (ApoE ε4) homozygotes AND • Member does not have any of the following: ○ Any medical or neurological condition other than Alzheimer's Disease that might be a contributing cause of the subject's cognitive impairment including (but not limited to) stroke/vascular dementia, tumor, dementia with Lewy bodies [DLB], frontotemporal dementia [FTD] or normal pressure hydrocephalus ○ Contraindications to PET, CT scan, or MRI ○ History of or increased risk of amyloid related imaging abnormalities ARIA-edema (ARIA-E) or ARIA-hemosiderin deposition (ARIA-H) ○ History of unstable angina, myocardial infarction, chronic heart failure, or clinically significant conduction abnormalities, stroke, transient ischemic attack (TIA), or unexplained loss of consciousness within 1 year prior to initiation of Kisunla (donanemab-azbt) ○ History of bleeding abnormalities or taking any form of anticoagulation therapy. Maximum Dose: 700 mg every 4 weeks for the first 3 doses, followed by 1,400 mg every 4 weeks. Initial Approval: 6 months Second Prior Authorization Approval: An additional 6 months of therapy may be approved with provider attestation that a follow-up MRI will be (or has been) completed prior to the 7th infusion Third and Subsequent Prior Authorization Approval: Approval for 6 months for third and subsequent prior authorization requests may be approved with provider attestation that the member has demonstrated a positive clinical response to treatment.	
KOSELUGO (selumetinib)	Minimum age: ≥ 1 year	
KUVAN (sapropterin) **SEPHIENCE (sepiapterin)** **ZELVYSIA (sapropterin)**	**Kuvan** (sapropterin dihydrochloride) or **Sephience** (sepiapterin) or **Zelvysia** (sepiapterin) may be approved if the following criteria are met: • Member is > 1 month old AND • Member has been diagnosed with hyperphenylalaninemia due to tetrahydrobiopterin responsive phenylketonuria AND • Prescriber is a metabolic specialist AND • Phenylalanine levels must be greater than 6 mg/dL for neonates through 12 years of age OR • Phenylalanine levels must be greater than 10 mg/dL for members between 13 to 17 OR • Phenylalanine levels must be greater than 15 mg/dL for members 18 years and older AND • Must be in conjunction with dietary restriction of phenylalanine	Initial approval one month

<table>
<tr><th>Drug Product(s)</th><th>Criteria</th><th>PA Approval Length</th></tr>
<tr><td></td><td>

Initial approval will be for 1 month. Authorization may be extended if:

Members on the 10mg/kg/day dose whose blood phenylalanine levels have not decreased from baseline after 1 month of treatment should increase to 20mg/kg/day. These members will be approved for another 1 month trial at the higher dose.
Members on the 20mg/kg/day dose whose blood phenylalanine levels have not decreased from baseline after 1 month are considered non-responders, and treatment will be discontinued.
Members responding to therapy receive additional authorization at 1-year intervals.

</td><td></td></tr>
<tr><td>LAMPIT (nifurtimox)</td><td>
Lampit (nifurtimox) may be approved if the following criteria are met:

Lampit (nifurtimox) is prescribed by or in conjunction with an infectious disease specialist, cardiologist or gastroenterologist AND
The member’s age falls between term newborn and < 18 years of age AND
The member’s weight is provided and is at least 2.5 kg (5.5 pounds) AND
The member has a diagnosis, documented and confirmed by blood smear, of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi AND
For pediatric members 2 to 12 years of age, the member has trialed and failed treatment with benznidazole. Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction AND
For female members of childbearing potential, a documented negative pregnancy test is obtained within 2 weeks of initiating therapy AND
The member has received counseling (when appropriate) to not consume alcohol during treatment with Lampit (nifurtimox) AND
The prescription meets the following recommended daily dosing:

<table>
<tr><th colspan="2">Lampit (nifurtimox) Dosing in Pediatric Patients</th></tr>
<tr><th>Body weight group</th><th>Total daily dose</th></tr>
<tr><td>40 kg or greater</td><td>8 to 10 mg/kg</td></tr>
<tr><td>Less than 40 kg</td><td>10 to 20 mg/kg</td></tr>
</table>
<u>Maximum Dosing</u>:
300mg three times a day (900mg/day) for 60 days
</td><td>One year</td></tr>
<tr><td>LEMTRADA (alemtuzumab)</td><td>
Lemtrada (alemtuzumab) may be approved if the following criteria are met:

For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member’s home or in a long-term care facility AND
Member is 18 years of age or older AND
Member has a relapsing form of multiple sclerosis AND
Member has experienced one relapse within the prior year or two relapses within the prior two years AND
Member has had trial and failure with Tysabri (natalizumab), Ocrevus (ocrelizumab), or two preferred agents in the “Disease Modifying Therapies” PDL drug class that are FDA-labeled for use for the same prescribed indication. Failure

</td><td>One year</td></tr>
</table>

Drug Product(s)	Criteria	PA Approval Length
	is defined as allergy, intolerable side effects, significant drug-drug interaction, or lack of efficacy. Lack of efficacy is defined as one of the following: o On MRI, presence of any new spinal lesions, cerebellar or brainstem lesions, or change in brain atrophy **OR** o Signs and symptoms on clinical exam consistent with functional limitations that last one month or longer **AND** • Lemtrada is prescribed by or in consultation with a neurologist or a physician that specializes in the treatment of multiple sclerosis **AND** • For members with known psychiatric conditions, prescriber acknowledges that consultation with the member's behavioral health provider will be conducted prior to the member's receiving treatment with a high dose corticosteroid as part of the Lemtrada premedication procedure **AND** • Baseline skin exam and thyroid function assessment are completed and documented prior to initiation of treatment with Lemtrada **AND** • Prescriber is enrolled in the Lemtrada Risk Evaluation and Mitigation Strategy (REMS) program. Exemption: If member is currently receiving and stabilized on Lemtrada (alemtuzumab), they may receive prior authorization approval to continue therapy.	
LEQEMBI (lecanemab-irmb)	**Leqembi** (lecanemab-irmb) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND • Member has documented diagnosis of mild cognitive impairment or mild dementia stage of Alzheimer's disease as evidenced by all of the following: o Positron Emission Tomography (PET) scan OR lumbar puncture positive for amyloid beta plaque AND o Clinical Dementia Rating global score (CDR-GS) of 0.5 or 1 (available at https://otm.wustl.edu/cdr-terms-agreement/) AND o Mini-Mental State Examination (MMSE) score of 24-30 OR Montreal Cognitive Assessment (moCA) Test score of 19-25 AND • Member is ≥ 50 years of age AND • The prescriber attests that member has been counseled on the approval and safety status of Leqembi (lecanemab-irmb) being approved under accelerated approval based on reduction in amyloid beta plaques AND • Prior to initiation of Leqembi (lecanemab-irmb), the prescriber attests that the member meets both of the following: o Member has had a brain MRI within the prior one year to treatment initiation, showing no signs or history of localized superficial siderosis, ≥ 10 brain microhemorrhages, and/or brain hemorrhage > 1 cm AND o Attestation that MRI will be completed prior to the 5th, 7th and 14th infusions AND o Member is negative for apolipoprotein E ε4 (ApoE ε4) homozygotes AND • Member does not have any of the following: o Any medical or neurological condition other than Alzheimer's Disease that might be a contributing cause of the subject's cognitive impairment including (but not limited to) stroke/vascular dementia, tumor, dementia	See criteria

Drug Product(s)	Criteria	PA Approval Length
	with Lewy bodies [DLB], frontotemporal dementia [FTD] or normal pressure hydrocephalus o Contraindications to PET, CT scan, or MRI o History of or increased risk of amyloid related imaging abnormalities ARIA-edema (ARIA-E) or ARIA-hemosiderin deposition (ARIA-H) o History of unstable angina, myocardial infarction, chronic heart failure, or clinically significant conduction abnormalities, stroke, transient ischemic attack (TIA), or unexplained loss of consciousness within 1 year prior to initiation of Leqembi (lecanemab-irmb) o History of bleeding abnormalities or taking any form of anticoagulation therapy AND • The requested medication is being prescribed by or in consultation with a neurologist AND • The prescribed regimen meets FDA-approved labeled dosing. Initial approval period: 6 months Subsequent approval: An additional 6 months of Leqembi (lecanemab-irmb) therapy may be approved with provider attestation that a follow-up MRI will be (or has been) completed prior to the 14th infusion. Maximum dose: 10 mg/kg IV every 2 weeks The above coverage standards will continue to be reviewed and evaluated for any applicable changes due to the evolving nature of factors including disease course, available treatment options and available peer-reviewed medical literature and clinical evidence. If request is for use outside of stated coverage standards, support with peer reviewed medical literature and/or subsequent clinical rationale shall be provided and will be evaluated at the time of request. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).	
LEQVIO (inclisiran)	**Leqvio** (inclisiran) may be approved if the following criteria are met: • To bill for the requested drug under the pharmacy benefit, the drug is being administered by a healthcare professional in the member's home or in a long-term care facility AND • Prescriber acknowledges that doses administered by a healthcare provider in the doctor's office or clinic are to be billed through the Health First Colorado medical benefit through the standard buy-and-bill process AND • Member is ≥ 18 years of age AND • The requested drug is being prescribed as an adjunct to diet and maximally tolerated statin therapy with ezetimibe for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD as defined below in Table 1), who require additional lowering of low-density lipoprotein cholesterol (LDL-C) AND • The requested drug is being prescribed by, or in consultation with, a cardiologist, Certified Lipid Specialist (CLS) or an endocrinologist AND • Member is concurrently adherent (> 80% of the past 180 days) on maximally tolerated dose of statin therapy (see Table 2 below), which should include a 30-day	Initial: 3 months Reauth: One year

<table>
<tr><th>Drug Product(s)</th><th>Criteria</th><th>PA Approval Length</th></tr>
<tr><td></td><td>trial of either atorvastatin OR rosuvastatin. If intolerant to a statin due to side effects, member must have a one month documented trial with at least two other statins. For members with a past or current incidence of rhabdomyolysis, one month trial and failure of two statins is not required AND
• Member must be concurrently treated (in addition to maximally tolerated statin) with ezetimibe AND have a treated LDL > 70 mg/dl for a clinical history of ASCVD or LDL > 100 mg/dl if familial hypercholesterolemia. For members who have an allergy, contraindication, or intolerable side effects to ezetimibe, concomitant use of ezetimibe is not required.

Maximum Dose: 284 mg/90 days
Quantity Limit: One 284 mg/1.5 mL prefilled syringe/90 days

Reauthorization: Additional one year approval for continuation may be granted with provider attestation to safety and efficacy with initial medication therapy.

Table 1: Conditions Which Define Clinical Cardiovascular Disease
• Acute coronary syndrome
• History of myocardial infarction
• Stable and unstable angina
• Coronary or other arterial revascularization
• Stroke
• Transient ischemic attack
• Peripheral arterial disease of atherosclerotic origin

Table 2: Maximum Daily Statin Doses
Atorvastatin 80 mg
Fluvastatin 80 mg
Lovastatin 80 mg
Pravastatin 80 mg
Rosuvastatin 40 mg
Simvastatin 40 mg (80 mg not used in practice)</td><td></td></tr>
<tr><td>LHRH/GnRH
Luteinizing Hormone Releasing Hormone/Gonadotropin Releasing Hormone</td><td>All claims for medications administered in a hospital, clinic, or physician's office are to be billed through the medical benefit. Claims billed through the pharmacy benefit may only receive approval if the medication is being administered in the member's home by a home health agency/provider or administered in a long-term care facility (see "Physician Administered Drugs" section).

Prior authorization may be approved for FDA-labeled indications only.

• Eligard (leuprolide): Palliative treatment of advanced prostate cancer
• Fensolvi (leuprolide acetate): Central precocious puberty
• Lupron (leuprolide): Prostate cancer, endometriosis, uterine leiomyomata (fibroids), precocious puberty. Lupron may be approved for gender dysphoria based on the following criteria:
o The member has a diagnosis of gender dysphoria which is made by a mental health professional with experience in treating gender dysphoria. Where available, the mental health professional should ideally have training in child and adolescent developmental psychology AND</td><td>One year</td></tr>
</table>

Drug Product(s)	Criteria	PA Approval Length
	○ The member should have at least 6 months of counseling and psychometric testing for gender identity prior to initiation of Lupron AND ○ The prescribing provider has training in puberty suppression using a gonadotropin releasing hormone agonist AND ○ Lupron may not be started until girls and boys exhibit physical changes of puberty (confirmed by levels of estradiol and testosterone, respectively) and no earlier than Tanner stages 2-3 (bilateral breast budding or doubling to tripling testicular size to 4-8 cc). ○ Duration of treatment: Lupron will be covered to a maximum of 16 years of age for gender dysphoria. • **Synarel** (nafarelin): Endometriosis, precocious puberty • **Trelstar** (triptorelin): Palliative treatment of advanced prostate cancer • **Triptodur** (triptorelin): Palliative treatment of advanced prostate cancer, precocious puberty	
LIVDELZI (seladelpar)	**Livdelzi** (seladelpar) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of primary biliary cholangitis and meets one of the following: ○ Combined therapy: Requested medication will be used in combination with ursodiol (ursodeoxycholic acid) if the member had an inadequate response (lack of efficacy) following at least one year of treatment with ursodiol (ursodeoxycholic acid) alone OR ○ Monotherapy: Requested medication will be used as monotherapy in members who have trialed and failed ursodiol (ursodeoxycholic acid) therapy. Failure is defined as allergy, intolerable side effects, or significant drug-drug interaction • AND • Medication is prescribed by or in consultation with a gastroenterologist, hepatologist, or liver transplant provider AND • Laboratory tests to evaluate ALT, AST, alkaline phosphatase and total bilirubin will be performed at baseline and during treatment with Livdelzi (seladelpar), according to product labeling AND • Prior to initiating therapy, the member does NOT have an elevated creatine phosphokinase (CPK) and/or signs/symptoms of muscle pain or myopathy, and prescriber attests that these parameters will be monitored throughout treatment with Livdelzi (seladelpar) AND • Member does not have complete biliary obstruction, cirrhosis, or other types of liver disease AND • Members without serologic evidence of immunity have received hepatitis A and hepatitis B vaccinations AND • Prescriber has considered the risk of fracture in patients treated with the requested product AND • Due to the risk of adverse reactions that maybe be associated with significant increases in Livdelzi (seladelpar) exposure, member is not taking an OAT3 inhibitor (such as gemfibrozil, probenecid, teriflunomide) OR a strong CYP2C9 inhibitor (such as fluconazole, fluorouracil, gemfibrozil, metronidazole), and member's medication profile has been reviewed for other potential clinically significant drug interactions according to product labeling AND • Prescriber attests the member has been counseled that the approval and safety status of Livdelzi (seladelpar) is based on reduction of alkaline phosphatase.	Initial: 6 months Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Maximum Dose: 10 mg/day Maximum Quantity: 30 tablets/30 days Initial Approval: 6 months Reauthorization: Member may receive approval for one year with provider attestation that a biochemical response (such as an alkaline phosphatase level less than 1.67-times the upper limit of normal) has been observed after 6 months of therapy.	
LIVERVANT (diazepam)	**Libervant** (diazepam) buccal film may be approved if the following criteria are met: • Member is 2 to 5 years of age AND • Member has a diagnosis of epilepsy with intermittent, stereotypic episodes of frequent seizure activity (such as seizure clusters, acute repetitive seizures) that are distinct from their usual seizure pattern AND • Member does not have acute-narrow angle glaucoma AND • Due to increased risk of additive effects, prescriber attests that members on concomitant CNS depressants will be closely monitored for central nervous system and respiratory depression after administration of Libervant (diazepam buccal film) AND • Based on the member's concurrent medication profile, prescriber has evaluated potential interactions that may occur between diazepam and: o Inhibitors of CYP2C19 (such as cimetidine, quinidine, tranylcypromine) and CYP3A4 (such as ketoconazole, clotrimazole) that could increase adverse reactions with diazepam AND o Inducers of CYP2C19 (such as rifampin) and CYP3A4 (such as carbamazepine, phenytoin, dexamethasone, phenobarbital) that could decrease the efficacy of diazepam AND • Initial prescription for the requested product is ordered by or in consultation with a pediatric neurologist AND • Parent/caregiver has been educated about appropriate identification of seizure cluster signs and symptoms, and proper Libervant buccal film administration. Quantity Limit: 4 films per year unless used / damaged / lost Continuation of Therapy: Members who are currently stabilized on Libervant (diazepam) buccal films as part of their epilepsy treatment plan may receive approval to continue use of the product. Members are limited to one prior authorization approval on file for Libervant (diazepam), Nayzilam (midazolam) or Valtoco (diazepam).	One year
LIPIDS/AMINO ACIDS/PLASMA PROTEINS	Approval will be given if administered in the member's home or in a long-term care facility. If given in the hospital or physician's office, the claim must be billed as a medical expense.	Lifetime
LIVTENCITY (maribavir)	**Livtencity** (maribavir) may be approved if the following criteria are met: • Member is ≥ 12 years of age and weighs ≥ 35 kg, AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Member has a diagnosis of post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet AND • Prescriber confirms that potentially significant drug-drug interactions (such as those with digoxin, anticonvulsants, rosuvastatin, strong CYP3A4 inducers, rifampin, and immunosuppressants) will be carefully evaluated prior to initiating therapy with Livtencity (maribavir), based on the current product labeling. Maximum Dose: • Usual dose: 800 mg/day • If co-administered with carbamazepine: 1,600 mg/day • If co-administered with phenytoin or phenobarbital: 2,400 mg/day Quantity Limits: • Usual dose: 120 tablets/30 days • If co-administered with carbamazepine: 240 tablets/30 days • If co-administered with phenytoin or phenobarbital: 360 tablets/30 days	
LUCEMYRA (lofexidine)	**Lucemyra** (lofexidine) may receive prior authorization approval for members meeting all of the following criteria: • Member is 18 years of age or older **AND** • Lucemyra® is prescribed for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation **AND** • Member is not pregnant or nursing **AND** • Member is not experiencing withdrawal symptoms from substances other than opioids **AND** • Member is not currently taking monoamine oxidase inhibitors or allergic to imidazole drugs **AND** • Member does not have an abnormal cardiovascular exam prior to treatment: o Clinically significant abnormal ECG (e.g., second or third degree heart block, uncontrolled arrhythmia, or QTc interval > 450 msec for males, and > 470 msec for females) o Heart rate less than 45 bpm or symptomatic bradycardia o Systolic blood pressure < 90 mm Hg or symptomatic hypotension (diastolic blood pressure < 60 mm Hg) o Blood pressure > 160/100 mm Hg o Prior history of myocardial infarction **AND** • Member has two-day trial and failed clonidine IR for opioid withdrawal symptoms. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction. Approval for Lucemyra (lofexidine) will be 14 days	14 days
LUMIZYME (alglucosidase alfa)	**Lumizyme** (alglucosidase alfa) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND • Member has a definitive diagnosis of Pompe disease confirmed by one of the following: o Deficiency of acid alpha-glucosidase (GAA) enzyme activity OR	One year

Drug Product(s)	Criteria	PA Approval Length
	○ Detection of biallelic pathogenic variants in the GAA by molecular genetic testing AND • The request meets one of the following based on indicated use: ○ If being administered for infantile-onset Pompe disease, member has documented baseline age-appropriate assessments, including motor function tests, muscle weakness, respiratory function, cardiac involvement testing, percent predicted forced vital capacity (FVC), and 6-minute walk test (6MWT) OR ○ If being administered for late-onset Pompe disease, member has documented baseline age-appropriate assessments, including motor function tests, muscle weakness, respiratory function, cardiac involvement testing, FVC and 6MWT. Reauthorization may be approved for one year if member met initial approval criteria at the time of initiation of therapy AND meets the following: • Member is being monitored for antibody formation and hypersensitivity AND • The request meets one of the following based on indicated use: ○ For infantile-onset Pompe disease: the member has shown clinical improvement defined as an improvement or stabilization in muscle weakness, motor function, respiratory function, cardiac involvement, percent predicted FVC, and/or 6MWT OR ○ For late-onset Pompe disease: the member has shown clinical improvement defined as an improvement or stabilization in percent predicted FVC and/or 6MWT. Maximum dose: Lumizyme 20mg/kg every 2 weeks (IV Infusion)	
LYNKUET (elinzanetant)	**Lynkuet** (elinzanetant) may be approved if the following criteria are met: • Member has been diagnosed with moderate to severe vasomotor symptoms (such as hot flashes and sweating) associated with menopause AND • Request meets one of the following: ○ Member has tried and failed two alternate oral or transdermal estrogen containing products. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction OR ○ Member has moderate to high risk for complications related to estrogen therapy AND • Member is not pregnant AND • At baseline, member has liver transaminase and total bilirubin levels that are ≤ 2 times the upper limit of normal AND • Member has been counseled to avoid grapefruit and grapefruit juice while taking Lynkuet (elinzanetant) AND • For members concurrently taking a moderate CYP3A4 inhibitor (such as diltiazem, erythromycin, fluconazole, verapamil), provider attests that the dose of Lynkuet (elinzanetant) will be appropriately reduced per product labeling AND • Member is not taking a strong CYP3A4 inhibitor (such as clarithromycin, itraconazole, ketoconazole, posaconazole, ritonavir, voriconazole) AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Member is not taking a strong or moderate CYP3A4 inducer (such as carbamazepine, phenytoin, rifampin, modafinil, phenobarbital) AND • Member has been counseled that some individuals may experience impaired driving ability while taking Lynkuet (elinzanetant). Maximum dose: Two 60 mg capsules per day Quantity limit: 60 capsules/30 days	
MAKENA (hydroxyprogesterone caproate)	**Makena** (hydroxyprogesterone caproate): Effective 04/06/23, Makena (hydroxyprogesterone caproate) is not eligible for coverage under the Health First Colorado pharmacy benefit based on the final decision by the U.S. Food and Drug Administration to withdraw approval for this medication.	See criteria
MALARIA PROPHYLAXIS EXCEEDING THIRTY DAYS	Prior authorization is required for claims exceeding a 30-day supply for medications used for malaria prophylaxis (e.g. atovaquone/proguanil, chloroquine, doxycycline, mefloquine, primaquine, tafenoquine) and may be approved for members meeting the following: • Prescriber verification that the member is traveling to a malaria endemic area for a period of time that requires duration of therapy exceeding thirty days. • Prescriber verification of member's duration of stay in the malaria endemic area and the total days needed for the malaria prophylaxis medication regimen. *Note: The Centers for Disease Control and Prevention recommendations for malaria prophylaxis therapy based on country of travel are available at www.cdc.gov*	See criteria
METRONIDAZOLE 125mg TABLET	**Metronidazole 125 mg tablet** may be approved if meeting the following criteria: • Clinical rationale is provided by the prescriber supporting the necessity of use of this specific dosage form AND • Clinical justification is provided supporting that no alternative tablet strength of metronidazole may be used.	One year
MIFEPRISTONE and MISOPROSTOL	Effective 1/1/26, pharmacy claims for **Cytotec** (misoprostol) or **Mifeprex** (mifepristone) require verification and submission of the ICD-10 diagnosis code associated with the prescribed use to be submitted on the pharmacy claim at point-of-sale (POS) for reimbursement. Claims do not require prior authorization when the associated ICD-10 diagnosis code is submitted on the claim. **Korlym** (mifepristone) - Prior authorization may be approved for members meeting the following: • Mifepristone is not being prescribed for use related to termination of pregnancy AND • Mifepristone is being prescribed for use for hyperglycemia secondary to hypercortisolism in adult patients with Cushing's Syndrome who have type 2 diabetes or glucose intolerance and have failed or are not candidates for surgery. *Note: See PDL for coverage information for misoprostol/NSAID combination products.*	One year unless specified in criteria
MIPLYFFA (arimoclomol citrate)	**Miplyffa** (arimoclomol citrate) may be approved if the following criteria are met: • Member is ≥ 2 years of age AND • Member has a documented diagnosis of Niemann-Pick disease type C, molecularly confirmed by genetic testing AND • Member is concurrently being treated with miglustat AND	6 months

Drug Product(s)	Criteria	PA Approval Length
	• Requested medication is being prescribed by a neurologist or other provider specializing in the treatment of Niemann-Pick disease type C AND • Prescriber attests that the member will be assessed using the NPC Clinical Severity Scale (NPCCSS) prior to initiating Miplyffa (arimoclomol citrate) therapy AND • For members with renal impairment (eGFR ≥ 15 to < 50 mL/min) the dose of Miplyffa (arimoclomol citrate) will be adjusted according to product labeling AND • Members of child-bearing potential been counseled that Miplyffa (arimoclomol citrate) may cause embryo-fetal harm and to consider pregnancy planning and prevention AND • Members are limited to one prior authorization approval on file for Miplyffa (arimoclomol citrate) OR Aqneursa (levacetylleucine). Maximum Dose: 372 mg/day Maximum Quantity: 90 tablets/30 days Initial Approval: 6 months Reauthorization: Members may receive approval for 6 months for continuation of therapy if all of the following criteria are met: • Based on ongoing response to treatment, the provider attests there is medical necessity justifying continuation of drug therapy AND • Member has demonstrated response to treatment based on quantitative scores using the same scale(s) previously used to assess Miplyffa (arimoclomol citrate) treatment (see bullet point 5 of the initial authorization criteria), AND • A brief explanation, including the provider name, must be submitted if a provider other than the one who initially performed the neurologic exam completes any follow-up exam(s) AND • A brief explanation must be submitted if an exam scale other than the scale used for initial authorization is used for reassessment.	
MOLNUPIRAVIR	Quantity limit: 40 capsules per 5 days	
MOXATAG (amoxicillin)	A prior authorization will only be approved if a member has an allergic/intolerance to inactive ingredients in immediate release amoxicillin.	One year
MULPLETA (lusutrombopag)	**Mulpleta** (lusutrombopag) prior authorization may be approved for members meeting the following criteria: • Member is 18 years of age or older AND • Member has a confirmed diagnosis of thrombocytopenia with chronic liver disease who is scheduled to undergo an elective procedure AND • Member has trialed and failed both dexamethasone and methylprednisolone (Failure is defined as a lack of efficacy, allergy, intolerable side effects, or significant drug-drug interactions) AND • Mulpleta is being prescribed by or in consultation with a hematologist, hepatologist, or gastroenterologist AND • Member has a baseline platelet count no more than 2 days before procedure. AND • Mulpleta (lusutrombopag) will not be administered with a thrombopoietic agent or spleen tyrosine kinase inhibitor (such as Promacta (eltrombopag), Nplate (romiplostim), or Tavalisse (fotamatinib) Quantity limit: 7 day supply per procedure	One year

Drug Product(s)	Criteria	PA Approval Length
MYALEPT (metreleptin)	**Myalept** (metreleptin) may be approved if all of the following criteria are met: • Prescriber is an endocrinologist who is enrolled in the Myalept REMS program AND • Member has a diagnosis of congenital or acquired generalized lipodystrophy AND • Member does not have HIV-related lipodystrophy AND • Member has a diagnosis of leptin deficiency AND • Member has been diagnosed with poorly controlled diabetes (HgA1c > 7) and/or hypertriglyceridemia (> 500 mg/dl) AND • Member has tried and failed two standard therapies for diabetes and/or hypertriglyceridemia	Six Months
MYCAPSSA (octreotide)	**Mycapssa** (octreotide) may be approved for members meeting the following criteria: • Member is an adult (≥ 18 years of age) with a confirmed diagnosis of acromegaly AND • Member has trialed and failed‡ treatment with bromocriptine mesylate at maximally tolerated doses AND • Member has responded to and tolerated 3 months of treatment with octreotide acetate injection (vial) OR lanreotide acetate injection AND • Member cannot be treated with surgical resection or pituitary irradiation AND • Member is not hypersensitive to octreotide of any components of Mycapssa (octreotide) capsules, which include but are not limited to gelatin, propylene glycol and povidone AND • Mycapssa (octreotide) is prescribed by, or in consultation with, an endocrinologist AND • Provider attests that insulin-like growth factor 1 (IGF-1) levels will be monitored every two weeks, along with member's signs and symptoms, during the dose titration period or as indicated, and that the Mycapssa (octreotide) dose will be adjusted based on these findings AND • Provider attests that blood glucose will monitored during initiation of treatment with Mycapssa (octreotide), and that blood glucose, thyroid function, and vitamin B12 levels will be monitored periodically during treatment AND • Provider confirms awareness of the potential for significant drug interactions between Mycapssa (octreotide) and other medications, including (but not limited to) cyclosporine, digoxin, lisinopril, oral contraceptives containing levonorgestrel, bromocriptine, beta blockers, and calcium channel blockers. Maximum Dose: 80 mg daily ‡Failure is defined as lack of efficacy with a 3-month trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction.	One year
MYFEMBREE (relugolix, estradiol hemihydrate, norethindrone acetate)	**Myfembree** (relugolix, estradiol hemihydrate, norethindrone acetate) may be approved if meeting the following criteria: 1. Member is 18 years of age or older AND 2. Member is pre-menopausal AND 3. Member has a confirmed diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) OR member has a diagnosis of moderate to severe pain associated with endometriosis AND 4. Member has tried and failed treatment with an estrogen-progestin contraceptive	6 months

Drug Product(s)	Criteria	PA Approval Length
	(oral tablets, vaginal ring, transdermal patch) OR a progestin releasing intrauterine device (IUD). Failure is defined as lack of efficacy, allergy, intolerable side effects, significant drug-drug interaction, or contraindication to therapy AND 5. The medication is prescribed by or in consultation with an obstetrician/gynecologist AND 6. Member does not have a high risk of arterial, venous thrombotic, or thromboembolic disorder, including: a. Women over 35 years of age who smoke OR b. Women with a past or current history of the following: i. DVT, PE, or vascular disease (such as cerebrovascular disease, coronary artery disease, peripheral vascular disease) OR ii. Thrombogenic valvular or thrombogenic rhythm diseases of the heart (such as subacute bacterial endocarditis with valvular disease, or atrial fibrillation) OR iii. Inherited or acquired hypercoagulopathies OR iv. Uncontrolled hypertension OR v. Headaches with focal neurological symptoms OR migraine headaches with aura if over age 35 AND 7. Member is not pregnant or breastfeeding AND 8. Member does not have known osteoporosis AND 9. Member does not currently have, or have a history of, breast cancer or other hormonally-sensitive malignancies AND 10. Member does not have known liver impairment or disease AND 11. Member will not receive Myfembree in combination with any medication that is contraindicated or not recommended per FDA labeling AND 12. Member has not previously received treatment with Orilissa (elagolix) 150 mg or Oriahnn (elagolix/estradiol/norethindrone acetate) for more than 24 months, or previous treatment with Orilissa (elagolix) 200 mg for more than 6 months AND 13. Member has been counseled that that Myfembree does not prevent pregnancy AND 14. Member has been instructed that only non-hormonal contraceptives should be used during Myfembree therapy and for at least 1 week following discontinuation AND 15. Prescriber acknowledges that assessment of bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) is recommended at baseline and periodically thereafter, and discontinuation of Myfembree should be considered if the risk associated with bone loss exceeds the potential benefit of treatment. Reauthorization: Members with a current 6-month prior authorization approval on file may receive an additional 6-month approval to continue therapy. Prior authorization requests for Myfembree will take into account exposure to all GnRH receptor antagonist medications (such as elagolix and relugolix) and will not be approved for a total exposure that exceeds 24 months. Maximum dose: 1 tablet daily (relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg)	
NAGLAZYME (galsulfase)	**Naglazyme** (galsulfase) may be approved for members meeting the following criteria: • Naglazyme (galsulfase) is being administered in a long-term care facility or in a member's home by a healthcare professional AND • Member is 5 years of age or older AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Member has a confirmed diagnosis of Mucopolysaccharidosis, Type VI confirmed by the following: o Detection of pathogenic mutations in the ARSB gene by molecular genetic testing OR o Arylsulfatase B (ASB) enzyme activity of <10% of the lower limit of normal in cultured fibroblasts or isolated leukocytes AND o Member has normal enzyme activity of a different sulfatase (excluding members with Multiple Sulfatase Deficiency) AND o Member has an elevated urinary glycosaminoglycan (uGAG) level above the upper limit of normal as defined by the reference laboratory AND • Member has a documented baseline 12-minute walk test (12-MWT), 3-minute stair climb test, and/or pulmonary function tests (such as FEV1) AND • Member has a documented baseline value for uGAG AND • Naglazyme (galsulfase) is being prescribed by or in consultation with a provider who specializes in inherited metabolic disorders <u>Reauthorization Criteria:</u> After one year, member may receive approval to continue therapy if meeting the following: • Has documented reduction in uGAG levels AND • Has demonstrated stability or improvement in one of the following: o 12-minute walk test OR o 3-minute stair climb test OR o Pulmonary function testing (such as FEV1) Max dose: 1 mg/kg as a 4-hour infusion weekly	
NAYZILAM (midazolam)	**Nayzilam** (midazolam) may be approved for members meeting the following criteria: • Member is 12 years of age or older AND • Nayzilam is being prescribed for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern and medical records are provided supporting this diagnosis AND • Member is stable on regimen of antiepileptic medications AND • Medication is being prescribed by or in conjunction with the same provider/provider team who manages the member's anti-epileptic regimen AND • Member is educated on appropriate identification of seizure cluster and Nayzilam (midazolam) administration not exceeding 2 doses per seizure cluster. Maximum dose: 4 nasal spray units per year unless used / damaged / lost Members are limited to one prior authorization approval on file for Valtoco (diazepam) and Nayzilam (midazolam). If member is currently receiving Nayzilam (midazolam) intranasal, they may receive prior authorization approval to continue.	One Year

Drug Product(s)	Criteria	PA Approval Length
NEWLY APPROVED PRODUCTS AND CHANGE IN PRODUCT PRIOR AUTHORIZATION STATUS	Newly marketed or approved products that fall within a PDL drug class will be subject to non-preferred prior authorization criteria for the drug class and will be included as part of the next regularly scheduled P&T Committee and DUR Board reviews for that class. Newly marketed or approved products that fall within a drug category on appendix P (such as "Blood Products") will be subject to prior authorization criteria listed for medications in that drug category on Appendix P. For change in prior authorization status for a product that is not included in a PDL drug class or on Appendix P, notice will be given regarding DUR Board review of prior authorization criteria for the product as part of the posted DUR Board meeting agenda located at https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board and posted at least 30 days prior to the DUR Board meeting during which the product is scheduled to be reviewed. Until such time that DUR Board review is conducted, products may receive prior authorization approval based on FDA-labeled indication, dose, age, and role in therapy as outlined in product package labeling. IV formulations or products where labeled use indicates that the medication should be administered by a healthcare professional will also be subject to meeting criteria for physician administered drugs (see "Physician Administered Drugs" section).	

NEXVIAZYME (avalglucosidase alpha)	**Nexviazyme** (avalglucosidase alpha) may be approved if the following criteria are met:
	• For claims billed through the pharmacy benefit, prescriber verifies that the product medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND
	• Member is ≥ 1 year of age AND
	• Member has a definitive diagnosis of late-onset (non-infantile) Pompe disease confirmed by one of the following:
	  ○ Deficiency of acid alpha-glucosidase (GAA) enzyme activity
	  OR
	  ○ Detection of biallelic pathogenic variants in the GAA by molecular genetic testing
	AND
	• The requested medication is not being used in combination with other enzyme replacement therapies AND
	• Member has documented baseline age-appropriate assessments, including motor function tests, muscle weakness, respiratory function, cardiac involvement testing, percent predicted forced vital capacity (FVC), and 6-minute walk test (6MWT) AND
	• Product is being prescribed by a provider specializing in the treatment of Pompe disease AND
	• Prescriber acknowledges consideration for administering antihistamines, antipyretics, and/or corticosteroids prior to Nexviazyme (avalglucosidase alpha) administration to reduce the risk of severe infusion-associated reactions.
	
	Reauthorization may be approved for one year if member met initial approval criteria at the time of initiation of therapy AND meets the following:
	• Member has shown clinical improvement defined as an improvement or stabilization in percent predicted FVC and/or 6MWT AND
	• Member is being monitored for antibody formation and hypersensitivity
	
	Maximum Dose:
	Members ≥30 kg, 20 mg/kg administered every 2 weeks
		One year

Drug Product(s)	Criteria	PA Approval Length
	Members ≤30 kg, 40 mg/kg administered every 2 weeks	
NORTHERA (droxidopa)	**Northera** (droxidopa) will be approved if all the following is met: • Member has a diagnosis of symptomatic neurogenic orthostatic hypotension (NOH) as defined by one of the following when an upright position is assumed or when using a head-up tilt table testing at an angle of at least 60 degrees. o At least a 20 mmHg fall is systolic pressure o At least a 10 mmHg fall in diastolic pressure AND • NOH caused by one of the following: o Primary autonomic failure (e.g, Parkinson's disease, multiple system atrophy, and pure autonomic failure o Dopamine beta-hydroxylase deficiency o Non-diabetic autonomic neuropathy AND • Member does not have orthostatic hypotension due to other causes (e.g, heart failure, fluid restriction, malignanacy) AND • Members has tried at least three of the following non-pharmacological interventions: o Discontinuation of drugs which can cause orthostatic hypotension [e.g., diuretics, antihypertensive medications (primarily sympathetic blockers), anti-anginal drugs (nitrates, excluding SL symptom treatment formulations), alpha-adrenergic antagonists, and antidepressants] o Raising the head of the bed 10 to 20 degrees o Compression stockings o Increased salt and water intake, if appropriate o Avoiding precipitating factors (e.g., overexertion in hot weather, arising too quickly from supine to sitting or standing) AND • Northera (droxidopa) is being prescribed by either a cardiologist, neurologist, or nephrologist AND • Member has failed a 30 day trial, has a contraindication, or intolerance to both Florinef (fludrocortisone) and ProAmatine (midodrine).	3 months
NPLATE (romiplostin)	**Nplate** (romiplostim) may be approved if the following criteria are met: • Prescriber verifies that the requested medication <u>will not</u> be administered in a doctor's office, clinic, outpatient hospital, or dialysis unit (medication claims for administration in these settings are only to be billed through the Health First Colorado medical benefit using the standard buy-and-bill process) **AND** • Member does not have thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than immune thrombocytopenia **AND** • The requested medication is not being used in an attempt to normalize platelet counts **AND** • If being administered for <u>hematopoietic subsyndrome of acute radiation syndrome,</u> member has been acutely exposed to myelosuppressive radiation levels greater than 2 gray (Gy) OR if being administered for <u>immune thrombocytopenia (ITP)</u>, the member meets the following: o Member has had an insufficient response to corticosteroids, immunoglobulins, or splenectomy **AND** o Member has ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding as indicated by a platelet count of ≤ 30,000/mm^3 **AND** o Laboratory value for platelet count is current (e.g., drawn within the previous 28 days) **AND**	One year

Drug Product(s)	Criteria	PA Approval Length
	○ If being administered for Acute ITP, member is at least 18 years of age or older OR if being administered for Chronic ITP, member meets both of the following: ▪ Member is at least 1 years of age or older AND ▪ Member has had chronic ITP for at least 6 months Maximum Dose: Hematopoietic Syndrome of Acute Radiation Syndrome: 10mcg/kg/dose ITP: 10 mcg/kg weekly Reauthorization (ITP indication): Reauthorization may be approved for ITP if member met the initial indication-specific approval criteria above and member responded to treatment by achieving and maintaining a platelet count of ≥ 50,000/mm^3, but <450,000/mm^3	
NUEDEXTA (dextromethorphan /quinidine)	**Nuedexta** (dextromethorphan/quinidine) may be approved for members who meet the following criteria: • Nuedexta is being prescribed for diagnosis of pseudobulbar affect secondary to an underlying neurologic condition (such as MS, ALS, or other underlying neurologic condition) AND • Member has a Center for Neurologic Study-Lability Scale (CNS-LS) score of 13 or higher AND • Member has frequent episodes of inappropriate laughing or crying per day before therapy AND • Member has a baseline electrocardiogram (ECG) with no significant abnormalities and no history of QT prolongation syndrome AND • Nuedexta is prescribed by a neurologist or in conjunction with a neurologist AND Member has trialed and failed one tricyclic antidepressant and one selective serotonin reuptake inhibitor within the past year (failure is defined as lack of efficacy, allergy, intolerable side effects, contraindication to therapy, or significant drug-drug interactions) Initial approval will be given for 3 months and continued approval for one year may be given if member has 50% reduction in daily episodes at 3 months of therapy Nuedexta® Max Dose: 2 capsules (dextromethorphan 20mg/quinidine 10mg) per day given every 12 hours Renewal: members currently stabilized on this medication may continue to receive it with a documented diagnosis of pseudobulbar affect and evidence of efficacy (documentation of decrease in pseudobulbar episodes by 50% from baseline)	Initial Approval: 3 months Continuation Approval: One year
OCREVUS (ocrelizumab) **OCREVUS ZUNOVO (ocrelizumab and hyaluronidase)**	**Ocrevus** (ocrelizumab) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility **AND** • The requested medication is being prescribed by a neurologist or in consultation with a neurologist **AND** • If prescribed for Relapsing Forms of Multiple Sclerosis (MS): ○ Member is 18 years of age or older **AND**	One year

Drug Product(s)	Criteria	PA Approval Length
	○ Member does not have active hepatitis B infection or hypogammaglobulinemia at baseline **AND** ○ Member has a diagnosis of a relapsing form of multiple sclerosis **AND** ○ Member has experienced one relapse within the prior year or two relapses within the prior two years **AND** ○ Request meets <u>one</u> of the following: ▪ Member has had a trial and failure* with any high-efficacy disease-modifying therapies OR trial and failure* of any preferred product in the PDL "Multiple Sclerosis Agents" drug class **OR** ▪ Member has a diagnosis of <u>highly active</u> relapsing MS (based on measures of relapsing activity and MRI markers of disease activity such as numbers of galolinium-enhanced lesions) • <u>If Prescribed for Primary Progressive Multiple Sclerosis:</u> ○ Member is 18 years of age or older **AND** ○ Member is not concomitantly taking other disease modifying therapies. <u>Maximum Dose:</u> 600mg every 6 months maintenance (Ocrevus) 920mg every 6 months (Ocrevus Zunovo) <u>Exemption</u>: If member is currently receiving and stabilized on Ocrevus (ocrelizumab), they may receive prior authorization approval to continue therapy. *Failure is defined as intolerable side effects, drug-drug interaction, contraindication, or lack of efficacy. Lack of efficacy is defined as one of the following: • On MRI, presence of any new spinal lesions, cerebellar or brainstem lesions, or change in brain atrophy **OR** • Signs and symptoms on clinical exam consistent with functional limitations that last one month or longer.	
OFEV (nintedanib)	**Ofev** (nintedanib) may be approved if all of the following criteria are met: • Member has been diagnosed with idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung disease with a progressive phenotype, or systemic sclerosis-associated interstitial lung disease (SSC-ILD) AND • Is being prescribed by or in conjunction with a pulmonologist AND • Member is 18 years or older AND • Member has baseline ALT, AST, and bilirubin prior to starting therapy AND • Member does not have moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment AND • Female members of reproductive potential must have been counseled regarding risk to the fetus and to avoid becoming pregnant while receiving treatment with Ofev and to use adequate contraception during treatment and at least 3 months after the last dose of Ofev AND • Member is not taking a P-gp or CYP3A4 inducer (e.g, rifampin, carbamazepine, phenytoin, St. John's Wort) Quantity Limits: 60 tablets/30 days	One year
ONAPGO (apomorphine)	**Onapgo** (apomorphine) may be approved if the following criteria are met: • Member is ≥ 18 years of age ANDc	Initial Approval:

Drug Product(s)	Criteria	PA Approval Length
	• Member has a confirmed diagnosis of advanced Parkinson's Disease AND • Member is experiencing "off" episodes such as muscle stiffness, slow movements, or difficulty starting movements for a minimum of 3 hours per day AND • The requested medication is being used as an adjunct therapy with other medications for acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) in patients with advanced Parkinson's disease AND • The medication is being prescribed by or in consultation with a neurologist AND • Member has tried and failed treatment (lack of efficacy or intolerable side effects) with Apokyn (apomorphine) AND • If the member is receiving antiemetic therapy, the request meets all of the following: o Due to the risk of profound hypotension and loss of consciousness, member will not be treated with a 5HT3 inhibitor such as ondansetron, granisetron, or palonosetron AND o Prescriber acknowledges that dopamine antagonists (such as haloperidol, chlorpromazine, promethazine, prochlorperazine, metoclopramide) should be avoided AND o Prescriber acknowledges that trimethobenazamide may be used as an antiemetic for pre-treatment and should only be continued as long as necessary to control nausea and vomiting (generally no longer than two months) AND • Onapgo (apomorphine) will be administered only as a subcutaneous infusion AND • For members with mild-to-moderate renal impairment, the recommended initial extra dose Onapgo (apomorphine) is 0.5 mg to 1 mg and should not exceed 1 mg AND • Prior to initiating treatment with Onapgo (apomorphine), member has been counseled about the risk of potentially significant drowsiness while on apomorphine therapy AND • The member's concurrent medications have been reviewed to avoid or minimize the use of medications with overlapping sedative effects AND • Prescriber acknowledges that to avoid increasing the severity of motor symptoms, Onapgo (apomorphine) must be tapered and not abruptly discontinued AND • Member has been counseled about the risk of falls due to decreases in blood pressure and to avoid concurrent use of sublingual nitroglycerin while taking Onapgo (apomorphine) AND • Prescriber attests that member is capable of understanding and using the delivery system themselves or by a caregiver AND • Prescriber attests that member will be educated on proper infusion device placement on the body, instructions for starting the infusion, and safe disposal of the used infusion device. Maximum dose: 98 mg/day Maximum quantity: One 98 mg single-dose prefilled cartridge/day Initial approval: 6 months	6 months Continuation Approval: One year

Drug Product(s)	Criteria	PA Approval Length
	Reauthorization: Onapgo (apomorphine) may be reauthorized for one year with prescriber attestation that the member has demonstrated response to treatment by showing significant clinical improvement or reduction in "off" time.	
OPIOID ANTAGONISTS (naloxone, naltrexone, nalmefene)	**Narcan** (naloxone) intranasal does not require prior authorization (including Rx and OTC naloxone intranasal formulations) **Zimhi** (naloxone) injection does not require prior authorization. **Naloxone** vial/prefilled syringe: • does not require prior authorization. • The atomizer device for use with naloxone can be obtained by the pharmacy billing as a DME claim code A4210. The unit limit is 1 atomizer per vial/syringe dispensed up to a total of 15 per year. A prior authorization is not required. **Opvee** (nalmefene) intranasal does not require prior authorization. **Vivitrol** (naltrexone ER) injection: • Effective January 14, 2022, no place of service prior authorization is required for extended-release injectable medications (LAIs) used for the treatment of mental health or substance use disorders (SUD), when administered by a healthcare professional and billed under the pharmacy benefit. In addition, LAIs may be administered in any setting (pharmacy, clinic, medical office or member home) and billed to the pharmacy or medical benefit as most appropriate and in accordance with all Health First Colorado billing policies. See additional information regarding pharmacist enrollment and claims billing at https://hcpf.colorado.gov/pharm-serv. **Revia** (naltrexone) tablet does not require prior authorization. **Evzio** (naloxone) autoinjector – Product is not Medicaid rebate eligible per current status in Medicaid Drug Rebate Program (MDRP); product excluded. *Note: For buprenorphine/naloxone products, see "Buprenorphine-containing Products" section.*	
ORAL CONTRACEPTIVES	Effective 10/1/2023, prescription oral contraceptive products are covered and do not require prior authorization. Brand name products that have an equivalent generic available will continue to be subject to coverage policies outlined for use of brand in the "Generic Mandate" section of this document. Effective 7/1/2022, prescription contraceptive products are eligible to be filled for up to a twelve-month supply.	
ORILISSA (elagolix)	**Orilissa** (elagolix) may be approved for members meeting the following criteria: • Member is a premenopausal woman 18-49 years of age **AND** • Orilissa is not being prescribed for dyspareunia or any other sexual function related indication **AND** • Member has a definitive diagnosis of endometriosis as noted by surgical histology of lesions **AND** • Member has failed a 6-month trial of contraceptive agents (progestins, combined contraceptives, medroxyprogesterone acetate, levonorgestrel IUD).	One year 6 months for moderate hepatic impairment (Child Pugh Class B)

Drug Product(s)	Criteria	PA Approval Length
	Failure is defined as lack of efficacy, allergy, intolerable side effects, significant drug-drug interaction, or contraindication to therapy **AND** • Member has failed a 1 month trial of NSAIDs. Failure is defined as lack of efficacy, allergy, intolerable side effects, significant drug-drug interaction, or contraindication to therapy **AND** • Member has failed a 3 month trial with a GnRH agonist (such as leuprolide). Failure is defined as lack of efficacy, allergy, intolerable side effects, significant drug-drug interaction, or contraindication to therapy **AND** • Member is not pregnant, breast feeding, planning a pregnancy within the next 24 months, or less than 6 months post-partum, post-abortion, or post-pregnancy **AND** • Member has been instructed that only non-hormonal contraceptives should be used during therapy and for at least 1 week following discontinuation **AND** • Member does not have osteoporosis or severe hepatic impairment (Child-Pugh Class C) **AND** • Member is not concomitantly taking a OATP 1B1 inhibitor (such as gemfibrozil, cyclosporine, ritonavir, rifampin). Maximum Dose: 150mg tablet daily, or 200mg tablet twice daily Approval will be limited to a maximum treatment duration of 6 months for members with moderate hepatic impairment (Child-Pugh Class B).	
ORKAMBI (lumacaftor/ivacaftor)	**Orkambi** (lumacaftor/ivacaftor) may be approved for members if the following criteria has been met: • Member must have diagnosis of cystic fibrosis with genetic testing performed to confirm that member is homozygous for the F508del mutation in the CFTR gene AND • Member is 1 year of age or older AND • Member is being treated by a pulmonologist AND • Member has < 5 times upper limit of normal (ULN) AST/ALT or < 3 times ULN AST/ALT if concurrently has > 2 times ULN bilirubin at time of initiation AND • Member has serum transaminase and bilirubin measured before initiation and every 3 months during the first year of treatment	One year
ORIAHNN (elagolix, estradiol, norethindrone acetate)	**Oriahnn** (elagolix, estradiol, norethindrone acetate) prior authorization may be approved for members meeting the following criteria: • Member is a woman 18 years of age or older **AND** • Member has a confirmed diagnosis of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) **AND** • Member has tried and failed treatment with an estrogen-progestin contraceptive (oral tablets, vaginal ring, transdermal patch) OR a progestin-releasing intrauterine device (IUD). Failure is defined as lack of efficacy, allergy, intolerable side effects, significant drug-drug interaction, or contraindication to therapy **AND** • The medication is prescribed by or in consultation with an obstetrician/gynecologist **AND** • Member does not have a high risk of arterial, venous thrombotic, or thromboembolic disorder, including: o Women over 35 years of age who smoke **OR** o Women with a past or current history of the following:	One year

Drug Product(s)	Criteria	PA Approval Length
	▪ DVT, PE, or cerebrovascular disease (such as cerebrovascular disease, coronary artery disease, peripheral vascular disease) **OR** ▪ Thrombogenic valvular or thrombogenic rhythm diseases of the heart (such as subacute bacterial endocarditis with valvular disease, or atrial fibrillation) **OR** ▪ Inherited or acquired hypercoagulopathies **OR** ▪ Uncontrolled hypertension **OR** ▪ Headaches with focal neurological symptoms OR migraine headaches with aura if over age 35 **AND** • Member is not pregnant **AND** • Member does not have known osteoporosis **AND** • Member does not have current or history of breast cancer or other hormonally-sensitive malignancies **AND** • Member does not have known liver impairment or disease **AND** • Member is not concomitantly taking not an OATP 1B1 inhibitor (such as gemfibrozil, ritonavir, rifampin, cyclosporine) **AND** • Member has been counseled that that Oriahnn does not prevent pregnancy **AND** • Member has been instructed that only non-hormonal contraceptives should be used during Oriahnn therapy and for at least 1 week following discontinuation **AND** • Prescriber acknowledges that assessment of bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) is recommended at baseline and periodically thereafter, and discontinuation of Oriahnn should be considered if the risk associated with bone loss exceeds the potential benefit of treatment. Reauthorization: Members with current one-year prior authorization approval on file may receive additional one-year prior authorization approval to continue therapy. Total duration for prior authorization approvals is limited to 2 years (or two one-year approvals). Maximum dose: 2 capsules daily (AM and PM daily doses supplied in blister pack)	
ORLYNVAH (sulopenem etzadroxil/ probenecid)	**Orlynvah** (sulopenem etzadroxil/probenecid) may be approved if the following criteria are met: • Member is female and ≥18 years of age AND • Member has a diagnosis of uncomplicated UTI proven or strongly suspected to be caused by E. coli, K. pneumoniae or P. mirabilis AND • Member has tried and failed‡ treatment with three of the following: o Ciprofloxacin o Fosfomycin o Levofloxacin o Nitrofurantoin o Sulfamethoxazole-trimethoprim AND • Member does not have a known blood dyscrasia AND • Member does not have known uric acid kidney stones AND • Member does not have a history of hypersensitivity to beta-lactam antibiotics AND • Member is not receiving any products that contain ketorolac or ketoprofen AND • Member does not have severe renal impairment (CrCl <15 mL/min) and is not receiving dialysis AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• If the member has a known history of gout, provider attests that appropriate therapy of gout has been instituted AND • Medication is being prescribed by or in consultation with an infectious disease specialist Maximum dose: 2 tablets/day Maximum quantity: One 5-day treatment course (ten 500 mg/500 mg tablets) per 30 days ‡Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction.	

OTC PRODUCTS*	Select OTC products in the following therapeutic categories are covered on the preferred drug list (PDL) *(see PDL for specific product names and coverage information)*:
	• Antihistamines
	• Newer generation antihistamine/decongestant combinations
	• Insulins
	• Intranasal corticosteroids
	• Ophthalmic allergy drops
	• Proton pump inhibitors (PPIs)
	• Topical NSAIDs (diclofenac gel)
	
	The following non-PDL OTC products are covered without prior authorization:
	• Aspirin
	• Bisacodyl (oral and suppository) *Effective 03/01/19*
	• Children's dextromethorphan suspension for ages 4-11 years
	• Children's liquid and chewable acetaminophen for ages < 12 years (note: acetaminophen use in patients younger than 42 days is not recommended)
	• Children's liquid and chewable ibuprofen for ages 6 months – 11 years
	• Docusate (oral) *Effective 03/01/19*
	• Nicotine replacement therapies (OTC patch, gum, and lozenge)
	• Naloxone *Effective 09/01/23*
	• Older generation antihistamine/decongestant combinations
	• Oral emergency contraceptive products
	• Opill (norgestrel) oral daily contraceptive *Effective 09/01/23*
	• Polyethylene glycol powder laxatives
	• Vitamin D infant dops *Effective 09/01/23*
	
	The following non-PDL OTC products may be covered with prior authorization if meeting criteria listed below:
	• Bisacodyl enema may be approved following adequate trial and failure with a bisacodyl oral formulation and bisacodyl suppository (Failure is defined as lack of efficacy with 10 day trial, allergy, intolerable side effects, or significant drug-drug interactions). *Effective 03/01/19*
	• Choline oral tablets may be approved if meeting the following criteria (*Effective 10/01/24*):
	  ○ Choline supplementation is directly related to one of the following conditions:
	  ▪ Member is pregnant or planning to become pregnant
	  ▪ Member is currently breastfeeding
		One year

Drug Product(s)	Criteria	PA Approval Length
	AND o Quantity limit is met (limited to quantity sufficient to achieve 550mg daily) AND o Choline prior authorization approvals are limited to the following OTC products (product list may be subject to change): ▪ Choline citrate 650 mg tablet (*Endurance manufacturer*): NDC 58487-0021-81 ▪ Choline SR 300 mg tablet (*Freeda Health manufacturer*): NDC 29135-0187-20 • Cough and Cold Products may be approved for members with a diagnosis of a chronic respiratory condition for which these medications may be prescribed or based on medical necessity supported by clinical practice recommendations • Cranberry tablets may be approved for urinary tract infections • Docusate enema may be approved following adequate trial and failure with a docusate oral formulation (Failure is defined as lack of efficacy with 10 day trial, allergy, intolerable side effects, or significant drug-drug interactions). *Effective 03/01/19* • Ferrous sulfate and ferrous gluconate may be approved with a diagnosis of iron deficient anemia OR anemia or unknown origin OR iron deficiency verified by low serum ferritin OR "at risk" members < 2 years of age (such as preterm infants or exclusively breastfed members who are at least 4 months old and not yet on iron-enriched solid food). • Fluoride supplements: See "Fluoride Products" section of this document • Guaifenesin 600mg LA may be approved for members having an abnormal amount of sputum • L-methylfolate may be approved for members with depression who are currently taking an antidepressant and are partial or non-responders • Members with a diagnosis of erythema bullosum (EB) may be approved to receive OTC medications (any Medicaid rebate-eligible OTC medications) • Nicomide may be approved for the treatment of acne • Poly-Vi-Sol with Iron (multivitamin with iron) oral liquid may be approved if the following criteria are met (*Effective 01/01/25*): o Member is < 1 year of age AND o Member is being treated for a diagnosis of anemia of prematurity OR is considered clinically "at risk" and requiring supplementation with an oral iron-containing multivitamin medication. Long Term Care Facilities (LTCFs): Various OTC drugs and supplies for LTCF residents shall be furnished by the facility, within the per diem rate, at no charge to the resident pursuant to 10 CCR 2505-10 Skilled Nursing Facility: 8.440 NURSING FACILITY BENEFITS. These OTC drugs and supplies, known as products on a "floor stock list", are not covered or eligible for prior authorization under the pharmacy benefit for LTCF members. ** Coverage criteria outlined in this section apply to prescriptions written by non-pharmacist prescribers. For coverage relating to pharmacist prescribers please see "Pharmacist Prescriptions" section.*	
OXANDRIN (oxandrolone)	**Oxandrin** (oxandrolone) may be approved if meeting all of the following criteria: • Medication is being prescribed for one of the following indications:	One year

Drug Product(s)	Criteria	PA Approval Length
	○ As adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, severe trauma, and without definite pathophysiologic reasons to fail to gain or maintain normal weight ○ To offset the protein catabolism associated with prolonged administration of corticosteroids ○ For the relief of bone pain frequently accompanying osteoporosis AND • Member does not have any of the following medical conditions: ○ Hypercalcemia ○ Known or suspected carcinoma of the prostate or the male breast ○ Carcinoma of the breast in females with hypercalcemia ○ Nephrosis, the nephrotic phase of nephritis AND • If member is female, has had a negative pregnancy test within the past month AND • Medication is being prescribed by or in consultation with an endocrinologist. Maximum Dose: Adults: 20mg daily for 4 weeks Children: ≤ 0.1 mg/kg per day for 4 weeks Adults ≥ 65 years old: 10mg daily for 4 weeks	
OXBRYTA (voxelotor)	**Oxbryta** (voxelotor) prior authorization may be approved for members meeting the following criteria: • Member is ≥ 4 years of age **AND** • Member has a confirmed diagnosis of sickle cell disease **AND** • Member has a hemoglobin ≥ 5.5 g/dL **AND** • OXBRYTA is prescribed by or in consultation with hematologist/oncologist or sickle cell disease specialist **AND** • Prior to initiation of therapy, member had at least two episodes of sickle cell related pain crises in the past 12 months **AND** • Member has trialed and failed a six-month trial of hydroxyurea (intolerance or contraindication) or is continuing concomitant hydroxyurea therapy following a six-month trial. Failure is defined as lack of efficacy, allergy, intolerable side effects, significant drug-drug interaction, or contraindication to therapy **AND** • Member is not receiving chronic transfusion therapy **OR** • Member has severe renal disease (GFR <30 mL/min) Initial approval: 6 months Reauthorization: Member may receive reauthorization approval for 1 year if meeting the following: • Member has a reduction in vasoocclusive events and/or increased hemoglobin response rate defined as a hemoglobin increase of more than 1 g/dL. Maximum dose: 1,500 mg per day (2,500 mg per day may be approved for members taking concomitant strong or moderate CYP3A4 inducers (such as carbamazepine, oxcarbazepine, phenytoin, phenobarbital, rifaximin, rifampin or dexamethasone-containing products).	Initial: 6 months Continued: One year
OXERVATE (cenegermin-bkbj)	**Oxervate** (cenegermin-bkbi) prior authorization may be approved for members meeting the following criteria: • Member is 2 years of age or older **AND**	8 weeks

<table>
<tr><th>Drug Product(s)</th><th>Criteria</th><th>PA Approval Length</th></tr>
<tr><td></td><td>

Member has a confirmed diagnosis of stage 2 neurotrophic keratitis (NK), persistent epithelial defect [PED], or stage 3 neurotrophic keratitis (corneal ulcers) AND
Oxervate is being prescribed in consultation with an ophthalmologist or optometrist AND
Member’s PED and/or corneal ulcer have been present for at least two weeks AND
Member has trialed and failed one of the following conventional non-surgical treatments: preservative-free lubricant eye drops or ointment, therapeutic soft contact lenses, or topical autologous serum application. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND
Member has decreased corneal sensitivity (≤4 cm using the Cochet-Bonnet esthesiometer) within the area of the PED or ulcer and outside the area of defect in at least one corneal quadrant AND
Prescriber attests to member’s discontinued use of preserved topical agents that can decrease corneal sensitivity AND
Member <u>does not</u> have any of the following:

Active ocular infection or active inflammation not related to NK in the affected eye
Schirmer test without anesthesia ≤3 mm/5 min in the affected eye
Any ocular surgery in the affected eye within the past 90 days that has not been determined to be the cause of NK
Corneal perforation, ulceration involving the posterior third of the corneal stroma, or corneal melting

Maximum dose: 12 drops daily
</td><td></td></tr>
<tr><td>OXLUMO (lumasiran)</td><td>
OXLUMO (lumasiran) may be approved if all the following criteria are met:

For billing under the pharmacy benefit, the medication is being administered by a healthcare professional in the member’s home or in a long-term care facility AND
Member has a diagnosis of Primary hyperoxaluria type 1 (PH1) confirmed by either:

Genetic testing that demonstrates a mutation of the alanine glyoxylate aminotransferase (AGXT) gene OR
Liver enzyme analysis demonstrating absent or significantly reduced AGXT

AND
Medication is being prescribed by, or in consultation with a nephrologist, neurologist, or other healthcare provider with expertise in treating PH1 AND
Member has documented baseline urinary oxalate excretion or plasma oxalate concentrations.

<u>Reauthorization</u>: Member demonstrates response to medication as indicated by a positive clinical response from baseline urinary oxalate excretion or plasma oxalate concentration

<u>Maximum Dose</u>: Weight-based dosing regimen as shown in the following table (documentation of patient’s current weight with the date the weight was obtained).
<table>
<tr><th>Body Weight</th><th>Loading Dose</th><th>Maintenance Dose</th></tr>
<tr><td>Less than 10 kg</td><td>6 mg/kg once monthly for three doses</td><td>3 mg/kg once monthly, beginning one month</td></tr>
</table>
</td><td>One year</td></tr>
</table>

<table>
<tr><th>Drug Product(s)</th><th>Criteria</th><th>PA Approval Length</th></tr>
<tr><td></td><td>
<table>
<tr><td></td><td></td><td>after the last loading dose</td></tr>
<tr><td>10 kg to less than 20 kg</td><td>6 mg/kg once monthly for three doses</td><td>6 mg/kg once every three months, beginning one month after the last loading dose</td></tr>
<tr><td>20 kg and above</td><td>3 mg/kg once monthly for three doses</td><td>3 mg/kg once every three months, beginning one month after the last loading dose</td></tr>
</table>
Members currently stabilized on a Oxlumo (lumasiran) regimen may receive prior authorization approval for continuation of therapy if meeting reauthorization criteria listed above.
</td><td></td></tr>
<tr><td>PALFORZIA (arachis hypogaea allergen powder-dnfp)</td><td>
Palforzia (arachis hypogaea allergen powder-dnfp) prior authorization may be approved for members meeting the following criteria:

Member is 4 -17 years of age at initiation of therapy AND
Member has a documented diagnosis of peanut allergy within the past 2 years (ICD-10 Z91.010) AND
Diagnosis of peanut allergy is made by or in consultation with an allergist or immunologist AND
Palforzia will be used in conjunction with a peanut-avoidant diet AND
Member does not have a past or current history of any of the following:

Severe, unstable or uncontrolled asthma
Eosinophilic esophagitis or other eosinophilic gastrointestinal disease
Mast cell disorder including mastocytosis, urticarial pigmentosa, and hereditary or idiopathic angioedema
Severe or life-threatening anaphylaxis within the previous 60 days

AND
Member has injectable epinephrine available for immediate use at all times and counseling regarding proper use has been provided AND
Prescriber acknowledges member preparedness to adhere to complex up-dosing schedule and frequent visits to the administering healthcare facility AND
Prescriber acknowledges that Palforzia doses administered by a healthcare provider in the doctor’s office or clinic are to be billed through the Health First Colorado medical benefit through the standard buy-and-bill process.

Reauthorization: Member may receive reauthorization approval for 1 year if meeting the following:

Palforzia continues to be used in conjunction with a peanut-avoidant diet AND
Member continues to tolerate the prescribed daily doses of Palforzia AND
Member continues to have injectable epinephrine available for immediate use at all times AND
Member has not experienced recurrent asthma exacerbations AND
Member does not have eosinophilic esophagitis or other eosinophilic gastrointestinal disease AND

</td><td>One year</td></tr>
</table>

Drug Product(s)	Criteria	PA Approval Length
	• Member does not have a mast cell disorder including mastocytosis, urticarial pigmentosa, and/or hereditary/idiopathic angioedema **AND** • Member has not experienced any treatment-restricting adverse effects (such as repeated systemic allergic reaction and/or severe anaphylaxis) Maximum dose (maintenance): 300 mg daily	
PALSONIFY (paltusotine)	**Palsonify** (paltusotine) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a confirmed diagnosis of acromegaly AND • Member has had an inadequate response to surgery or surgery is not an option AND • Palsonify (paltusotine) is being prescribed by, or in consultation with, an endocrinologist AND • Member has trialed and failed‡ treatment with a dopamine agonist (bromocriptine mesylate or cabergoline) at maximally tolerated doses AND • Member has responded to and tolerated 3 months of treatment with octreotide acetate injection OR lanreotide acetate injection AND • Provider attests that blood glucose, growth factor levels, thyroid function, and vitamin B12 levels will be monitored periodically during treatment with Palsonify (paltusotine) AND • Prescriber verifies that concomitant medications have been assessed for potential drug interactions (CYP3A4 inhibitors, CYP3A4 inducers, proton pump inhibitors) and any needed paltusotine dose adjustments have been made in accordance with package labeling AND • Member is not hypersensitive to povidone, copovidone, or crospovidone, an inactive excipient in Palsonify (paltusotine) tablets AND • Prescriber is aware that dose adjustments of concomitantly used drugs with bradycardic effects (such as beta-blockers, digoxin, calcium channel blockers) may be necessary during Palsonify (paltusotine) therapy AND • Member will be periodically monitored for signs and symptoms of cholelithiasis. Maximum Dose: 120 mg daily Quantity Limit: 120 tablets/30 days Continuation of Therapy: Members who are currently stabilized on Palsonify (paltusotine) may receive approval for continuation of therapy with that agent. ‡Failure is defined as lack of efficacy with a 3-month trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction.	One year
PALYNZIQ (pegvaliase-pqpz)	**Palynziq** (pegvaliase-pgpz) prior authorization may be approved for members meeting the following criteria: • Member is at 18 years of age or older **AND** • Member has a diagnosis of phenylketonuria (PKU) **AND** • Member has a blood phenylalanine concentration > 600 mcmol/L **AND** • Member is not receiving Palynziq in combination with Kuvan (sapropterin dihydrochloride) **AND** • Member is actively on a phenylalanine-restricted diet **AND**	One year

Drug Product(s)	Criteria	PA Approval Length
	• Member will have a phenylalanine blood level measured at baseline prior to initiation and every four weeks until a maintenance dose is established **AND** • Prescriber acknowledges that first dose is being administered under the supervision of a healthcare provider equipped to manage anaphylaxis **AND** • Prescriber acknowledges that any doses administered in the doctor's office or clinic are to be billed to the Health First Colorado medical benefit through the standard buy-and-bill process. Reauthorization: Member may receive reauthorization approval for 1 year if meeting the following: • Member is showing signs of continuing improvement, as evidenced by one of the following: o Blood phenylalanine level decrease of at least 20% from pre-treatment baseline **OR** o Reduction of blood phenylalanine below 600 mcmol/L at current dose or maximum dose after 16 weeks of treatment. Maximum dose: 60 mg per day	
PAXLOVID* (nirmatrelvir/ritonavir) **FDA-approved NDA-labeled product formulations*	Quantity limits: 30 tablets per 5 days (300mg/100mg) 20 tablets per 5 days (150mg/100mg) Minimum age: 12 years *Note: Effective 01/01/2025, 340B pharmacy claims for the FDA-approved NDA-labeled Paxlovid may be submitted through the Health First Colorado pharmacy benefit instead of the Pfizer PAXCESS™ Patient Support Program.*	
PHARMACIST PRESCRIPTIONS	**OTC Products:** The following OTC products are eligible for coverage with a written prescription by an enrolled† pharmacist: • Oral emergency contraceptive products • Opill (norgestrel) oral daily contraceptive *(effective 09/01/2023)* • Naloxone *(effective 09/01/2023)* • Nicotine replacement therapy products including: o Nicotine gum (up to 220 units/fill) o Nicotine patch (up to 30 patches/30days) o Nicotine lozenge (up to 288 units/fill) • Children's dextromethorphan suspension for members age 4-11 years (up to 150 ml per 30 days) • Children's liquid and chewable acetaminophen for members age 2-11 years (up to 240 ml per 30 days) • Children's liquid and chewable ibuprofen for members age 6 months-11 years (up to 240 mL per 30 days) **Prescription Products:** The following prescription products are eligible for coverage with a written prescription by an enrolled† pharmacist: • Oral contraceptives • MAT medications used for treatment of OUD (effective 05/01/2025) • Topical patch contraceptives*	

Drug Product(s)	Criteria	PA Approval Length
	• Vaginal ring contraceptives* *(effective 11/30/22)* • Depo medroxyprogesterone contraceptive injection *(effective 11/30/22)* • Oral HIV pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) medications • Smoking cessation medications (Chantix, varenicline, generic Zyban) • Nicotine replacement therapy products (Nicotrol) • Naloxone product formulations FDA-approved for use for the emergency treatment of opioid overdose *(effective 5/12/22; retroactive to 1/14/22)* • Opvee (nalmefene) intranasal • Paxlovid *(effective 7/26/22; retroactive to 7/6/22)* • Statins *(effective 11/30/22)* **Other Medications:** Effective November 15, 2023, pharmacists may be indicated as a prescribing provider for certain medications which fall outside of collaborative practice agreements and statewide protocols; and pharmacy claims where pharmacists are enrolled† and indicated as the prescribing provider for these medications must meet the following criteria (note: claims submitted for criteria 1, 2, and 3 for an enrolled† pharmacist prescriber will receive denial code 6Z/50602 - "Provider Not Elig To Perform Serv/Dispense Product" and the prescribing pharmacist must call the Prime Therapeutics pharmacy help desk at 1-800-424-5725 in order to complete a prior authorization for the claim): 1. The member is 12 years of age or older AND 2. The drug being prescribed is not a controlled substance AND 3. The condition does not require a new diagnosis, is minor and generally self-limiting or has a Clinical Laboratory Improvement Amendments (CLIA)-waived test which the pharmacist administers and uses to guide clinical decision-making. OR 4. The prescription falls within prescriptive authority as outlined under Department of Regulatory Agencies (DORA) Rules incorporated in 3 CCR 719-1 17.00.00. OR 5. The prescription is for a medication which has Emergency Use Authorization (EUA) issued by the US Food and Drug Administration (FDA) that supersedes state law and allows a pharmacist to prescribe said medication. *See Preferred Drug List (PDL) for listing of preferred products. †Additional information regarding pharmacist enrollment can be found at https://hcpf.colorado.gov/provider-enrollment	
PHYSICIAN ADMINISTERED DRUGS	Medications administered in a doctor's office, clinic, outpatient hospital, or dialysis unit are only to be billed by those facilities through the Health First Colorado medical benefit using the standard buy-and-bill process and following procedures outlined in the PAD Billing Manual (located at https://www.colorado.gov/hcpf/physician-administered-drugs). Physician administered drugs (PADs) include any medication or medication formulation that is administered intravenously or requires administration by a healthcare professional (including cases where FDA package labeling for a medication specifies that administration should be performed by or under the direct supervision of a healthcare professional) and may only be billed through the pharmacy benefit when given in a long-term care facility or when administered in the member's home by a healthcare professional or home health	

Drug Product(s)	Criteria	PA Approval Length
	service. Prior authorization for physician administered drugs requires documentation of the following (in addition to meeting any other prior authorization criteria if listed): • For drugs administered in the member's home by a home health agency or healthcare professional (home health administered): 1. Name of home health agency or healthcare professional 2. Phone number 3. Date and authorization number for home health authorization on file (when applicable for home health agencies) • For drugs administered in a long-term care facility: 1. Name of long-term care facility 2. Phone number of long-term care facility Effective January 18, 2022, a select number of PADs billed through the medical benefit will be subject to prior authorization requirements. Additional policy and procedure information, including the list of PADs subject to the new utilization management policy, can be found on the PAD Resources Page at https://hcpf.colorado.gov/physician-administered-drugs. For policies and procedures regarding extended-release injectable medications (LAIs) used for the treatment of mental health or substance use disorders, please see the applicable Appendix P section(s) for these products.	
PIASKY (crovalimab)	**Piasky** (crovalimab) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND • Member is ≥ 13 years of age AND • Member weighs at least 40 kg (88.2 pounds) AND • Member has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) confirmed by high sensitivity flow cytometry AND • The requested medication is being prescribed by or in consultation with a hematologist, immunologist or nephrologist AND • Member has a lactate dehydrogenase (LDH) level ≥ 2 times the upper limit of normal AND • Member has had at least one PNH-related sign or symptom (such as hemoglobinuria, fatigue, dyspnea, abdominal pain, dysphagia) within the past 3 months AND • Member has a hemoglobin level measured at baseline AND • Member does not have any active infections caused by an encapsulated bacteria (such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b) AND • Member has been vaccinated against Neisseria meningitidis (serogroups A, C, W, Y and B) within the 3 years prior to initiation of treatment with Piasky (crovalimab) OR will be vaccinated against Neisseria meningitidis within 7 days after starting treatment AND • Member has been vaccinated against Streptococcus pneumoniae and Haemophilus influenzae type b (Hib) according to ACIP recommendations. If urgent Piasky (crovalimab) therapy is indicated in a patient who is not up to date with vaccines, or the vaccines were administered within the last 2 weeks, prescriber attests that the member will receive appropriate antibacterial drug prophylaxis and the vaccines will be administered as soon as possible AND	Initial: 6 months Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	• Members of childbearing age have been counseled that fetal effects of Piasky (crovalimab) during pregnancy are unknown, and to avoid breastfeeding during treatment with Piasky (crovalimab) and for 9 months following the final dose AND • Due to the risk of forming drug-target-drug complexes (DTDCs) and Type III hypersensitivity reactions, monitor patients switching from another C5 inhibitor to Piasky (crovalimab) or from Piasky (crovalimab) to another C5 inhibitor for at 30 days as outlined in the full prescribing information. Maximum dose: 1,500 mg intravenous loading dose 340 mg subcutaneous loading doses (Days 2, 8, 15, 22) 1,020 mg subcutaneous maintenance doses (Day 29 and every 4 weeks thereafter) Quantity limit: Initial IV loading dose: 5 single-dose 340 mg/2 mL vials Subcutaneous loading doses: 4 single-dose 340 mg/2 mL vials Subcutaneous maintenance doses: 3 single-dose 340 mg/2 mL vials every 28 days Reauthorization: Approval for 1 year may be given with prescriber attestation that member meets at least one of the following 6 months after initiation of treatment: • Member has achieved BOTH of the following: o Hemolysis control, defined as LDH ≤ 1.5× ULN during the first 6 months of treatment AND o Transfusion avoidance, defined as not receiving a transfusion of packed red blood cells during the first 6 months of treatment OR • Member has been monitored for breakthrough hemolysis and meets BOTH of the following: o Member has a documented initial reduction of LDH ≤ 1.5 × ULN while on treatment AND o Member has not experienced at least one new or worsening symptom or sign of intravascular hemolysis in the presence of elevated LDH ≥ 2 × ULN after the prior reduction of LDH ≤ 1.5 × ULN while on treatment OR • Member has achieved hemoglobin stabilization, defined as avoidance of a ≥ 2 g/dL decrease in hemoglobin level from baseline in the absence of transfusion.	
POMBILITI and OPFOLDA (cipaglucosidase alfa-atga and miglustat)	**Pombiliti** (cipaglucosidase alfa-atga) and **Opfolda** (miglustat) may be approved when the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND • Member is ≥18 years of age AND • Member has an actual body weight of ≥ 40 kg AND • Member has a definitive diagnosis of late-onset Pompe disease confirmed by one of the following: o Deficiency of acid alpha-glucosidase (GAA) enzyme activity OR o Detection of biallelic pathogenic variants in the GAA by molecular genetic testing AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Requested product is being prescribed by a provider specializing in the treatment of Pompe disease AND • Member has tried and failed† Lumizyme (alglucosidase alfa) or Nexviazyme (avalglucosidase-ngpt) AND • Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) will be used in combination according to the approved product labeling AND • The requested medications will not be used in combination with other lysosomal acid alpha glucosidase (GAA) enzyme replacement therapies AND • More frequent monitoring of vital signs will be performed during Pombiliti infusion for members who are susceptible to fluid volume overload and those with acute underlying respiratory illness or compromised cardiac or respiratory function AND • Member is not pregnant or breastfeeding, and member and partners have been counseled on appropriate use of contraception AND • Member has documented baseline age-appropriate assessments, including motor function tests, muscle weakness, respiratory function, cardiac involvement testing, percent predicted forced vital capacity (FVC), and 6-minute walk test (6MWT) AND • Prescriber acknowledges consideration for administering antihistamines, antipyretics, and/or corticosteroids prior to Pombiliti (cipaglucosidase alfa) administration to reduce the risk of severe infusion-associated reactions. Reauthorization: Pombiliti (cipaglucosidase alfa) and Opfolda (miglustat) may be approved for one year if member met initial approval criteria at the time of initiation of therapy AND meets the following: • Member has shown clinical improvement defined as an improvement or stabilization in percent predicted FVC and/or 6MWT AND • Member is being monitored for antibody formation and hypersensitivity Maximum Dose: Pombiliti (cipaglucosidase alfa): Members ≥40 kg: 20 mg/kg administered every 2 weeks Opfolda (miglustat): 8 capsules per 28 days †Failure is defined as lack of efficacy or intolerable side effects.	
PRALUENT (alirocumab)	**Praluent** (alirocumab) may be approved if the following criteria are met: • The requested medication is being prescribed for one of the following indications based on the member's age: o Members ≥ 18 years of age: ▪ Reducing the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in a member with established cardiovascular disease OR ▪ As an adjunct to diet, to reduce LDL-C (alone or in combination with other LDL-C lowering therapies) to treat primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) OR ▪ As an adjunct to other LDL-C-lowering therapies, to treat homozygous familial hypercholesterolemia (HoFH) o Members 8 to 17 years of age:	One year

Drug Product(s)	Criteria	PA Approval Length
	▪ As an adjunct to diet and other LDL-C-lowering therapies to treat heterozygous familial hypercholesterolemia (HeFH) AND • The requested medication is being prescribed by, or in consultation with a cardiologist, Certified Lipid Specialist (CLS) or an endocrinologist AND • Member has failed to achieve desired LDL-C with maximally tolerated therapy with one high-potency statin (atorvastatin or rosuvastatin) in combination with ezetimibe. Failure is defined as lack of efficacy (member with ASCVD and LDL-C >55 mg/dL or member with HoFH and LDL-C >100 mg/dL) after a 3-month trial, allergy, intolerable side effects, contraindication, or significant drug-drug interaction. For members with past or current incidence of rhabdomyolysis, trial and failure of statin therapy is not required AND • Prescriber acknowledges that hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization have been reported with Praluent (alirocumab) use, and prescriber attests that evolocumab will be discontinued and treatment and monitoring according to standard of care will occur until symptoms resolve if a serious hypersensitivity reaction occurs AND • Member will be counseled that Praluent (alirocumab) pens must be stored in a refrigerator, protected from exposure to light, not shaken, and brought to room temperature prior to use. Reauthorization: Reauthorization may be approved for 1 year with provider attestation confirming efficacy in lowering LDL-C. Maximum Dose (adults): 150 mg every two weeks Quantity Limits: 75 mg/mL single-dose prefilled pen: 2 pens/month 150 mg/mL single-dose prefilled pen: 2 pens/month	
PRETOMANID	**Pretomanid** prior authorization may be approved for members meeting the following criteria: • Member is an adult (≥ 18 years of age) **AND** • Member has a confirmed diagnosis of multidrug resistant tuberculosis **AND** • Pretomanid is prescribed by or in conjunction with an infectious disease specialist **AND** • Pretomanid is prescribed in combination with bedaquiline and linezolid by directly observed therapy (DOT) **AND** • Prescriber acknowledges member readiness and anticipated compliance with undergoing directly observed therapy (DOT) **AND** • Prescriber acknowledges that Pretomanid doses administered by a healthcare provider in a hospital, doctor's office, or clinic are to be billed through the Health First Colorado medical benefit through the standard buy-and-bill process. Maximum dose: 200 mg orally once daily	One year
PREVYMIS (letermovir)	**Prevymis** (letermovir) may be approved for members that meet the following criteria: • Member is a CMV-seropositive transplant recipient AND • Member meets one of the following: o Member is 12 years of age or older and has received an allogeneic hematopoietic stem cell transplant or kidney transplant OR	100 days

Drug Product(s)	Criteria	PA Approval Length
	○ Member is 6 months to 12 years of age and has received an allogenic hematopoietic stem cell transplant AND • Member does not have severe hepatic impairment (Child-Pugh Class C). • Member is not receiving pitavastatin or simvastatin co-administered with cyclosporine AND • Member is not receiving pimozide or ergot alkaloids AND • The requested drug is being prescribed by or in consultation with an oncologist, hematologist, infectious disease specialist, or transplant specialist AND • Provider agrees to monitor for CMV reactivation AND • Dosing does not exceed 480 mg orally or dose does not exceed 240mg if co-administered with cyclosporine AND • If request is for the oral pellet formulation, provider attests that the member is unable to take the tablet formulation AND • If request is for the IV injectable formulation, must provide medical justification why the patient cannot use oral therapy. AND • If request is for the IV injectable formulation, must be administered in a long-term care facility or in a member's home by a home healthcare provider. <u>Length of Approval</u>: Prevymis may only be approved for 100 days. <u>Reauthorization</u>: Authorization may be reviewed every 100 days to confirm that current medical necessity criteria are met and that the medication is effective (e.g. no evidence of CMV viremia).	
PROCYSBI (cysteamine)	Approval will be granted if the member is 1 years of age or older **AND** Has a diagnosis of nephropathic cystinosis **AND** documentation is provided to the Department that treatment with cysteamine IR (Cystagon®) was ineffective, not tolerated, or is contraindicated.	One year
PROMACTA (eltrombopag)	**Promacta** (eltrombopag) prior authorization may be approved for members meeting criteria for the following diagnoses: <u>Chronic immune idiopathic thrombocytopenia purpura:</u> • Confirmed diagnosis of chronic (> 3 months) immune idiopathic thrombocytopenia purpura AND • Must be prescribed by a hematologist AND • Member is at risk (documented) of spontaneous bleed as demonstrated by the following labs: AND ○ Platelet count less than 20,000/mm3 or ○ Platelet count less than 30,000/mm3 accompanied by signs and symptoms of bleeding • In the past 6 months, member has tried and failed (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions) systemic corticosteroids (e.g. prednisone 1 to 2 mg/kg for 2 to 4 weeks, or pulse dexamethasone 40 mg daily for 4 days), immunoglobulin replacement, or splenectomy. <u>Thrombocytopenia associated with hepatitis C:</u> • Member must have confirmed diagnosis of chronic hepatitis C associated thrombocytopenia AND	One year*

Drug Product(s)	Criteria	PA Approval Length
	• Must be prescribed by a gastroenterologist, infectious disease specialist, transplant specialist or hematologist AND • Member has clinically documented thrombocytopenia defined as platelets < 60,000 microL AND • Patients' degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy <u>Severe aplastic anemia:</u> • Member must have confirmed diagnosis of severe aplastic anemia AND • Must be prescribed by a hematologist AND • Member must have had a documented insufficient response to immunosuppressive therapy [antithymocyte globulin (ATG)] alone or in combination with cyclosporine and/or a corticosteroid *All initial prior authorization approvals will be granted for 12 months. Further approvals for a maximum of 6 months require lab results and documentation for efficacy.	
PROPECIA (finasteride)	***Not covered for hair loss*** *Not qualified for emergency 3 day supply PA*	One year
PULMOZYME (dornase alfa)	**Pulmozyme** (dornase alfa) may be approved for members that meet the following criteria: • Member has a diagnosis of cystic fibrosis AND • Member is five years of age or older o For children < 5 years of age, Pulmozyme will be approved if the member has severe lung disease as documented by bronchoscopy or CT scan Pulmozyme twice daily will only be approved if patient has tried and failed an adequate trial of once daily dosing for one month All prior authorization renewals are reviewed on an annual basis to determine the Medical Necessity for continuation of therapy. Authorization may be extended at 1-year intervals based upon documentation from the prescriber that the member continues to benefit from Pulmozyme therapy. Quantity Limits: 30 ampules (2.5 mg/2.5 ml) per month	
PYRUKYND (mitapivat)	**Pyrukynd** (mitapivat) may be approved if the following criteria are met: • Member is ≥ 18 years of age **AND** • The requested medication is being used for treatment of hemolytic anemia with pyruvate kinase deficiency with least 2 variant alleles in the pyruvate kinase liver and red blood cell (PKLR) gene, of which at least 1 is a missense variant **AND** • Member does not have moderate to severe hepatic impairment, **AND** • Due to the risk of developing acute hemolysis, provider confirms that member has been counseled to avoid abrupt discontinuation of PYRUKIND (mitapivat) therapy **AND** • Prescriber confirms that potentially significant drug-drug interactions (such as those with itraconazole, ketoconazole, fluconazole, rifampin, efavirenz and other CYP3A	Initial: 6 months Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	inhibitors and inducers) will be carefully evaluated prior to initiating therapy with PYRUKIND (mitapivat), based on the current product labeling Maximum Dose: 100 mg/day Quantity Limit: 2 tablets/day Reauthorization: Reauthorization may be approved for 12 months if prescriber attests to observed benefit after 24 weeks of Pyrukynd (mitapivat) therapy, based on hemoglobin and/or markers of hemolysis and transfusion requirements.	
QBREXZA (glycopyrronium)	*Note: Qbrexza is currently not a participating product in the Medicaid Drug Rebate Program (MDRP).* **Qbrexza** (glycopyrronium) prior authorization may be approved for members meeting the following criteria: • Member is 9 years of age or older **AND** • Member has a diagnosis of primary hyperhidrosis occurring more than once weekly and symptoms cease at night **AND** • Member has a documented Hyperhidrosis Disease Severity Scale (HDSS) score of 3 or 4 **AND** • There is documentation that the axillary hyperhidrosis is severe, intractable and disabling in nature as documented by at least one of the following: o Significant disruption of professional and/or social life as a result of excessive sweating **OR** o The condition is causing persistent or chronic cutaneous conditions (such as skin maceration, dermatitis, fungal infections, secondary microbial infections) **AND** • Prescriber has considered a trial of OTC topical antiperspirants (such as 20% aluminum chloride hexahydrate,15% aluminum chloride hexahydrate, or 6.25% aluminum chloride hexahydrate) Initial approval: 3 months Reauthorization: Member may receive reauthorization approval for 1 year if meeting the following: • Member has documented improvement of at least two points in Hyperhidrosis Disease Severity Scale (HDSS) score following initiation (or ongoing use) of Qbrexza regimen. Maximum dose: 1 cloth per day	Initial: 3 months Continued: One year
RADICAVA (edaravone)	**Radicava** (edaravone) may be approved if meeting the following criteria: • Member is ≥ 18 years of age AND • For requests for the IV formulation, the medication is being administered in a long-term care facility or in a member's home by a home healthcare provider OR for requests for the oral suspension formulation, the prescriber attests that the member is not a candidate for use for the IV formulation of Radicava (edaravone) AND	6 months

Drug Product(s)	Criteria	PA Approval Length
	• Member has a "definite" or "probable" diagnosis of amyotrophic lateral sclerosis (ALS) based on medical history and diagnostic testing which may include imaging and nerve conduction conditions studies AND • The requested medication is prescribed by or in consultation with a neurologist AND • The request meets all of the following: o Member has a diagnosis of ALS for 2 or less years (for new starts only) AND o Diagnosis has been established by or with the assistance of a neurologist with expertise in ALS using El Escorial or Airlie House diagnostic criteria (ALSFRS-R) AND o Member has normal respiratory function as defined as having a percent-predicated forced vital capacity of greater than or equal to 80% AND o The ALSFRS-R score is greater than or equal to 2 for all items in the criteria AND o Member does not have severe renal impairment (CrCl< 30 ml/min) or end stage renal disease. Quantity Limits: • IV Formulation: 28 bags per 28 days (initial dose) for the first month and 20 bags per 28 days for the remainder of the 6 months. • Oral Suspension Initiation: 14 doses of 105 mg each (28-day supply): Two cartons, each containing one 35 mL bottle of oral suspension or one carton containing two 35 mL bottles of oral suspension. • Oral Suspension Maintenance: 10 doses of 105 mg each, within 14 days: One carton containing one 50 mL bottle Renewal: Authorization may be reviewed every six months to confirm that current medical necessity criteria are met and that the medication is effective per improvement in ALSFRS-R score.	
RANITIDINE Capsule/Solution	Prescription ranitidine capsule and liquid formulations require prior authorization. Ranitidine capsule: Require the prescribing provider to certify that capsules are medically necessary and that the member cannot use the tablets. Ranitidine liquid: A prior authorization will be approved for members with a feeding tube or who have difficulty swallowing. A prior authorization is not required for children under 12 years of age.	One year
RAVICTI (glycerol phenylbutyrate)	**Ravicti** (glycerol phenylbutyrate) will only be approved for members meeting the following criteria: • Member must have a documented diagnosis of urea cycle disorder (UCD) • Member must be on a dietary protein restriction (verified by supporting documentation) • Member must have tried and failed Buphenyl as evidenced by uncontrolled hyperammonia over the past 365 days • Medication must be prescribed by a physician experienced in the management of UCD (e.g., geneticist)	One year
REBATE DISPUTE DRUGS	Medical necessity. Not qualified for emergency 3 day supply PA	One year

Drug Product(s)	Criteria	PA Approval Length
RECORLEV (levoketoconazole)	**Recorlev** (levoketoconazole) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of endogenous hypercortisolemia with Cushing's syndrome AND • Pituitary surgery is not an option or the member had surgery and it was not curative AND • The requested drug is NOT being prescribed to treat a fungal infection AND • Member does not concomitantly take a proton pump inhibitor, H2-receptor antagonist, sucralfate, or have excessive alcohol intake AND • The requested drug is being prescribed by, or in consultation with, an endocrinologist AND • Member does not have cirrhosis, acute liver disease, poorly controlled chronic liver disease, extensive metastatic liver disease, recurrent symptomatic cholelithiasis, or a prior history of azole antifungal-induced liver injury AND • Provider attests that the member's care plan will include frequent monitoring for significant adverse events (such as hepatotoxicity, QTc prolongation, hypercortisolism, low serum testosterone and major drug-drug interactions) as described in product labeling. Maximum Dose: 1,200 mg/day	One year
RELYVRIO (sodium phenylbutyrate /taursodiol)	**Relyvrio** (sodium phenylbutyrate/taursodiol) may be approved if the following criteria are met: • Member is ≥ 18 years of age **AND** • Member has a definite diagnosis of sporadic or familial ALS, as defined by the revised El Escorial (Airlie House) criteria, with symptom onset within the past 18 months (for new starts only), **AND** • ALS disease progression is recorded at baseline (prior to initiation) using the Revised ALS Functional Rating Scale (ALSFRS-R), **AND** • The requested medication is prescribed by or in consultation with a neurologist **AND** • Member has normal respiratory function, defined as having a forced vital capacity (FVC) ≥ 80% of predicted, **AND** • Due to the high sodium content of this product, provider attests that member does NOT have heart failure, hypertension, renal impairment or other salt-sensitive medical conditions. Initial Approval: 6 months Reauthorization: After 6 months, members may receive approval to continue therapy if the following criteria are met: • The member has shown no adverse events due to Relyvrio treatment AND • The member has demonstrated response to Relyvrio treatment by showing significant clinical improvement or no decline documented using the Revised ALS Functional Rating Scale (ALSFRS-R). Authorization may be reviewed every six months to confirm that current medical necessity criteria are met, and that the medication is effective based on improvement or no decline based on the ALSFRS-R score.	Initial Approval: 6 months Continuation Approval: One year

Drug Product(s)	Criteria	PA Approval Length
	Maximum dose: 2 packets (dissolved in water) per day Quantity limit: 60 packets/30 days The above coverage criteria will continue to be reviewed and evaluated for any applicable changes due to the evolving nature of factors including disease course, available treatment options and available peer-reviewed medical literature and clinical evidence. If use outside of stated coverage standards is requested, support with peer reviewed medical literature and/or subsequent clinical rationale shall be provided and will be evaluated at the time of request. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).	
REPATHA (evolocumab)	**Repatha** (evolocumab) may be approved if the following criteria are met: • The requested medication is being prescribed for one of the following indications based on the member's age: o Members ≥ 18 years of age: ▪ To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in a member with established cardiovascular disease OR ▪ As an adjunct to diet, to reduce LDL-C (alone or in combination with other LDL-C lowering therapies) to treat primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) o Members ≥10 years of age: ▪ As an adjunct to diet and other LDL-C lowering therapies to treat heterozygous familial hypercholesterolemia (HeFH) OR ▪ As an adjunct to other LDL-C-lowering therapies to treat homozygous familial hypercholesterolemia (HoFH) AND • The requested drug is being prescribed by or in consultation with a cardiologist, Certified Lipid Specialist (CLS), or an endocrinologist AND • Member has failed to achieve desired LDL-C with maximally tolerated therapy with one high-potency statin (atorvastatin or rosuvastatin) in combination with ezetimibe. Failure is defined as lack of efficacy (member with ASCVD and LDL-C >55 mg/dL or member with HoFH and LDL-C >100 mg/dL) after a 3-month trial, allergy, intolerable side effects, contraindication, or significant drug-drug interaction. For members with past or current incidence of rhabdomyolysis, trial and failure of statin therapy is not required AND • Prescriber acknowledges that hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization have been reported with Repatha (evolocumab) use, and prescriber attests that evolocumab will be discontinued and treatment and monitoring according to standard of care will occur until symptoms resolve if a serious hypersensitivity reaction occurs AND • Member will be counseled that Repatha (evolocumab) pens must be stored in a refrigerator, protected from exposure to light, not shaken, and brought to room temperature prior to use. Reauthorization: Additional authorization for one year may be approved with provider attestation to efficacy in LDL-C lowering.	One year

Drug Product(s)	Criteria	PA Approval Length
	Maximum Dose: 420 mg monthly Quantity Limits: 140 mg/mL single-dose prefilled autoinjector: 6 autoinjectors/month 140 mg/mL single-dose prefilled syringe: 6 prefilled syringes/month 420 mg/3.5 mL single-dose on-body infusor: 1 infusor/month	
REVCOVI (elapegademase-lvlr)	**Revcovi** (elepegademase-lvlr) may be approved if the following criteria are met: • Member has a diagnosis of adenosine deaminase severe combined immune deficiency (ADA-SCID). Maximum Dose: 0.4mg/kg per week (based on ideal body weight, IM administration)	One year
REZDIFFRA (resmetirom)	**Rezdiffra** (resmetirom) may be approved if meeting the following criteria: • Member is ≥ 18 years of age AND • Member has a diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) with stage F2 to F3 fibrosis that has been confirmed by clinical presentation along with laboratory findings and/or imaging and/or biopsy results AND • The member does not have decompensated cirrhosis AND • The member's cardiovascular risk factors (such as hypertension, dyslipidemia, diabetes) have been evaluated and appropriately treated AND • Members who are overweight or have obesity have been counseled regarding implementation of lifestyle interventions (diet modification and exercise) to promote weight loss AND • The medication is being prescribed by or in consultation with a gastroenterologist, hepatologist, endocrinologist, or obesity medicine specialist AND • If member is concurrently taking a CYP2C8 inhibitor (such as clopidogrel), the dose of Rezdiffra will be appropriately adjusted per product labeling AND • Regarding concurrent statin therapy, provider attests that: o If member is concurrently taking rosuvastatin or simvastatin, the dose of the statin will be limited to 20 mg/day OR o If member is concurrently taking pravastatin or atorvastatin, the dose of the statin will be limited to 40 mg/day AND • Prescriber acknowledges that continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Maximum Dose: 100 mg/day Quantity Limit: 30 tablets/30 days	One year
RHAPSIDO (remibrutinib)	**Rhapsido** (remibrutinib) may be approved if the following criteria are met: • Member is ≥ 12 years of age AND • Member is being treated for chronic spontaneous urticaria AND • Member remains symptomatic despite H1 antihistamine treatment AND • Member does not have liver impairment (Child-Pugh Class A, B, or C) AND • Member has tried and failed‡ at least three of the following: o High-dose second generation H1 antihistamine	One year

Drug Product(s)	Criteria	PA Approval Length
	○ H2 antihistamine ○ First-generation antihistamine ○ Leukotriene receptor antagonist ○ Hydroxyzine or doxepin AND • Member has trialed and failed‡ treatment with Dupixent (dupilumab) or Xolair (omalizumab) AND • Member is not concurrently taking a strong or moderate CYP3A4 inhibitor (such as clarithromycin, itraconazole, ketoconazole, posaconazole, ritonavir, voriconazole, diltiazem, erythromycin, fluconazole, verapamil) AND • Member is not concurrently taking a strong or moderate CYP3A4 inducer (such as carbamazepine, phenytoin, rifampin, modafinil, phenobarbital) AND • Member has been counseled that Rhapsido (remibrutinib) may increase the risk of bleeding. Therapy should be interrupted for 3 to 7 days before and after planned surgeries or invasive procedures. Quantity Limit: 60 tablets/30 days Continuation of Therapy: Members who are currently stabilized on Rhapsido (remibrutinib) may receive approval for continuation of therapy with that agent. ‡Failure is defined as lack of efficacy, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interaction.	
RIVFLOZA (nedosiran)	**Rivfloza** (nedosiran) may be approved if meeting the following criteria: • Member is 9 years of age or older AND • Member has a diagnosis of primary hyperoxaluria type 1 (PH1) confirmed by either: ○ Genetic testing that demonstrates a mutation of the alanine glyoxylate aminotransferase (*AGXT*) gene OR ○ Liver analysis demonstrating absent or significantly reduced AGXT enzyme AND • Member has relatively preserved kidney function (eGFR ≥ 30 mL/min/1.73 m^2) AND • Medication is being prescribed by, or in consultation with a nephrologist or other healthcare provider with expertise in treating PH1 AND • Member has documented baseline urinary oxalate excretion or plasma oxalate concentrations. Quantity limit: one single-dose vial or prefilled syringe/month Initial approval: one year Reauthorization: Member demonstrates response to medication as indicated by a positive clinical response from baseline urinary oxalate excretion or plasma oxalate concentration Members currently stabilized on a Rivfloza (nedosiran) regimen may receive prior authorization approval for continuation of therapy if meeting reauthorization criteria listed above.	One year

Drug Product(s)	Criteria	PA Approval Length
ROLVEDON (eflapegrastim-xnst)	**Rolvedon** (eflapegrastim-xnst) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND • Member is ≥ 18 years of age AND • Member has been diagnosed with a non-myeloid malignancy and is receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia, AND • Member is receiving Rolvedon (eflapegrastim-xnst) to decrease the incidence of infection, as manifested by febrile neutropenia AND • Member does not have mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation AND • The requested medication is being prescribed by or in consultation with an oncologist, hematologist, or critical care provider AND • Member has failed† an adequate trial of one preferred product in the Colony Stimulating Factor therapeutic class on the Preferred Drug List (PDL) OR prescriber attests to the clinical necessity for use of the requested agent. Approval: 1 year Maximum dose: 13.2 mg/14 days Quantity limit: one 13.2 mg prefilled syringe/14 days †Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interaction.	
RUZURGI (amifampridine)	**Ruzurgi** (amifampridine) may be approved for members meeting the following criteria: • Member is 6 to less than 17 years of age AND • Member has a diagnosis of Lambert-Eaton myasthenic syndrome (LEMS) Maximum dose: 100mg daily	One year
RYSTIGGO (rozanolixizumab)	**Rystiggo** (rozanolixizumab) may be approved if the following criteria are met: • For billing under the pharmacy benefit, medication is being administered in the member's home or in a long-term care facility (LTCF) by a healthcare professional AND • Member is ≥ 18 years of age AND • Member has a diagnosis of generalized myasthenia gravis that falls within Myasthenia Gravis Foundation of America (MGFA) Class II to IVa disease, AND • Member has a positive serologic test for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies AND • Requested product is being prescribed by or in consultation with a neurologist AND • A baseline Quantitative Myasthenia Gravis (QMG) assessment has been documented, AND • Patient has a MG-Activities of Daily Living (MG-ADL) total score of ≥3 (with at least 3 points from non-ocular symptoms), AND • Patient has failed† treatment over at least 1 year with at least 2 immunosuppressive therapies (such as azathioprine, cyclosporine, tacrolimus, mycophenolate), or has failed at least 1 immunosuppressive therapy and required chronic therapeutic plasma exchange or intravenous immunoglobulin (IVIG) AND	Initial Approval: 6 months Continuation Approval: One year

Drug Product(s)	Criteria	PA Approval Length
	• As a precaution, consider discontinuation or Rystiggo and use of alternative therapies in members receiving long term therapy with medications that bind to the human Fc receptor (such as IVIG, other immunoglobulins, or other C5 complement inhibitors). † Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction Maximum Dose: 840 mg (6 mL) by subcutaneous infusion every 6 weeks Quantity Limit: One single-dose vial weekly for 6 weeks Reauthorization: Reauthorization for one year may be approved with prescriber attestation that member has experienced a positive clinical response to rozanolixizumab based on documented Quantitative Myasthenia Gravis (QMG) assessment AND/OR MG-Activities of Daily Living (MG-ADL) score. Continuation of Therapy: Members who are currently stabilized on the requested medication may receive one year approval to continue treatment if meeting reauthorization criteria listed above.	
SANDOSTATIN (octreotide)	Approved for acromegaly; carcinoid tumors; and vasoactive intestinal peptide tumors.	Lifetime
SAPHNELO (anifrolumab)	**Saphnelo** (anifrolumab) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility **AND** • Member is ≥ 18 years of age with active, autoantibody-positive, moderate to severe systemic lupus erythematosus (SLE) AND is currently receiving standard therapy **AND** • The product is NOT being prescribed for severe active lupus nephritis or severe active central nervous system lupus **AND** • Member has had incomplete response to standard therapy from at least two of the following therapeutic classes: antimalarials, immunosuppressants and glucocorticoids **AND** • Member will maintain standard therapy for SLE while receiving Saphnelo (anifrolumab) therapy **AND** • Prescriber acknowledges that there are limited human data available for the use of anifrolumab in pregnancy, and data are insufficient to inform on drug-associated risks. A registry monitors pregnancy outcomes in women exposed to anifrolumab during pregnancy. Maximum Dose: 300 mg IV every 4 weeks Quantity Limit: One 300 mg vial/28 days	One year
SIVEXTRO (tedizolid)	**Sivextro** (tedizolid) may be approved if the following criteria are met: • The member is an adult, or the member is a pediatric patient that is at least 26 weeks gestational age and weighing at least 1 kg AND • Member has diagnosis of acute bacterial skin and skin structure infection (ABSSSI) caused by one of the following Gram-positive microorganisms:	Six months

Drug Product(s)	Criteria	PA Approval Length
	Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), *Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus* Group (including *Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus*), and *Enterococcus faecalis.* AND • Member has adequate trial and/or failure of linezolid 600mg twice daily for 10 days. Failure is defined as: lack of efficacy with 10 day trial, allergy, intolerable side effects or significant drug-drug interactions Maximum dosing: 200mg daily for 6 days total duration	
SKYCLARYS (omaveloxolone)	**Skyclarys** (omaveloxolone) may be approved if the following criteria are met: • Member is ≥ 16 years of age AND • Member has a diagnosis of Friedreich's ataxia based on genetic testing confirming loss-of-function mutations in the frataxin (FXN) gene AND • Requested product is being prescribed by or in consultation with a neurologist or physical medicine and rehabilitation physician AND • Member does not have severe hepatic impairment (Child-Pugh Class C) AND • If the member is ambulatory, a baseline neuromuscular assessment that includes all of the following elements has been performed and documented: o Bulbar function (swallowing or speaking) o Upper limb coordination o Lower limb coordination o Upright stability AND • Member is not concurrently taking any of the following medications: o Moderate or strong CYP3A4 inhibitor o Moderate or strong CYP3A4 inducer Initial approval: 6 months First reauthorization after 6 months: Reauthorization approval may be received for 1 year with provider attestation that: • Member is being monitored for clinically significant adverse effects such as: o Elevated ALT or AST (>5 times the ULN) with no evidence of liver dysfunction o Elevated ALT or AST (>3 times the ULN) with evidence of liver dysfunction (such as elevated bilirubin) o Elevated B-type natriuretic peptide (BNP) o Lipid abnormalities Subsequent reauthorizations: Reauthorization approval may be received for 1 year with provider attestation that: • Member has a demonstrated response to Skyclarys (omaveloxolone) treatment by showing clinical improvement or no decline in bulbar function, upper and lower limb coordination, and upright stability AND • Member is being monitored for clinically significant adverse effects such as: o Elevated ALT or AST (>5 times the ULN) with no evidence of liver dysfunction o Elevated ALT or AST (>3 times the ULN) with evidence of liver dysfunction (such as elevated bilirubin)	See criteria

Drug Product(s)	Criteria	PA Approval Length
	o Elevated B-type natriuretic peptide (BNP) o Lipid abnormalities Maximum dose with normal hepatic function: 150 mg/day Maximum dose with hepatic impairment: 100 mg/day Quantity limit: 90 capsules/30 days	
SODIUM CHLORIDE (Inhalation)	Broncho Saline is not covered under the pharmacy benefit. Sodium chloride (inhalation use) must be billed through medical.	N/A
SOFDRA (sofpironium)	**Sofdra** (sofpironium) may be approved when the following criteria are met: • Member is ≥ 9 years of age AND • Member has a diagnosis of primary axillary hyperhidrosis with a minimum duration of 6 months AND • Member has a documented Hyperhidrosis Disease Severity Scale-Axillary (HDSS-Ax-7) score of 3 or greater AND • Member does not have glaucoma, paralytic ileus, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis or Sjögren's syndrome AND • Prescriber attests that Sofdra (sofpironium) will be initiated with caution for members who have urinary retention, BPH, or bladder neck obstruction AND • There is documentation to support that the member's axillary hyperhidrosis is severe, intractable and disabling in nature as documented by at least one of the following: o Significant disruption of professional and/or social life as a result of excessive sweating OR o The condition is causing persistent or chronic cutaneous conditions (such as skin maceration, dermatitis, fungal infections, secondary microbial infections) AND • Member has tried and failed OTC clinical strength topical antiperspirant formulation(s). Failure is defined as inadequate control of symptoms with a 3-month trial, allergy, or intolerance AND • Sofdra (sofpironium) administration is avoided in combination with the following: o Other anticholinergic drugs (such as diphenhydramine, tricyclic antidepressants, atropine, and oxybutynin) AND o Strong inhibitors of CYP2D6 (such as fluoxetine, paroxetine, bupropion) AND o Member that is pregnant or plans to become pregnant AND o Member that is breastfeeding or plans to breastfeed AND • Member has been counseled on each of the following points regarding use of Sofdra (sofpironium): o Do not shower or wash underarms for at least 30 minutes before or at least 8 hours after application of the gel AND o Do not shave armpits at least 8 hours before applying the gel AND o Allow gel to dry completely (5 minutes) before putting on clothing and avoid using with occlusive dressings AND o Do not apply to broken skin AND o Wash hands immediately with soap and avoid the transfer of gel into or around the eyes AND	Initial: 3 months Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	○ Sofdra (sofpironium) gel is flammable. Fire, flame, or smoking during and immediately following application must be avoided AND ○ In the presence of high ambient temperature, heat illness can occur. Watch for generalized lack of sweating when in hot or very warm environmental temperatures and avoid using gel if not sweating under these conditions AND ○ Transient blurred vision may occur. If blurred vision occurs, discontinue use and avoid engaging in activities that require clear vision, such as operating a motor vehicle or other machinery or performing hazardous work, until the symptoms have resolved. Reauthorization: Member may receive reauthorization approval for 1 year if there is documented improvement of at least two points in the member's Hyperhidrosis Disease Severity Scale-Axillary (HDSS-Ax-7) score following initiation of Sofdra (sofpironium). Quantity limit: One 50 mL pump bottle per 30 days	
SOHONOS (palovarotene)	**Sohonos** (palovarotene) may be approved for members meeting the following criteria: • Member is 8 years and older if female and 10 years and older if male AND • Member has a confirmed diagnosis of fibrodysplasia ossificans progressiva (FOP) AND • For members of reproductive potential, a negative pregnancy test has been obtained within one week prior to initiating Sohonos (palovarotene) therapy AND • Member is not pregnant AND • Prescriber has evaluated, and member has received, all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment AND • Member is not taking a tetracycline derivative, strong CYP3A4 inhibitor (such as ketoconazole, itraconazole, voriconazole, ritonavir) or strong CYP3A4 inducer (such as carbamazepine, rifampin) AND • Members who are able to become pregnant have been counseled to use effective contraception starting at least one month before starting Sohonos (palovarotene) therapy, during treatment, and for at least one month after the last dose AND • Member (and/or parent or caregiver) has been counseled about the potential for premature epiphyseal closure and resulting growth failure, and provider attests that member will be monitored for this effect. Initial approval: 6 months Reauthorization: Sohonos (palovarotene) may be approved for one year if new heterotopic ossification is reduced in volume from baseline, as verified by imaging.	Initial Approval: 6 months Continuation Approval: One year
SOLIRIS (eculizumab)	**Soliris** (ecluizumab) may be approved for members meeting all of the following criteria: • Medication is being administered in the member's home or in a long-term care facility by a healthcare professional AND • Member is diagnosed with either Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Mysthenia Gravis (gMG), or Neuromyleitis Optica Spectrum Disorder (NMOSD) AND • Member does not have a systemic infection AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Member must be administered a meningococcal vaccine at least two weeks prior to initiation of Soliris therapy and revaccinated according to current medical guidelines for vaccine use AND • Prescriber is enrolled in the Soliris (eculizumab) Risk Evaluation and Mitigation Strategy (REMS) program AND • Medication is prescribed by or in conjunction with a hematologist for PNH and by or in conjunction with a hematologist or nephrologist for aHUS and by or in conjunction with a neurologist for gMG or NMOSD AND • Member meets criteria listed below based on specific diagnosis: <u>Paroxysmal Nocturnal Hemoglobinuria</u> • Member is 18 years of age or older AND • Diagnosis of PHN must be accompanied by detection of PNH clones by flow cytometry diagnostic testing AND • Member demonstrate the presence of at least 2 different glycosylphosphatidylinositol (GPI) protein deficiencies (e.g. CD55, CD59, etc.) within at least 2 different cell lines (granulocytes, monocytes, erythrocytes) AND • Member has one of the following indications for therapy: o Presence of a thrombotic event o Presence of organ damage secondary to chronic hemolysis o Patient is pregnant and potential benefit outweighs potential fetal risk o Patient is transfusion dependent o Patient has high LDH activity (defined as ≥1.5 x ULN) with clinical symptoms AND • Member has documented baseline values for one or more of the following: o Serum lactate dehydrogenase (LDH) o Hemoglobin level o Packed RBC transfusion requirement <u>Atypical Hemolytic Uremic Syndrome</u> • Member is 2 months or older AND • Thrombotic Thrombocytopenic Purpura (TTP) has been ruled out by evaluating ADAMTS13 level (ADAMTS-13 activity level > 10%); AND • Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS) has been ruled out; AND • Other causes have been ruled out such as coexisting diseases or conditions (e.g. bone marrow transplantation, solid organ transplantation, malignancy, autoimmune disorder, drug-induced, malignant hypertension, HIV infection, etc.), Streptococcus pneumonia or Influenza A (H1N1) infection, or cobalamin deficiency AND • Documented baseline values for one or more of the following: o Serum lactate dehydrogenase (LDH) o Serum creatinine/eGFR o Platelet count	

Drug Product(s)	Criteria	PA Approval Length
	○ Plasma exchange/infusion requirement Generalized Myasthenia Gravis • Member is 18 years or older AND • Patient has Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to IV disease; AND • Patient has a positive serologic test for anti-acetylcholine receptor (AchR) antibodies; AND • Physician has assessed the baseline Quantitative Myasthenia Gravis (QMG) score; AND • Patient has a MG-Activities of Daily Living (MG-ADL) total score of ≥6; AND • Patient has failed treatment over at least 1 year with at least 2 immunosuppressive therapies (e.g. azathioprine, cyclosporine, mycophenolate, etc), or has failed at least 1 immunosuppressive therapy and required chronic plasmapheresis or plasma exchange (PE) or intravenous immunoglobulin (IVIG) Neuromyelitis Optica Spectrum Disorder • Member is 18 years or older AND • Member has a past medical history of one of the following: ○ Optic neuritis ○ Acute myelitis ○ Area postrema syndrome; episode of otherwise unexplained hiccups or nausea and vomiting ○ Acute brainstem syndrome ○ Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions ○ Symptomatic cerebral syndrome with NMOSD-typical brain lesions AND • Member has a positive serologic test for anti-aquaporin-4 immunoglobulin G (AQP4-IgG)/NMP-IgG antibodies; AND • Diagnosis of multiple sclerosis or other diagnoses have been ruled out AND • Member has not failed a previous course of Soliris (eculizumab) therapy AND • Member has a history of failure, contraindication, or intolerance to rituximab therapy AND • Member has at least one of the following: ○ History of at least two relapses during the previous 12 months prior to initiating Soliris (eculizumab) ○ History of at least three relapses during the previous 24 months, at least one relapse occurring within the past 12 months prior to initiating Soliris (eculizumab) AND • Member is not receiving Soliris in combination with any of the following:	

Drug Product(s)	Criteria	PA Approval Length
	○ Disease modifying therapies for the treatment of multiple sclerosis (such as Gilenya (fingolimod), Tecfidera (dimethyl fumarate), Ocrevus (ocrelizumab), etc.) OR ○ Anti-IL6 therapy Maximum Dose: 900mg weekly for 4 weeks induction followed by 1200mg every 2 weeks maintenance dose.	
SOLOSEC (secnidazole)	**Solosec** (secnidazole) may be approved for members meeting the following criteria: • Solosec® is being prescribed for bacterial vaginosis in an adult female member AND • Member has adequately trialed and failed an oral OR topical formulation of metronidazole (Failure is defined as lack of efficacy of a 7 day trial, allergy, intolerable side effects, significant drug-drug interaction, or contraindication to therapy) AND • Member has adequately trialed and failed an oral OR topical formulation of clindamycin (Failure is defined as lack of efficacy of a 7 day trial, allergy, intolerable side effects, significant drug-drug interaction, or contraindication to therapy) Maximum Quantity: 1 packet of 2 grams per 30 days	One year
SOLU-CORTEF (hydrocortisone sodium succinate)	**Solu-Cortef** (hydrocortisone sodium succinate) injection may be approved if meeting the following criteria: • The requested medication is being prescribed for emergency use for adrenal insufficiency OR • The medication is being administered in the member's home or in a long-term care facility by a healthcare professional	One year
STRENSIQ (asfotase alfa)	**Strensiq** (asfotase alfa) may be approved if all of the following criteria are met: Member has a diagnosis of either perinatal/infantile- OR juvenile-onset hypophosphatasia (HPP) based on all of the following a. Member was ≤ 18 years of age at onset b. Member has/had clinical manifestations consistent with hypophosphatasia at the age of onset prior to age 18 (e.g. vitamin B6-dependent seizures, skeletal abnormalities: such as rachitic chest deformity leading to respiratory problems or bowed arms/legs, "failure to thrive"). c. Member has/had radiographic imaging to support the diagnosis of hypophosphatasia at the age of onset prior to age 18 (e.g. infantile rickets, alveolar bone loss, craniosynostosis) d. Member has one of the following: elevated urine concentration of phosphoethanolamine (PEA), elevated serum concentration of pyridoxal 5'-phosphate (PLP) in the absence of vitamin supplements within one week prior to the test, or elevated urinary inorganic pyrophosphate (PPi) AND e. Molecular genetic test has been completed confirming mutations in the ALPL gene that encodes the tissue nonspecific isoenzyme of ALP (TNSALP) within 30 days of initiation. If genetic test is negative, approval will not be granted past 30 days. f. Prescriber is a specialist in the area of the members disease (such as an endocrinologist)	Six months

Drug Product(s)	Criteria	PA Approval Length

SYMDEKO (tezacaftor/ivacaftor and ivacaftor)	**Symdeko** (tezacaftor/ivacaftor and ivacaftor) may be approved for members that meet the following criteria:
	• The member has a diagnosis of cystic fibrosis AND
	• The member is 6 years of age or older AND
	• The member has one of the following mutations:
	  o Homozygous for the F508del mutation in the CFTR gene 2 OR
	  o Heterozygous for the F508del mutation in the CFTR gene and one of the following mutations: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D1270N, D579G, 711+3A-G, E831X, S945L, S977F, F1052V, K1060T, A1067T, R1070W, F1074L, D1152H, 3272-26A-G, 2789+5G-A, 3849-10kbC-T, or another FDA approved gene mutation
	  AND
	• Member has ALT, AST, and bilirubin at baseline and tested every 3 months for the first year AND
	• Member has a baseline ophthalmological examination and periodic follow-up exams for cataracts AND
	• Must be prescribed by or in consultation with a pulmonologist or gastroenterologist AND
	• Member is not receiving dual therapy with another cystic fibrosis transmembrane conductance regulator (CFTR) potentiator AND
	• Member has had 2 negative respiratory cultures for any of the following organisms: *Burkholeria cenocepacia*, *Burkholderia dolosa*, or *Mycobacterium abscessus* in the past 12 months.
		One year

SYNAGIS (palivizumab)	**Synagis (palivizumab) will no longer be available as of 12/31/25 due to manufacturer discontinuation of all Synagis (palivizumab) strengths. Prior authorizations for Synagis will include prescriber attestation to verifying that adequate product is available to complete all of the required doses of the Synagis regimen prior to initiating Synagis therapy. Requests for Synagis will not be approved unless availability of all regimen doses has been verified. If product availability is unable to be verified by the prescriber, alternative RSV preventative treatments should be considered.** **Pharmacy prior authorization requests for Synagis must be submitted by fax using the Synagis prior authorization form found at https://hcpf.colorado.gov/pharmacy-resources and is for home or long-term care facility administration only. The 2025-2026 Synagis season will begin October 1, 2025 and end April 1, 2026. The Department will continue to monitor RSV reporting and reassess Health First Colorado member needs based on CDC virology reporting and AAP guidance.** **Synagis given in a doctor's office, hospital or dialysis unit is to be billed directly by those facilities as a medical benefit. Medical prior authorization requests must be submitted at https://hcpf.colorado.gov/par. Synagis may only be a pharmacy benefit if the medication is administered in the member's home or long-term care facility.** **Key Points** 1. No more than five (5) doses per season. Five (5) doses provides more than six (6) months of protective serum concentration. 2. Synagis is not recommended for controlling outbreaks of health care-associated disease.	Maximum of 5 doses per season

Drug Product(s)	Criteria	PA Approval Length
	3. Synagis is not recommend for prevention of health care-associated RSV disease. 4. Infants born later in the season may require less than 5 doses to complete therapy to the end of the season. 5. Monthly prophylaxis should be discontinued in any child who experiences a breakthrough RSV hospitalization. 6. Synagis is not recommended to prevent wheezing, nosocomial disease, or treatment of RSV. 7. Synagis is not routinely recommended for patients with a diagnosis of Down syndrome unless they also have a qualifying indication listed below. 8. Synagis should not be administered if Beyfortus (nirsevimab) has been administered. 9. If Synagis is initiated for the season and <5 doses were administered, if nirsevimab is available the infant should receive one dose of nirsevimab. No further Synagis should be administered. In the **first year of life** Synagis is recommended for: a. For infants born before 29w 0d gestation. b. For infants born before 32w 0d **AND** with chronic lung disease (CLD) of prematurity **AND** requirements of >21% oxygen for at least 28 days after birth. c. For infants with hemodynamically significant heart disease (acyanotic heart disease who are receiving medication to control congestive heart failure (CHF) and will require cardiac surgical procedures or infants with moderate to severe pulmonary hypertension**) AND** born within 12 months of onset of the RSV season. d. Infants who undergo cardiac transplantation during the RSV season. e. For infants with cyanotic heart defects **AND** in consultation with a pediatric cardiologist **AND** requirements of >21% oxygen for at least 28 days after birth **AND** continue to require medical intervention (supplemental oxygen, chronic corticosteroid, or diuretic therapy) f. Infants with neuromuscular disease or pulmonary abnormality **AND** is unable to clear secretions from the upper airways g. Infants who will be profoundly immunocompromised during the RSV season (solid organ or hematopoietic stem cell transplantation, receiving chemotherapy) h. An infant with cystic fibrosis with clinical evidence of CLD **AND/OR** nutritional compromise In the **second year of life** Synagis is recommended for: a. Children born before 32w 0d **AND** with CLD of prematurity **AND** requirements of >21% oxygen for at least 28 days after birth **AND** continue to require medical intervention (supplemental oxygen, chronic corticosteroid, or diuretic therapy) b. A child who will be profoundly immunocompromised during the RSV season (solid organ or hematopoietic stem cell transplantation, receiving chemotherapy) c. Children with manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities of chest radiography or chest computed tomography that persist when stable) **OR** weight for length less than the 10th percentile. d. Children who undergo cardiac transplantation during the RSV season. **Additional Prior Authorization Request (PAR) Instructions** • All pharmacy Synagis PARs must be signed by the prescribing physician, even if submitted by a home health agency or long-term care facility. • Members or providers may appeal Synagis prior authorization denials through the normal member appeals process.	

Drug Product(s)	Criteria	PA Approval Length
	• Synagis given in a doctor's office, hospital or dialysis unit is to be billed directly by those facilities as a medical benefit. Synagis may only be a pharmacy benefit if the medication is administered in the member's home or long-term care facility, or when administered in a doctor's office because the patient cannot access home health services.	
SYPRINE (trientine)	**Syprine** (trientine) may be approved if all of the following criteria are met: • Must be prescribed in conjunction with a gastroenterologist, hepatologist, or liver transplant specialist. **AND** • Member has a diagnosis of Wilson's Disease meeting at least one of the following criteria: o Hepatic parenchymal copper content of ≥250µg/g dry weight o Presence of Kayser-Fleischer Ring in cornea o Serum ceruloplasmin level <50mg/L o Basal 24-hour urinary excretion of copper >100µg (1.6 µmoles) o Genetic testing results indicating mutation in ATP7B gene **AND** • Member has failed a three-month trial or is intolerant to penicillamine. Failure is defined as a lack of efficacy, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions **AND** • Member has failed a three-month trial or is intolerant to generic trientine. Failure is defined as a lack of efficacy, allergy, intolerable side effects, contraindication to, or significant drug-drug interactions.	One year
TAVALISSE (fostamatinib)	**Tavalisse** (fostamatinib) prior authorization may be approved for members meeting the following criteria: • Member is 18 years of age or older AND • Member has a documented diagnosis of chronic immune thrombocytopenia AND • Member has trialed and failed at least ONE of the following therapies (Failure is defined as a lack of efficacy, allergy, intolerable side effects, or significant drug-drug interactions): o Promacta (eltrombopag) or other thrombopoietin receptor agonist o Corticosteroids o Immunoglobulin o Splenectomy AND • Baseline platelet count prior to initiation is less than $30x10^9$/L or $30x10^9$/L to $50x10^9$/L with symptomatic bleeding AND • Prescriber attests to monitoring liver function tests and CBC monthly until a stable dose is achieved AND • Tavalisse (fostamatinib) is not being used as dual therapy with a thrombopoietin receptor agonist AND • Tavalisse (fostamatinib) is being prescribed by or in consultation with a hematologist AND • Initial prior authorization approval will be for 3 months. Continuation may be approved with verification of documented platelet response (platelet count ≥50x109/L) Quantity Limit: 60 tablets per 30 days	Initial Approval: 3 months Continuation Approval: One year

Drug Product(s)	Criteria	PA Approval Length
TAVNEOS (avacopan)	**Tavneos** (avacopan) may be approved when the following criteria are met: • Member is ≥18 years of age AND • Severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis AND • Member did not achieve sustained remission within one year of treatment with glucocorticoid therapy AND • Member is currently receiving, and will continue to be on a standard care plan for ANCA-associated vasculitis that includes a glucocorticoid AND • Member does not have active, untreated and/or uncontrolled chronic liver disease (such as chronic active hepatitis B, untreated hepatitis C, uncontrolled autoimmune hepatitis and cirrhosis) AND • A baseline liver panel (ALT, AST, alkaline phosphatase, total bilirubin) will be obtained before initiating Tavneos (avacopan), then every 4 weeks after start of therapy for the first 6 months of treatment and as clinically indicated thereafter AND • Labs to screen for Hepatitis B infection (HBsAg and anti-HBc) have been evaluated prior to initiation of Tavneos (avacopan) therapy AND • Member is not currently taking a strong CYP3A4 inducer (such as carbamazepine, phenytoin, rifampin, phenobarbital) AND • If member is on concurrent therapy with a strong CYP3A4 inhibitor (such as itraconazole, ketoconazole diltiazem, ritonavir), Tavneos (avacopan) dose will be adjusted according to the approved product labeling. <u>Reauthorization</u>: Tavneos (avacopan) may be approved for one year if: • Member met initial approval criteria at the time of initiation of therapy AND • Provider attests that sustained remission was achieved on Tavneos (avacopan) therapy within the previous 12 months. Maximum dose: 60 mg/day Quantity limit: 180 capsules/30 days Continuation of therapy: Members who are currently stabilized on Tavneos (avacopan) therapy may receive approval to continue that medication.	One year
TARGETED IMMUNE MODULATORS (IV and physician-administered products*) Abatacept, Certolizumab, Golimumab, Infliximab, Mepolizumab, Mirikizumab, Omalizumab, Risankizumab, Rituximab,	**Entyvio** (vedolizumab) **IV injection** may be approved if meeting the following criteria: • If billing under the pharmacy benefit, the medication is being administered in the member's home or in a long-term care facility AND • The member is ≥ 18 years of age with moderately-to-severely active ulcerative colitis or moderately-to-severely active Crohn's disease AND • The member has had an inadequate response with, is intolerance to, or had demonstrated dependence on corticosteroids AND • The member is not receiving Entyvio (vedolizumab) in combination with Cimzia, Enbrel, Humira, infliximab, Simponi or Tysabri AND <u>For Members Treating Crohn's Disease:</u> • Entyvio (vedolizumab) is initiated and titrated per FDA-labeled dosing for Crohn's disease AND • The member meets <u>one</u> of the following:	One year

Drug Product(s)	Criteria	PA Approval Length
Secukinumab, Spesolimab, Tocilizumab, Ustekinumab, Vedolizumab *Coverage criteria for self-administered formulations of products listed in this section are included on the Preferred Drug List (PDL).	○ The member has trialed and failed‡ therapy with Humira (adalimumab) or an infliximab-containing product (such as Renflexis) OR ○ The member is ≥ 65 years of age with increased risk of serious infection. For Members Treating Ulcerative Colitis: • Entyvio (vedolizumab) is initiated and titrated per FDA-labeled dosing for ulcerative colitis AND • The member meets one of the following: ○ The member has trialed and failed‡ therapy with Humira (adalimumab) or Simponi (golimumab) or an infliximab-containing product (such as Renflexis) OR ○ The member is ≥ 65 years of age with increased risk of serious infection. **Infliximab** (Remicade brand/generic and infliximab biosimilar products) **IV injection** may be approved if meeting the following criteria: • If billing under the pharmacy benefit, the medication is being administered in the member's home or in a long-term care facility AND • The member has one of the following diagnoses: ○ Crohn's disease (and ≥ 6 years of age) ○ Ulcerative colitis (and ≥ 6 years of age) ○ Rheumatoid arthritis (and ≥ 4 years of age) ○ Psoriatic arthritis (and ≥ 18 years of age) ○ Ankylosing spondylitis (and ≥ 18 years of age) ○ Juvenile idiopathic arthritis (and ≥ 4 years of age) ○ Plaque psoriasis (and ≥ 18 years of age) ○ Hidradenitis suppurativa (HS) AND • The request meets one of the following: ○ The prescribed infliximab agent is Renflexis (infliximab-abda) OR ○ If the prescribed agent is brand Remicade or an infliximab product formulation other than Renflexis, then the member has trialed and failed Renflexis. Failure is defined as lack of efficacy or intolerable side effects with the preferred infliximab product formulation. AND • The member meets one of the following, based on prescribed indication: ○ For continuation of infliximab therapy that was initiated in the hospital setting for treating severe ulcerative colitis, no additional medication trial is required OR ○ For treatment of moderate to severe hidradenitis suppurativa, no additional medication trial is required OR ○ For all other prescribed indications, the request meets criteria listed on the Preferred Drug List (PDL) in the "Targeted Immune Modulators" drug class for the prescribed indication (see PDL "Targeted Immune Modulators" at https://hcpf.colorado.gov/pharmacy-resources#PDLP). Maximum Dose: 10 mg/kg Prior authorization requests for pharmacy benefit coverage of all other products included in the "Targeted Immune Modulator IV and Physician-Administered Products" category may be approved if meeting the following criteria:	

Drug Product(s)	Criteria	PA Approval Length

	• For billing under the pharmacy benefit, the prescriber confirms that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND
	• The requested medication is being prescribed for an FDA-labeled indicated use AND
	• The request meets one of the following:
	  o The request meets criteria listed on the Preferred Drug List (PDL) in the "Targeted Immune Modulators" drug class for the product ingredient name for the prescribed indication (see PDL "Targeted Immune Modulators" at https://hcpf.colorado.gov/pharmacy-resources#PDLP). IV ustekinumab-containing biosimilar agents are subject to meeting criteria for preferred ustekinumab biosimilar agents for the prescribed indication listed on the PDL OR
	  o For products that do not have criteria listed for the product name on the PDL in the "Targeted Immune Modulators" drug class for the prescribed indication, no additional criteria apply.
	
	‡Failure is defined as lack of efficacy with a three-month trial, allergy, intolerable side effects, contraindication to therapy, or significant drug-drug interaction. Trial and failure of Xeljanz IR will not be required when the requested medication is prescribed for ulcerative colitis for members ≥ 50 years of age that have an additional CV risk factor. Trial and failure of preferred TNF inhibitors will not be required when the requested medication is prescribed for pJIA in members with documented clinical features of lupus.	

TARPEYO (budesonide)	**Tarpeyo** (budesonide) may be approved if the following criteria are met: • Member is ≥ 18 years of age **AND** • Member has proteinuria associated with primary immunoglobulin A nephropathy (IgAN) with a risk of rapid disease progression **AND** • The diagnosis has been confirmed by biopsy, **AND** • Most recent labs indicate a urine protein-to-creatinine ratio (UPCR) of ≥1.5 g/g, **OR** proteinuria > 0.75 g/day, **AND** • Member has been receiving the maximum (or maximally tolerated) dose of either an ACE inhibitor **OR** angiotensin receptor blocker (ARB) for at least 90 days, **AND** • Member has had an adequate trial of a generic oral budesonide regimen at maximally tolerated recommended doses and has failed to achieve a clinically significant response **AND** • The medication is prescribed by or in consultation with a nephrologist **AND** • Prescriber plans to reduce dosage from 16 mg/day to 8 mg/day during the final 2 weeks of the 9-month course of treatment • Approval will be limited to 10 months for completion of 9-month course of therapy. Maximum dose: 16 mg/day Quantity limit: 120 4 mg capsules/30 days This indication is approved under accelerated approval based on a reduction in proteinuria. It has not been established whether delayed-release budesonide slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.	10 months

Drug Product(s)	Criteria	PA Approval Length
TEPEZZA (teprotumumab)	**Tepezza** (teprotumumab) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long term care facility **AND** • Member is 18 years of age or older **AND** • Member has a documented diagnosis of Thyroid Eye Disease (TED) **AND** • Member's prescriber must be in consultation with an ophthalmologist or endocrinologist **AND** • Member does not require immediate surgical ophthalmological intervention **AND** • Member does not currently require orbital (eye) surgery and is not planning corrective surgery/irradiation during therapy **AND** • Member is euthyroid, mild hypothyroid, mild hyperthyroid (defined as free thyroxine (FT4) and free triiodothyronine (FT3) levels less than 50% above or below the normal limits) or seeking care for dysthyroid state from an endocrinologist or other provider experienced in the treatment of thyroid diseases **AND** • Member does not have corneal decompensation unresponsive to medical management **AND** • Member had an inadequate response, or there is a contraindication or intolerance, to high-dose intravenous glucocorticoids **AND** • Member is not pregnant prior to initiation of therapy and effective forms of contraception will be implemented during treatment and for 6 months after the last dose of teprotumumab. If member becomes pregnant during treatment, Tepezza should be discontinued, **AND** • If member is diabetic, member is being managed by an endocrinologist or other provider experienced in the treatment and stabilization of diabetes **AND** • Authorization will be issued for one course of therapy of eight infusions Maximum Dose: Eight infusions per one year	See criteria
THIOLA EC (tiopronin DR)	**Thiola EC** (tiopronin DR) may be approved for members meeting the following criteria: Member is an adult or pediatric weighing 20kg or more AND Member has severe homozygous cystinuria AND Member has increased fluid intake and diet modifications have been implemented for the prevention of cysteine stone formation AND Member has trial and failure of urinary alkalization agent (such as potassium citrate or potassium bicarbonate) AND • Member has trial and failure of Thiola IR (tiopronin). Failure is defined as lack of efficacy with 14 day trial, allergy, intolerable side effects or significant drug-drug interactions. Maximum dose: Thiola EC 1500mg per day	One year
THROMBOLYTIC ENZYMES	Approved for **IV Catheter Clearance or Occluded AV Cannula** if given in member's home or long-term care facility.	One year

Drug Product(s)	Criteria	PA Approval Length
TOBACCO CESSATION	Effective 11/01/18 prior authorization will not be required for tobacco cessation medications including nicotine gum, nicotine patch, nicotine lozenge, nicotine inhaler (Nicotrol®), varenicline (Chantix®), and bupropion SR (Zyban®). Smoking and tobacco cessation resources are available at no charge to members or providers through the Colorado QuitLine found at coquitline.org or by calling 1-800-QUIT-NOW.	
TOPICAL COMPOUND CLAIMS	Effective 7/1/2024, compound claims for topical formulations exceeding $200.00 require prior authorization and are subject meeting the following: • The prescriber attests that a reasonable effort has been made to use the more cost-effective compound product ingredient when multiple products with the same active ingredient are available, covered, and clinically appropriate for use in the compound AND • Each active ingredient in the compounded medication is FDA-approved or national compendia supported for the condition being treated AND • The compound ingredient therapeutic amounts and combinations are supported by national compendia or peer-reviewed literature for the condition being treated in the requested route of delivery AND • Any compound product ingredient requiring drug specific prior authorization will be subject to meeting criteria listed on the Health First Colorado Preferred Drug List or Appendix P.	One year
TPN PRODUCTS	Approval will be given if included as part of TPN therapy administered in the member's home or in a long-term care facility by a home healthcare provider. If given in the hospital or physician's office, the claim must be billed as a medical expense.	Lifetime
TRIKAFTA (elexacaftor, tezacaftor, ivacaftor)	**Trikafta** (elexacaftor, tezacaftor, ivacaftor) may be approved for members meeting the following criteria: • Member is ≥ 6 years of age (oral tablet) OR 2 to 5 years of age (oral granules) AND • Member has at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CTFR) gene or a mutation in the CFTR gene that is responsive based on in vitro data AND • Member continues to receive standard of care CF therapies (such as bronchodilators, inhaled antibiotics, dornase alfa, and hypertonic saline) AND • If initiating therapy, member must have liver function tests checked within 3 months without abnormal results (ALT, AST, ALP, or GGT ≥ 3 × ULN, or total bilirubin ≥2 × ULN) AND • Baseline Forced Expiratory Volume (FEV1) must be collected Maximum Dose: 84 tablets per 28 days	One year
TRYNGOLZA (olezarsen sodium)	**Tryngolza** (olezarsen sodium) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of familial chylomicronemia syndrome AND • Member's diagnosis has been confirmed by genetic testing AND • Tryngolza (olezarsen sodium) is being prescribed as adjunct therapy with lifestyle interventions including a low-fat diet and abstaining from alcohol consumption AND • Provider attests that member will be educated on proper injection technique and safe storage and disposal of autoinjectors. <u>Maximum dose</u>: 80 mg subcutaneously once monthly	One year

Drug Product(s)	Criteria	PA Approval Length
	Maximum quantity: one 80 mg/0.8 mL single-dose autoinjector/month	

TRYVIO (aprocitentan)	**Tryvio** (aprocitentan) may be approved for members meeting the following criteria:
	• Member is 18 years of age or older AND
	• Member has a diagnosis of hypertension AND
	• Member has a blood pressure > 140/90 mmHg and meets both of the following:
	  o The requested product is being prescribed concurrently with a regimen containing at least three preferred antihypertensive agents from different drug classes AND
	  o Member has trialed and failed a trial of an antihypertensive regimen containing three preferred antihypertensive agents from different drug classes at maximally tolerated doses (failure is defined as lack of efficacy with 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction)
	• AND
	• Member is not receiving a concurrent endothelin receptor antagonist, AND
	• Member does not have NYHA class III-IV heart failure AND
	• Prescriber attests that member's liver function tests are less than 3 times the upper limit of normal (ULN) prior to initiating Tryvio (aprocitentan) therapy, the member does not have moderate to severe hepatic impairment, and that liver function tests, complete blood count (CBC) and hemoglobin will be monitored during therapy AND
	• Prescriber attests that members who can become pregnant have been counseled regarding the potential for major birth defects and to use acceptable contraception prior to initiation of treatment, during treatment, and for one month after stopping Tryvio (aprocitentan) therapy.
	
	Dose limit: 12.5 mg/day
	
	Initial approval: 3 months
	
	Reauthorization: Tryvio (aprocitentan) may be approved for one year if, after 3 months of therapy, the member's blood pressure is within the goals established by national guidelines.
		Initial: 3 months
		
		Continued: One year

TYBOST (cobicistat)	**Tybost** (cobicistat) may be approved for members meeting the following criteria: • Member has a diagnosis of HIV-1 AND • Member is currently being treated with atazanavir or darunavir only AND • Member is not taking cobicistat-containing drugs, or ritonavir-containing drugs AND • Member has failed treatment with ritonavir (failure defined as intolerable side effect, allergy, or lack of efficacy).	One year
TYSABRI (natalizumab)	**Tysabri** (natalizumab) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility **AND** • Medication is not currently being used in combination with immunosuppresants (azathioprine, 6-mercaptopurine, methotrexate) or TNF-alpha inhibitors (adalimumab, certolizumab pegol, infliximab) **AND** • Member does not have anti-JC virus antibodies at baseline **AND** • If prescribed for induction of remission of moderate to severe Crohn's disease: o The patient is ≥ 18 years of age **AND**	One year

Drug Product(s)	Criteria	PA Approval Length
	○ Prescriber and member are enrolled in the CD TOUCH® REMS program **AND** ○ Member has tried and failed aminosalicylates **AND** ○ Member has tried and failed corticosteroids **AND** ○ Member has tried and failed immunomodulators **AND** ○ Member has tried and failed two TNF-alpha inhibitors (such as adalimumab, certolizumab pegol, or infliximab). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interactions **AND** ○ Tysabri (natalizumab) is prescribed by or in consultation with a gastroenterologist. • <u>If prescribed for relapsing remitting multiple sclerosis (RRMS)</u>: ○ The patient is ≥ 18 years of age; **AND** ○ Prescriber and member are enrolled in the MS TOUCH® REMS program **AND** ○ Tysabri is prescribed by or in consultation with a neurologist or a physician that specializes in the treatment of multiple sclerosis **AND** ○ Request meets <u>one</u> of the following: ▪ Member has had trial and failure* with any <u>two</u> high efficacy disease-modifying therapies (such as ofatumumab, ocrelizumab, fingolimod, rituximab, or alemtuzumab) **OR** ▪ Member has a diagnosis of highly active relapsing MS (based on measures of relapsing activity and MRI markers of disease activity such as numbers of galolinium-enhanced lesions) AND has had trial and failure* with any <u>one</u> high efficacy disease-modifying therapy (such as ofatumumab, fingolimod, rituximab, ocrelizumab, or alemtuzumab). <u>Exemption</u>: If member is currently receiving and stabilized on Tysabri (natalizumab), they may receive prior authorization approval to continue therapy. *Failure is defined as intolerable side effects, drug-drug interaction, contraindication, or lack of efficacy. Lack of efficacy is defined as one of the following: • On MRI, presence of any new spinal lesions, cerebellar or brainstem lesions, or change in brain atrophy **OR** • Signs and symptoms on clinical exam consistent with functional limitations that last one month or longer.	
TZIELD (teplizumab-mzwv)	**Tzield** (teplizumab-mzwv) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND • Member is ≥ 8 years of age AND • Member has a diagnosis of Stage 2 type 1 diabetes, AND • The member's clinical history does not suggest type 2 diabetes, AND • The requested medication is being prescribed in consultation with an endocrinologist AND • Prescriber attests that patient will be monitored for Cytokine Release Syndrome (CRS) AND • Prescriber attests that appropriate premedication will be administered prior to each Tzield (teplizumab-mzwv) infusion, AND • Prescriber attests that lymphocyte counts and liver function tests will be closely monitored during the treatment period, AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Member has no serious infections at time of starting therapy AND • Member is not pregnant or planning to become pregnant. Dosing limit: Approval will be placed to allow for one 14-day course of treatment	
ULTOMIRIS (ravulizumab)	**Ultomiris** (ravulizumab) may be approved if the following criteria are met: • For requests for the IV formulation, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility **AND** • Member is diagnosed with either Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Neuromyelitis Optica Spectrum Disorder (NMOSD), or Generalized Myasthenia Gravis (gMG) **AND** • Member has been vaccinated for meningococcal disease according to current ACIP guidelines at least two weeks prior to Ultomiris initiation OR member is receiving 2 weeks of antibacterial drug prophylaxis if meningococcal vaccination cannot be administered at least 2 weeks prior to starting Ultomiris **AND** • Member does not have unresolved *Neisseria meningitidis* or any systemic infection **AND** • Prescriber is enrolled in the Ultomiris Risk Evaluation and Mitigation Strategy (REMS) program **AND** • Medication is administered by or in consultation with a hematologist for PNH and by or in consultation with a hematologist or nephrologist for aHUS, by or in consultation with a neurologist for gMG, or by or in consultation with a neurologist or ophthalmologist for NMOSD **AND** • Member meets criteria listed below for specific diagnosis: o Paroxysmal nocturnal hemoglobinuria (PNH): ▪ Member is one month of age or older if prescribing the IV formulation OR is ≥ 18 years of age if prescribing the subcutaneous formulation **AND** ▪ Diagnosis of PNH must be accompanied by detection of PNH clones by flow cytometry diagnostic testing **AND** ▪ Baseline values are documented for the following: • Serum lactate dehydrogenase (LDH) • Hemoglobin levels • Packed RBC transfusion requirement **AND** ▪ Member has one of the following indications for therapy: • Presence of a thrombotic event • Presence of organ dysfunction secondary to chronic hemolysis • Member is transfusion dependent • Member has uncontrolled pain secondary to chronic hemolysis o Atypical hemolytic uremic syndrome (aHUS): ▪ Member is one month of age or older if prescribing the IV formulation OR ≥ 18 years of age if prescribing the subcutaneous formulation **AND** ▪ Member does not have Shiga toxin E. coli related HUS (STEC-HUS) **AND**	One year

Drug Product(s)	Criteria	PA Approval Length
	▪ Thrombotic Thrombocytopenic Purpura (TTP) has been ruled out by evaluating ADAMTS13 level or a trial of plasma exchange did not result in clinical improvement **AND** ▪ Baseline values are documented for the following: • Serum LDH • Serum creatinine/eGFR • Platelet count • Dialysis requirement o Generalized myasthenia gravis: ▪ Member is 18 years of age or older **AND** ▪ Member has a positive serologic test for anti-acetylcholine receptor (AchR) antibodies **AND** ▪ Member has Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of Class II to IV disease **AND** ▪ Member has a MG-Activities of Daily Living (MG-ADL) total score of ≥ 6 **AND** ▪ Member has trial and failure of treatment over at least 1 year with at least 2 immunosuppressive therapies (such as azathioprine, cyclosporine, mycophenolate, etc.) OR has failed at least 1 immunosuppressive therapy and required chronic plasmapheresis or plasma exchange (PE) or intravenous immunoglobulin (IVIG). o Neuromyelitis optica spectrum disorder (NMOSD): ▪ Member is 18 years of age or older **AND** ▪ Member has a positive test for anti-aquaporin-4 (AQP4) antibodies **AND** ▪ Exclusion of alternative diagnoses have been evaluated **AND** ▪ Member has at least one of the following clinical characteristics: • Optic neuritis • Acute myelitis • Area postrema syndrome (episode of otherwise unexplained hiccups or nausea and vomiting) • Acute brainstem syndrome • Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions • Symptomatic cerebral syndrome with NMOSD-typical brain lesions. Maximum dose: 3.6 g every 8 weeks (IV formulation) 490 mg once weekly (subcutaneous formulation)	
UPLIZNA (inebilizumab)	**Uplizna** (inebilizumab) may be approved for members meeting the following criteria: • Medication is being administered in the member's home or in a long-term care facility by a healthcare professional AND • Member is an adult (≥ 18 years of age) AND has a positive serologic test for anti-aquaporin-4 (AQP4) antibodies AND has a documented diagnosis of neuromyelitis optica spectrum disorder (NMOSD) AND • Member has a past medical history of at least one of the following: o Optic neuritis o Acute myelitis	One year

Drug Product(s)	Criteria	PA Approval Length
	○ Area postrema syndrome; episode of otherwise unexplained hiccups or nausea and vomiting ○ Acute brainstem syndrome ○ Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions ○ Symptomatic cerebral syndrome with NMOSD-typical brain lesions AND • Member does not have active Hepatitis B infection, as confirmed by negative surface antigen [HBsAg] and anti-HBV tests AND • Provider has screened for immunizations the member is due to receive according to immunization guidelines AND any live or live-attenuated vaccines will be administered at least 4 weeks prior to initiation of Uplizna (inebilizumab) AND • Member does not have active or untreated latent tuberculosis AND • For members of child-bearing potential, member is not pregnant or breastfeeding and has been counseled to use effective contraception while receiving Uplizna (inebilizumab) and for at least 6 months after the last dose AND • Uplizna (inebilizumab) is prescribed by, or in consultation with, a neurologist AND • Member will receive corticosteroid, antihistamine, and antipyretic premedication prior to each infusion. Maximum dose: Initial 300 mg IV infusion followed by 300mg IV infusion 2 weeks later, followed by 300mg IV infusion every 6 months (starting 6 months from the initial infusion).	
VACCINES	Pharmacy Benefit: Vaccine claims are only billed through the pharmacy benefit for the following three cases (all other vaccine claims must be billed through medical): 1. The vaccine is being administered by a healthcare professional in a long-term care facility (LTCF) 2. The vaccine is Vivotif oral typhoid vaccine prescribed for out-patient administration 3. The vaccine claim is being submitted by a pharmacy that is registered with the Vaccines for Children (VFC) program solely for administration fee reimbursement (see VFC section below). Vaccines for Children (VFC) Program Pharmacy Administrative Fee Reimbursement: Effective 8/6/23, pharmacies registered with the Vaccines for Children (VFC) program may bill the pharmacy benefit and receive reimbursement for the administration fee only when the claim is for a VFC acquired vaccine. Reimbursement by pharmacy claim submission for vaccine administration fees may only be received for children under 19 if the pharmacy is registered with the VFC program AND if the vaccine product included on the claim submission was provided at zero cost through the VFC program. For administration fee reimbursement that is not submitted as a pharmacy claim, providers may bill for reimbursement through medical. If assistance is needed for VFC program-registered pharmacies processing pharmacy claims for vaccine administration fee reimbursement, please contact the Prime Therapeutics pharmacy help desk at 1-800-424-5725. For additional billing information, refer to the Immunizations Billing Manual . For additional information regarding the VFC program, refer to the VFC Program webpage . Medical Benefit: Refer to the Immunizations Billing Manual for medical benefit vaccine billing information.	

Drug Product(s)	Criteria	PA Approval Length
VAFSEO (vadadustat)	**Vafseo** (vadadustat) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of anemia due to chronic kidney disease (CKD) and has been receiving dialysis for at least three months AND • Member does not have uncontrolled hypertension AND • Member does not have cirrhosis or acute, active liver disease AND • Member does not have any known active malignancies AND • Member has trialed and failed at least one month of treatment with an erythropoiesis-stimulating agent (ESA) AND • Laboratory tests to evaluate ALT, AST, alkaline phosphatase, total bilirubin, hemoglobin and iron status will be performed at baseline and during treatment with Vafseo (vadadustat), according to product labeling AND • Prescriber has counseled members who are taking an oral iron supplement, other products containing iron, or a phosphate binder that Vafseo (vadadustat) should be administered at least 1 hour before taking these products to avoid reducing the effectiveness of Vafseo (vadadustat) AND • Prescriber attests that member's medication profile has been reviewed for clinically significant drug interactions, including: o BCRP substrates (such as sulfasalazine, ciprofloxacin, acyclovir, nitrofurantoin, zidovudine): Monitor patients more frequently for adverse reactions and consider dose reduction of the BCRP substrate drug AND o OAT1 inhibitors (such as probenecid, rifampicin) AND o OAT3 inhibitors (such as gemfibrozil, probenecid, teriflunomide): Closely monitor for too large or too rapid an increase in hemoglobin response and for adverse reactions AND • Regarding concurrent statin therapy, provider attests that: o If member is concurrently taking simvastatin, the dose of simvastatin will be limited to 20 mg/day OR o If member is concurrently taking rosuvastatin, the dose of rosuvastatin will be limited to 5 mg/day AND • The requested medication is not being prescribed as a substitute for red blood cell transfusions in patients who require immediate correction of anemia AND • The requested medication is not being prescribed for treatment of anemia of chronic kidney disease in patients who are not on dialysis AND • Member has been counseled that Vafseo (vadadustat) tablets should not be cut, crushed or chewed. <u>Maximum Dose</u>: 600 mg/day <u>Initial Approval</u>: 6 months <u>Reauthorization</u>: Reauthorization for 6 months may be approved with documentation of lab results that indicate a clinically meaningful increase in hemoglobin level since initiation of treatment with Vafseo (vadadustat). *Note: Vafseo (vadadustat) should not be continued beyond 24 weeks of therapy if a clinically meaningful increase in hemoglobin level has not been achieved. Alternative explanations for an inadequate response should be sought and treated before re-starting therapy.*	6 months

<table>
<tr><th>Drug Product(s)</th><th>Criteria</th><th>PA Approval Length</th></tr>
<tr><td>VALCYTE (valganciclovir hydrochloride)</td><td>Effective 10/15/19: Brand Valcyte solution is no longer covered as a favored product (see section “Brand Name Medications and Generic Mandate” for brand product coverage details).

Valcyte® will be approved for members with diagnosis of Cytomegalovirus (CMV) retinitis AND acquired immunodeficiency Syndrome (AIDS) per dosing guidelines below
OR
For members that require prophylactic treatment for CMV post kidney, heart, liver, or kidney-pancreas transplant per dosing guidelines below
OR
For members ≤ 16 years of age that are at high risk of CMV infection and need prophylactic treatment post heart, liver, or kidney transplant per dosing guidelines below.

<table>
<tr><th colspan="2">Adult Dosage</th></tr>
<tr><td>Treatment of CMV retinitis</td><td>Induction: 900 mg (two 450 mg tablets) twice a day for 21 days
Maintenance: 900 mg once a day</td></tr>
<tr><td>Prevention of CMV disease in heart or kidney-pancreas patients</td><td>900 mg once a day within 10 days of transplantation 100 days post-transplantation</td></tr>
<tr><td>Prevention of CMV disease in kidney transplant patients</td><td>900 mg once a day within 10 days of transplantation until 200 days post-transplantation</td></tr>
<tr><td>Prevention of CMV disease in liver transplant patients</td><td>900 mg once a day for 100 days after transplantation</td></tr>
<tr><th colspan="2">Pediatric Dosage</th></tr>
<tr><td>Prevention of CMV disease in kidney transplant patients 4 month to 16 years of age</td><td>Dose once daily within 10 days of transplantation until 200 days post-transplantation</td></tr>
<tr><td>Prevention of CMV disease in heart transplant patients 1 month to 16 years of age</td><td>Dose once a day within 10 days of transplantation until 100 days post-transplantation</td></tr>
<tr><td>Prevention of CMV disease in liver transplant for children</td><td>For patients < 15 kg: 15 mg/kg/dose PO once daily.
For patients > 15 kg: 500 mg/m^2/dose PO once daily).
Maximum dose: 900 mg/dose once daily for 3-6 months after transplantation.</td></tr>
</table>
</td><td>One year</td></tr>
<tr><td>VALTOCO (diazepam)</td><td>Valtoco (diazepam) may be approved for members meeting the following criteria:
• Member is 2 years of age or older AND
• Valtoco is being prescribed for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern and medical records are provided supporting this diagnosis AND
• Member is stable on regimen of antiepileptic medications AND</td><td>One year</td></tr>
</table>

Drug Product(s)	Criteria	PA Approval Length
	• Medication is being prescribed by or in conjunction with the same provider/provider team who manages the member's anti-epileptic regimen AND • Member is educated on appropriate identification of seizure cluster and Valtoco (diazepam) administration and not to exceed 2 doses per seizure cluster. Quantity Limits: Limited to one 5-dose package per year unless used / damaged / lost / dose increased (limited to one 5-dose package per fill). Members are limited to one prior authorization approval on file for Valtoco (diazepam) and Nayzilam (midazolam). If member is currently receiving Valtoco (diazepam) intranasal, they may receive prior authorization approval to continue.	
VANRAFIA (atrasentan)	**Vanrafia** (atrasentan) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has a diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy and is at risk of rapid disease progression AND • Member has a baseline urine protein-to-creatinine ratio of ≥1.5 g/g or proteinuria ≥ 1 g/day AND • Member has an eGFR ≥ 30 mL/min/1.73 m2 AND • Member is not pregnant or breastfeeding AND • Member has tried and failed† maximally tolerated dose of an immunosuppressant AND • Member has not achieved desired clinical outcomes with maximally tolerated ACE inhibitor or ARB therapy for three months and will continue on ACE inhibitor or ARB therapy unless the member has an allergy, intolerance, or contraindication to ACE inhibitor or ARB therapy AND • Member will continue to receive concomitant ACE inhibitor or ARB therapy unless the member has an allergy, intolerance, or contraindication to ACE inhibitor or ARB therapy AND • Provider attests that member's medication profile has been reviewed for drug interactions between Vanrafia (atrasentan) and strong/moderate CYP3A inhibitors, strong CYP3A inducers, OATP1B1/1Be inhibitors and other agents that may result in clinically significant interactions, according to product labeling AND • Member is not concurrently taking another endothelin receptor antagonist (such as ambrisentan, bosentan or sparsentan) AND • Prior to initiation of Vanrafia (atrasentan) therapy, the member's hepatic aminotransferases (ALT, AST) are not greater than 3 times the upper limit of normal AND • Requested medication is being prescribed by or in consultation with a nephrologist or immunologist AND • Prescriber acknowledges that continued FDA approval of Vanrafia (atrasentan) to slow kidney function decline in patients with IgAN may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Maximum Dose: 0.75 mg per day	One year

Drug Product(s)	Criteria	PA Approval Length
	Maximum Quantity: 1 tablet per day Reauthorization: Reauthorization may be approved for one year if meeting the following: • Member has experienced disease improvement and/or stabilization as indicated by: o Decrease of urine protein-to-creatinine ratio (UPCR) or decrease in proteinuria from baseline AND o Member has not experienced any treatment-restricting adverse effects such as clinically relevant liver transaminase elevations, increase in bilirubin greater than 2 times upper limit of normal, or clinical symptoms of hepatotoxicity. †Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction.	
VELTASSA (patiromer)	**Veltassa** (patiromer) prior authorization will be approved for members that meet the following criteria: • Documented diagnosis of hyperkalemia (serum potassium > 5 mEq/L) AND • Veltassa is not being used for emergent hyperkalemia AND • Member does not have severe gastrointestinal motility dysfunction AND • Member does not have hypomagnesemia (serum magnesium < 1.4 mg/dL).	One year
VEOZAH (fezolinetant)	Veozah (fezolinetant) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has been diagnosed with moderate to severe vasomotor symptoms (such as hot flashes and sweating) associated with menopause AND • Member has tried and failed two alternate oral or transdermal estrogen-containing products. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction OR member has moderate to high risk for complications related to estrogen therapy AND • Member does not have known cirrhosis AND • Member does not have severe renal impairment (eGFR 15 to 29mL/min/1.73 m2) or end-stage renal disease (ESRD) AND • Member's baseline hepatic transaminases prior to starting fezolinetant therapy have been documented and are less than two times the upper limit of normal AND • Provider attests that hepatic transaminases will be closely monitored during fezolinetant therapy as described in the FDA product labeling AND • Member is not taking a medication that is a CYP1A2 inhibitor (fluvoxamine, mexiletine, cimetidine, and others). Maximum dose: One 45 mg tablet/day Quantity limit: 30 tablets/30 days	One year
VERIPRED (prednisolone)	A prior authorization will only be approved if a member has tried and failed on a generic prednisolone product (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions.)	One year
VERQUVO (vericiguat)	**Verquvo** (vericguat) may be approved if the following criteria are met: • Member is 18 years of age or older AND • Member is not pregnant AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Member has a diagnosis of heart failure with reduced ejection fraction (LVEF <45%) AND • Member is not concurrently taking long-acting nitrates or nitric oxide donors (such as isosorbide dinitrate, isosorbide mononitrate, or transdermal nitroglycerin), riociguat, or PDE-5 inhibitors (such as vardenafil or tadalafil) AND • Member has a trial and failed ONE agent from EACH of the following drug classes (failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions): o ACE inhibitor (such as enalapril or lisinopril) OR ARB (such as valsartan or candesartan) OR angiotensin receptor-neprilysin inhibitor [ARNI] (such as sacubitril/valsartan) o Beta blocker (bisoprolol, carvedilol, metoprolol succinate) o Aldosterone antagonist (spironolactone or eplerenone) o SGLT-2 inhibitor: Farxiga (dapagliflozin), Jardiance (empagliflozin) or Invokana (canagliflozin). Maximum dose: 10 mg/day Quantity limits: • 2.5mg: 2 tablets/day • 5mg: 2 tablets/day • 10mg: 1 tablet/day	
VERSED (midazolam) Injection	*Effective 09/25/2019 prior authorization is no longer required for generic midazolam vial/syringe formulations.*	
VIJOICE (alpelisib)	**VIJOICE** (alpelisib) may be approved if the following criteria are met: • Member is ≥ 2 years of age **AND** • Member requires systemic therapy for severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) **AND** • Due to the risk of severe adverse reactions, provider confirms that VIJOICE (alpelisib) will not be used in the oncology setting **AND** • Prescriber confirms that potentially significant drug-drug interactions with strong CYP3A4 inducers (such rifampin, carbamazepine, phenytoin and St. John's Wort) will be carefully evaluated prior to initiating therapy with VIJOICE (alpelisib), based on the current product labeling **AND** • Prescriber attests that a pre-treatment pregnancy test will be performed for members of reproductive potential and that member will be advised to use effective contraception (including condoms for male patients) during treatment and for 1 week after the final dose **AND** • Provider and patient or caregiver are aware that continued US FDA approval of VIJOICE (alpelisib) for PIK3CA-Related Overgrowth Spectrum may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Maximum Dose: 250 mg/day	One year
VILTEPSO (viltolarsen)	**Viltepso** (viltolarsen) may receive approval if meeting the following criteria: • Medication is being administered in the member's home or in a long-term care facility by a healthcare professional AND • Member must have genetic testing confirming mutation of the Duchenne muscular dystrophy (DMD) gene that is amenable to exon 53 skipping AND	Initial: 6 months Continuation: One year

Drug Product(s)	Criteria	PA Approval Length
	• Medication is prescribed by or in consultation with a neurologist or a provider who specializes in treatment of DMD (i.e. neurologist, cardiologist, pulmonologist, or physical medicine and rehabilitation physician) AND • Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting Viltepso (viltolarsen). Consider measurement of glomerular filtration rate prior to initiation of Viltepso (viltolarsen) AND • Members with known renal function impairment should be closely monitored during treatment with Viltepso (viltolarsen), as renal toxicity has occurred with similar drugs AND • If the member is ambulatory, functional level determination of baseline assessment of ambulatory function is required OR if not ambulatory, member must have a baseline Brooke Upper Extremity Function Scale score or Forced Vital Capacity (FVC) documented AND • Provider and patient or caregiver are aware that continued US FDA approval of Viltepso (viltolarsen) for Duchenne muscular dystrophy (DMD) may be contingent upon verification and description of clinical benefit in a confirmatory trial. Reauthorization: After 24 weeks of treatment with Viltepso (viltolarsen), member may receive approval to continue therapy for one year if the following criteria are met: • Member has shown no intolerable adverse effects related to Viltepso (viltolarsen) treatment at a dose of 80mg/kg IV once a week AND • Member has normal renal function or stable renal function if known impairment AND • Provider attests that treatment with Viltepso (viltolarsen) is necessary to help member improve or maintain functional capacity based on assessment of trajectory from baseline for ambulatory or upper extremity function or Forced Vital Capacity (FVC). Maximum dose: 80 mg/kg administered as an IV infusion once weekly (documentation of patient's current weight with the date the weight was obtained). Above coverage standards will continue to be reviewed and evaluated for any applicable changes due to the evolving nature of factors including disease course, available treatment options, and available peer-reviewed medical literature and clinical evidence.	
VIMIZIM (elosulfase alfa)	**Vimizim** (elosulfase alfa) prior authorization may be approved for members meeting the following criteria: • Member is ≥ 5 years of age **AND** • Member has a confirmed diagnosis of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome) **AND** • Medication is being administered by a healthcare provider in the member's home or in a long-term care facility (and meets approval criteria listed in "Physician Administered Drug" section of Appendix P) **AND** • Vimizim is prescribed by or in consultation with an endocrinologist **AND** • Prescriber acknowledges that Vimizim will be administered under close medical observation due to risk of life-threatening anaphylactic reactions.	One year
VITAMINS* (prescription vitamins)	**Coverage criteria outlined in this section apply to vitamin products available as prescription drugs. For over-the-counter product coverage, please see "OTC Products" section.* The following prescription vitamin products will be covered without prior authorization: • Vitamin D	One year

Drug Product(s)	Criteria	PA Approval Length
	• Vitamin K **General prescription vitamin criteria: Prescription vitamin products will be approved for: • ESRD, CRF, renal insufficiency, diabetic neuropathy or renal transplant OR • Members under the age of 21 with a disease state or clinical diagnosis associated with prohibited nutritional absorption processes as a secondary effect OR • Members with Erythema Bullosum Hydroxocobalamin injection will be approved for: • Members meeting any general prescription vitamin criteria** OR • Methylmalonic acidemia (MMA) Cyanocobalamin will be approved for: • Members meeting any general prescription vitamin criteria** OR • Vitamin B12 deficiency Folic acid prescription products will be approved for: • Members meeting any general prescription vitamin criteria** OR • Folic acid 1mg will be approved for female members without a prior authorization OR • Members currently taking methotrexate or pemetrexed OR • Documented folic acid deficiency by the treating clinician (megaloblastic and macrocytic anemia are the most common. Some drugs or other conditions may cause deficiency as well) OR • Homocysteinemia OR • Sickle cell disease OR • Female members prescribed folic acid for the prevention of a neural tube defect during pregnancy or for the prevention of miscarriage Cyanocobalamin/folic acid/pyridoxine prescription products will be approved for: • Members meeting any general prescription vitamin criteria** OR • Members with homocysteinemia or homocystinuria OR • Members on dialysis OR • Members with (or at risk for) cardiovascular disease For prescription iron-containing products see “Anti-anemia Medications” Metanx will be approved for members with non-healing diabetic wounds.	
VOWST (fecal microbiota spore, live-brpk)	**Vowst** (fecal microbiota spore, live-brpk) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • Member has had recent laboratory confirmation of a positive C. difficile stool sample AND • Member has a history of ≥ three episodes of C. difficile infection (CDI) within the past 12 months that were treated with appropriate antibiotic therapy and is receiving Vowst following completion of treatment for the third (or further) CDI episode AND • Treatment with the requested medication is following treatment of recurrent CDI with appropriate antibiotic therapy AND	One treatment course

Drug Product(s)	Criteria	PA Approval Length
	• Requested product is being prescribed by or in consultation with a gastroenterologist or infectious disease specialist AND • Antibacterial therapy for CDI has been discontinued 2 to 4 days prior to initiating Vowst therapy and concurrent antibacterial therapy will not be initiated during the 3-day course of Vowst therapy AND • Member has been evaluated to rule out dysphagia, known esophageal stricture, Zenker's diverticulum, gastroparesis, prior history of small bowel obstruction, prior colectomy or colostomy AND • Provider attests that member has (1) received instructions regarding the magnesium citrate (or polyethylene glycol electrolyte solution) pre-treatment regimen, and (2) has been advised to take nothing by mouth except water for at least 8 hours prior to taking the first dose of Vowst. Approval will be placed to allow for one treatment course. Quantity limit: 12 capsules	
VOXZOGO (vosoritide)	**Voxzogo** (vosoritide) may be approved if the following criteria are met: • Member has a genetically-confirmed diagnosis of achondroplasia with open epiphyses AND • Prescriber acknowledges that in order to reduce the risk of low blood pressure the member should have adequate food intake and drink 240 to 300 mL of fluid in the hour prior to Voxzogo administration, AND • Prescriber agrees to monitor body weight, growth, and physical development every 3 to 6 months, and to permanently discontinue Voxzogo upon confirmation of no further growth potential, indicated by closure of epiphyses AND • Provider and patient or caregiver are aware that continued US FDA approval of Voxzogo (vosoritide) for achondroplasia with open epiphyses may be contingent upon verification and description of clinical benefit in confirmatory trial(s). Maximum Dose: 0.8 mg/day Quantity Limit: Three 10-packs of 0.4 mg, 0.56 mg, or 1.2 mg vials/30 days Initial Authorization: 6 months Reauthorization for Voxzogo (vosoritide) for 12 months may be approved if linear growth is improving and closure of epiphyses has not yet occurred.	Initial: 6 months Continued: One year
VOYDEYA (danicopan)	**Voydeya** (danicopan) may be approved if the following criteria are met: • Member is ≥18 years of age AND • Member has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) confirmed by high sensitivity flow cytometry AND • Voydeya (danicopan) is being prescribed to treat breakthrough hemolysis with symptomatic residual anemia as add-on therapy to current C5 inhibitor therapy with ravulizumab or eculizumab AND • Member does not have severe hepatic disease (Child-Pugh Class C) AND • Member does not have any active infections caused by an encapsulated bacteria (such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b) AND • Member has received vaccination against encapsulated bacteria (such as Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b) at least 2 weeks prior to initiation of Voydeya (danicopan) therapy AND	Initial: 6 months Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	• Member has residual anemia (hemoglobin < 9.5 g/dL) at baseline, with absolute reticulocyte count ≥ 120 × 109/L with or without transfusion support, and has been stable on ravulizumab or eculizumab therapy for at least 6 months AND • If urgent Voydeya (danicopan) therapy is indicated in a patient who is not up to date with vaccines, or the vaccines were administered within the last 2 weeks, prescriber attests that the member will receive appropriate antibacterial drug prophylaxis, and the vaccines will be administered as soon as possible AND • Requested product is being prescribed by or in consultation with a hematologist, immunologist or nephrologist AND • Prescriber attests that member's medication profile has been reviewed for clinically significant drug interactions, including: o BCRP substrates: Monitor patients more frequently for adverse reactions and consider dose reduction of the BCRP substrate drug (ciprofloxacin, atorvastatin, rosuvastatin, acyclovir, nitrofurantoin, zidovudine and others) AND o For concomitant rosuvastatin, the dose should not exceed 10 mg once daily AND o P-gp substrates: Dose adjustment might be necessary for P-gp substrates (apixaban, colchicine, cyclosporine, dabigatran, digoxin, edoxaban, rivaroxaban, tacrolimus) where minimal concentration changes may lead to serious adverse reactions. Quantity limit: 120 tablets/30 days Maximum dose: 600 mg/day Initial Approval: 6 months Reauthorization: Approval for 1 year may be given with prescriber attestation that member's hemoglobin has increased by ≥2 g/dL from baseline while on Voydeya (danicopan) therapy.	
VUSION OINTMENT (miconazole/zinc oxide/white petrolatum)	A prior authorization will only be approved if a member has failed on an OTC antifungal **and** a generic prescription antifungal. (Failure is defined as: lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions)	One year
VYALEV (foscarbidopa/ foslevodopa)	**Vyalev** (foscarbidopa/foslevodopa) may be approved for members that meet the following criteria: • Member is ≥ 18 years of age AND • Member is diagnosed with advanced Parkinson's Disease AND • Member is experiencing "off" episodes such as muscle stiffness, slow movements, or difficulty starting movements AND • Member is experiencing a minimum of 2.5 hours of "off" time per day AND • Member is taking ≥ 400 mg of levodopa per day (alone or in combination with COMT inhibitors) AND • Member has previously tried, or is currently receiving, ONE other treatment for "off" episodes (such as entacapone, rasagiline, pramipexole IR, ropinirole IR, selegiline) AND • Member is not taking a non-selective monoamine oxidase (MAO) inhibitor or has recently (within 2 weeks) taken a non-selective MAO inhibitor, AND • Prescriber attests that member is capable of understanding and using the delivery system themselves or by a caregiver AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Prescriber attests that the member has been trained on proper use and delivery system prior to initiation AND • The medication is prescribed by or in consultation with a neurologist. Maximum dose: 3,525 mg of foslevodopa (approximately 2,500 mg levodopa) Quantity Limit: 42 vials (10 mL each) per 28 days Reauthorization: Vyalev (foscarbidopa/foslevodopa) may be reauthorized for one year with provider attestation that the member has demonstrated response to treatment by showing significant clinical improvement or reduction in "off" time.	
VYEPTI (eptinezumab)	**Vyepti** (eptinezumab) may be approved if the following criteria are met: • For claims billed through the pharmacy benefit, prescriber verifies that the medication is being administered by a healthcare professional in the member's home or in a long-term care facility **AND** • Member is 18 years of age or older **AND** • Member has a diagnosis of episodic (fewer than 15 headache days monthly) or chronic migraine (headaches occurring 15 days or more monthly, where at least 8 of these days per month for at least 3 months are migraine days with or without aura) **AND** • Member has tried and failed two oral preventive pharmacological agents listed as Level A per the most current American Headache Society/American Academy of Neurology guidelines (such as divalproex, topiramate, metoprolol, propranolol). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction AND • The requested medication is not being used in combination with another CGRP medication **AND** • Member has trial and failure of three preferred calcitonin gene-related peptide inhibitors (CGRPis) indicated for preventative therapy listed on the pharmacy benefit preferred drug list **AND** • Initial dose is no more than 100 mg every 3 months, and if Vyepti 300 mg is requested, prescriber verifies the member has tried and had an inadequate response (no less than 30% reduction in headache frequency in a 4-week period) to the 100 mg dosage **AND** • Initial authorization will be limited to 6 months. Continuation (12-month authorization) will require documentation of clinically relevant improvement with no less than 30% reduction in headache frequency in a 4-week period. Maximum dose: 300 mg IV every 3 months	Initial: 6 months Continued: One year
VYJUVEK (beremagene geperpavec-svdt)	**Vyjuvek** (beremagene geperpavec-svdt) may be approved if the following criteria are met: • For billing under the pharmacy benefit, medication is being administered in the member's home or in a long-term care facility (LTCF) by a healthcare professional AND • Member is ≥ 6 months of age, AND • Member has a documented diagnosis of dystrophic epidermolysis bullosa AND • Member must have undergone genetic testing confirming mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• The requested medication is being prescribed by or in consultation with a provider who has expertise in treating dystrophic epidermolysis bullosa AND • Member has been counseled regarding use of highly effective contraceptive method(s) while receiving treatment. Quantity limit: one 1 mL vial of biological suspension plus one 1.5 mL excipient gel vial per week Reauthorization: Prescribing provider attests that clinical condition is improving on Vyjevek (beremagene geperpavec-svdt) therapy.	
VYKAT XR (diazoxide choline)	**Vykat XR** (diazoxide choline) may be approved if the following criteria are met: • Member is ≥ 4 years of age AND • Member has a diagnosis of Prader-Willi syndrome (PWS) confirmed by genetic testing indicating mutation on chromosome 15 AND • Member is being treated for hyperphagia associated with PWS AND • Vykat XR (diazoxide choline) is being prescribed by or in consultation with an endocrinologist, gastroenterologist, genetics/metabolic physician, nutrition physician, or developmental pediatrician AND • Prior to initiation of therapy, baseline fasting glucose and HbA1c labs have been drawn and blood glucose has been optimized in members who have hyperglycemia AND • Prescriber acknowledges that Vykat XR (diazoxide choline) may precipitate congestive heart failure in patients with compromised cardiac reserve and it should be used with caution in these patients AND • Prescriber acknowledges important Vykat XR (diazoxide choline) dose adjustment considerations for members who are taking concomitant strong CYP1A2 inhibitors, per product labeling AND • After initiation of treatment, fasting glucose, HbA1c, and signs or symptoms of edema or fluid overload will be monitored according to product labeling. Note: Diazoxide oral suspension should not be substituted for Vykat XR (diazoxide choline) tablets due to differences in the pharmacokinetic profiles for these products. Maximum Dose: 525 mg/day Maximum Quantities: 25 mg tablets: 4 tablets/day 75 mg tablets: 2 tablets/day 150 mg tablets: 3 tablets/day	One year
VYNDAMAX (tafamidis)	**Vyndamax** (tafamidis) may be approved for members meeting the following criteria: • Member is an adult ≥ 18 years of age AND • Member has a diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) AND • Member has a documented history of heart failure with NYHA functional class I-III Maximum dose: Vyndamax (tafamidis) 61mg daily	One year

Drug Product(s)	Criteria	PA Approval Length
VYNDAQEL (tafamidis meglumine)	**Vyndaqel** (tafamidis meglumine) may be approved for members meeting the following criteria: • Member is an adult ≥ 18 years of age AND • Member has a diagnosis of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) AND • Member has a documented history of heart failure with NYHA functional class I-III Maximum dose: Vyndaqel (tafamidis meglumine) 80mg daily	One year
VYONDYS 53 (golodirsen)	**Vyondys 53** (golodirsen) may be approved if all the following criteria are met: • For billing under the pharmacy benefit, medication is being administered in the member's home or in a long-term care facility by a healthcare professional AND • Member must have genetic testing confirming mutation of the Duchenne Muscular Dystrophy (DMD) gene that is amenable to exon 53 skipping AND • Medication is prescribed by or in consultation with a neurologist or a provider who specializes in treatment of DMD (i.e., neurologist, cardiologist, pulmonologist or physical medicine and rehabilitation physician) AND • The member must be on corticosteroids at baseline or has a contraindication to corticosteroids AND • If the member is ambulatory, functional level determination of baseline assessment of ambulatory function is required OR if not ambulatory, member must have a Brooke Upper Extremity Function Scale of five or less documented OR a Forced Vital Capacity of 30% or more. Reauthorization: Provider attests that treatment with Vyondys 53 (golodirsen) is necessary to help member improve or maintain functional capacity based on assessment of trajectory from baseline for ambulatory or upper extremity function or Forced Vital Capacity (FVC). Maximum Dose: 30 mg/kg per week *(documentation of patient's current weight with the date the weight was obtained*) *Above coverage standards will continue to be reviewed and evaluated for any applicable changes due to the evolving nature of factors including disease course, available treatment options, and available peer-reviewed medical literature and clinical evidence.*	Initial: One year Continued: One year
VYVGART (efgartigimod alfa) **VYVGART HYTRULO (efgartigimod alfa/ hyaluronidase)**	**Vyvgart** (efgartigimod alfa) single-dose vial for IV administration may be approved if the following criteria are met: • Prescriber confirms that the requested medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND • Member is ≥ 18 years of age AND • The requested medication is being prescribed for treatment of generalized myasthenia gravis (gMG) that is anti-acetylcholine receptor (AChR) antibody positive AND • The member meets the criteria for Myasthenia Gravis Foundation of America (MGFA) clinical classification class II to IV AND • The requested medication is being prescribed by or in consultation with a neurologist AND	One year

Drug Product(s)	Criteria	PA Approval Length
	• Provider will perform a myasthenia gravis functionality score at baseline using a measure such as the Myasthenia Gravis Activities of Daily Living (MG-ADL) or Quantitative Myasthenia Gravis (QMG) scoring tool. **Vyvgart Hytrulo** (efgartigimod alfa/hyaluronidase) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • If the request is for Vyvgart Hytrulo single-dose vial for subcutaneous injection, the prescriber confirms that the requested medication is being administered by a healthcare professional in the member's home or in a long-term care facility AND • The requested medication is being prescribed by or in consultation with a neurologist AND • The request meets the following criteria for the prescribed treatment diagnosis: <u>For Generalized Myasthenia Gravis</u>**:** • The requested medication is being prescribed for the treatment of generalized myasthenia gravis (gMG) that is anti-acetylcholine receptor (AChR) antibody positive AND • The member meets the criteria for Myasthenia Gravis Foundation of America (MGFA) clinical classification class II to IV AND • Provider will perform a myasthenia gravis functionality score (such as the MGADL or QMG) at baseline. <u>For Chronic Inflammatory Demyelinating Polyneuropathy:</u> • The requested medication is being prescribed for treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) AND • Member has a diagnosis of definite or probable CIDP using the most current European Federation of Neurological Societies/Peripheral Nerve Society criteria for progressing or relapsing forms AND • Provider will perform a functionality score, such as the Inflammatory Rasch-built Overall Disability Scale (I-RODS) or the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale, at baseline AND • Member has failed to demonstrate objective improvement after receiving all of the treatments (failure is defined as a lack of efficacy, allergy, intolerable side effects, contraindication, or significant drug-drug interaction): o Oral or IV corticosteroids o IV immunoglobulin (IVIG) o Plasma exchange <u>Dosing and Formulations for gMG:</u> • Vyvgart single-dose vial (IV): 10 mg/kg every 4 weeks, up to a maximum dose of 1,200 mg IV every 4 weeks • Vyvgart Hytrulo single-dose vial (subcutaneous): 1,008 mg once weekly • Vyvgart Hytrulo prefilled syringe (subcutaneous): 1,000 mg once weekly <u>Dosing and Formulations for CIDP:</u> • Vyvgart Hytrulo single-dose vial (subcutaneous): 1,008 mg once weekly • Vyvgart Hytrulo prefilled syringe (subcutaneous): 1,000 mg once weekly	

Drug Product(s)	Criteria	PA Approval Length
	Quantity Limits: • Vyvgart single-dose vial (IV): Twelve 400 mg/20 mL single-dose vials per 28 days • Vyvgart Hytrulo single-dose vial (subcutaneous): Four 1,008 mg single-dose vials per 28 days • Vyvgart Hytrulo prefilled syringe (subcutaneous): Four 1,000 mg prefilled syringes per 28 days Reauthorization: • Reauthorization requests for gMG treatment may receive additional one-year approval with provider attestation that a follow-up myasthenia gravis functionality assessment was performed and indicates stable symptoms or clinical improvement OR • Reauthorization requests for Vyvgart Hytrulo for CIDP treatment may receive additional one-year approval may with provider attestation that a follow-up CIDP functionality assessment was performed and indicates stable symptoms or clinical improvement. *Note: Single dose vial formulations for IV and subcutaneous administration must be administered by a healthcare professional. A member or caregiver may inject Vyvgart Hytrulo (efgartigimod alfa/hyaluronidase) prefilled syringe after proper instruction on subcutaneous injection technique.*	
WAYRILZ (rilzabrutinib)	**Wayrilz** (rilzabrutinib) may be approved if the following criteria are met: • Member is ≥18 years of age AND • Member has a diagnosis of persistent or chronic immune thrombocytopenia (ITP) AND • The member's degree of thrombocytopenia and clinical condition increase the risk for bleeding as demonstrated by a baseline platelet count within the past 28 days of ≤ 30,000/mm3 AND • Member does not have severe renal impairment (CrCl <46 mL/min) AND • Member has had bilirubin and hepatic transaminases drawn at baseline AND • Member does not have moderate or severe hepatic impairment AND • Prescriber is aware that Wayrilz (rilzabrutinib) may increase the risk of severe and potentially life-threatening hepatotoxicity and that hepatic function must be monitored before and during therapy AND • Member is not pregnant or breastfeeding AND • Requested medication is being prescribed by a hematologist AND • Member has had an insufficient response to corticosteroids, immunoglobulins, or splenectomy AND • Member has trial and failure of Promacta (eltrombopag) or rituximab. Failure is defined as a lack of efficacy, allergy, intolerable side effects, or significant drug-drug interactions AND • Member will be monitored for signs and symptoms of infection and treated appropriately if needed AND • Member has received counseling to avoid the use of proton pump inhibitors and to take Wayrilz (rilzabrutinib) tablets at least 2 hours before doses of antacid or histamine H2 receptor antagonists AND that Wayrilz (rilzabrutinib) tablets should not be split, chewed, or crushed.	Initial: Six months Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	Maximum dose: 800 mg/day Maximum quantity: 60 tablets/30 days Initial approval: 6 months Reauthorization: Reauthorization may be approved for one year with verification of documented durable platelet count response, defined as: • Platelet count ≥50 x 109/L (50,000/mm3) OR • Platelet count between 30 × 109/L (30,000/mm3) and <50 × 109/L (50,000/mm3) AND at least doubled from baseline in the absence of rescue therapy. ‡Failure is defined as lack of efficacy, allergy, intolerable side effects or significant drug-drug interactions.	
WINREVAIR (sotatercept-csrk)	**Winrevair** (sotatercept-csrk) may be approved if the following criteria are met: • Member is an adult ≥ 18 years of age AND • Member has a diagnosis of pulmonary arterial hypertension (PAH), WHO group 1 AND • Member is not currently experiencing serious bleeding AND • Member has been counseled and evaluated regarding signs and symptoms of blood loss AND • Member's pre-treatment platelet count is >50,000/mm3 AND • Member is not pregnant or planning to become pregnant AND • Member will not be breastfeeding during and within 4 months after last dose AND • Initial prescription for the requested product is being prescribed by or in consultation with a pulmonologist or cardiologist AND • Member has tried and failed‡ a preferred medication from one of the following categories: o Phosphodiesterase Inhibitors o Endothelin Receptor Antagonists o Prostacyclin Analogues and Receptor Agonists AND • Since Winrevair (sotatercept-csrk) is intended for use under the guidance of a healthcare professional, prescriber attests that the member self-administering the drug will be permitted to do so only when (1) it is considered appropriate, and (2) after they have received adequate initial training and administration technique assessment from a healthcare professional AND • Prescriber attests that hemoglobin (Hgb) and platelet counts will be assessed before each dose for the first 5 doses of Winrevair (or longer if lab values are unstable), and also monitored periodically thereafter to assess the need for dose adjustments. Maximum dose: 0.7 mg/kg every 3 weeks Continuation of therapy: Members who are currently stabilized on Winrevair (sotatercept-csrk) may receive approval to continue use of the product. ‡Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction	One year
XDEMVY (lotilaner)	**Xdemvy** (lotilaner) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND	See criteria

Drug Product(s)	Criteria	PA Approval Length
	• Member has a documented diagnosis of moderate to severe Demodex blepharitis confirmed through microscopic examination AND • Requested product is being prescribed by or in consultation with an ophthalmologist or optometrist AND • Member has failed to experience clinical improvement of Demodex blepharitis with regular lid hygiene practices including warm compresses, lid massage, eyelid washing for at least two months AND • Member has tried and failed† therapy with ivermectin OR clinical rationale is provided supporting why this medication cannot be trialed AND • Member has been advised that Xdemvy (lotilaner) solution may discolor soft contact lenses. Dosing limit: Approval will be given for one course of therapy (1 drop in each eye every 12 hours for 6 weeks) † Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction	
XERMELO (telotristat ethyl)	**Xermelo** (telotristat ethyl) prior authorization may be approved for members meeting the following criteria: • Member is at 18 years of age or older **AND** • Member has a diagnosis of carcinoid syndrome diarrhea **AND** • Member has trialed and failed three months of somatostatin analog therapy (such as octreotide). Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction **AND** • Xermelo is being used in combination with somatostatin analog therapy Maximum dose: 750 mg per day	One year
XIFAXAN (rifaximin)	*Note: Xifaxan is currently not a participating product in the Medicaid Drug Rebate Program (MDRP).* **Xifaxan** (rifaximin) prior authorization will be approved for members meeting the following criteria: • For members prescribed Xifaxan for prophylaxis of hepatic encephalopathy (HE) in adults: o Member must be concomitantly taking lactulose or other non-absorbable disaccharide AND o Member must not have undergone transjugular intrahepatic portosystemic shunt (TIPS) procedure within the last 3 months AND o Xifaxan is being prescribed for secondary prophylaxis of HE (member has experienced previous episode of HE) AND o Maximum dosing regimen is 550mg twice daily o Members meeting criteria will receive approval for one year • For members prescribed Xifaxan for irritable bowel syndrome with diarrhea (IBS-D): o Maximum dosing regimen is 550mg three times daily for 14 days AND o Approval is limited to <u>two</u> 14-day treatment courses per 14 week time period • For members prescribed Xifaxan for traveler's diarrhea: o Member must be ≥ 12 years of age AND o Maximum dosing regimen is 200mg three times daily for 3 days o Members meeting criteria will receive approval for one year	See Criteria

Drug Product(s)	Criteria	PA Approval Length
XOLREMDI (mavorixafor)	**Xolremdi** (mavorixafor) may be approved if the following criteria are met: • Member is ≥ 12 years of age AND • Member has a diagnosis of WHIM syndrome (warts, hypogammaglobulinemia, infections, myelokathexis) AND • Diagnosis of WHIM is based on a genotype-confirmed pathogenic variant in the CXCR4 gene AND • Member has a confirmed absolute neutrophil count of ≤ 400 cells/µL AND • The requested drug is being prescribed by a provider specializing in the treatment of WHIM (such as an immunologist, geneticist, hematologist, dermatologist, or infectious disease specialist) AND • Member has a recent creatinine clearance of 30 mL/min or greater AND • Member does not moderate to severe hepatic impairment AND • Provider attests that QTc interval will be assessed at baseline and monitored during treatment as clinically indicated AND • Prescriber attests that members of reproductive potential will be advised to use effective contraception while on Xolremdi (mavorixafor) therapy AND • Prescriber attests that members of reproductive potential will be advised that breastfeeding is not recommended during treatment and for 3 weeks after last dose of Xolremdi (mavorixaflor) AND • Due to the risk of adverse reactions that maybe be associated with significant increases in Xolremdi (mavorixafor) exposure, member is not concurrently taking a medication that is highly dependent on CYP2D6 for clearance (such as dextromethorphan, fluoxetine, nortriptyline, oxycodone, paroxetine, quinidine) OR a strong CYP3A4 inducer (such as carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifampin, rifabutin, rifapentine, dexamethasone, efavirenz, etravirine, nevirapine, darunavir/ritonavir, ritonavir, St John's Wort) AND • Member's medication profile has been reviewed for other potential clinically significant drug interactions according to product labeling AND • Member is not being treated with any other CXCR4 antagonists AND • Member has been counseled to take Xolremdi (mavorixaflor) on an empty stomach after an overnight fast, and at least 30 minutes before food and counseled that Xolremdi (mavorixaflor) capsules should not be cut, crushed or chewed. Maximum Dose: 400 mg/day Maximum Quantity: 120 capsules (100 mg strength)/30 days Reauthorization: Member may receive approval for one year with provider attestation to the efficacy of treatment based on a sustained increase in absolute neutrophil count with ongoing monitoring.	One year
XYREM (sodium oxybate)	**Xyrem** (sodium oxybate) may be approved for adults and children 7 to 17 years of age if all the following criteria are met: • Member has a diagnosis of cataplexy or excessive daytime sleepiness with narcolepsy (confirmed by one of the following): o Cataplexy episodes occurring three or more times per month OR o Hypocretin deficiency OR o Nocturnal sleep polysomnography showing rapid eye movement (REM) sleep latency less than or equal to 15 minutes, or a Multiple	Initial: 30 days Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	Sleep Latency Test (MSLT) showing a mean sleep latency less than or equal to 8 minutes and two or more sleep-onset REM periods AND • Baseline excessive daytime sleepiness is measured using the Epworth Sleepiness Scale or cataplexy episode count AND • Member has adequately trialed and failed therapy with 3 stimulants for narcolepsy (examples include methylphenidate and amphetamine salts) Failure is defined as: lack of efficacy with 2 week trial, allergy, intolerable side effects, or significant drug-drug interactions. AND • Member must not have recent (within 1 year) history of substance abuse AND • Member is not taking opioids, benzodiazepines, sedative hypnotics (such as zolpidem, zaleplon, eszopiclone, chloral hydrate, etc.) or consuming alcohol concomitantly with Xyrem (sodium oxybate) AND • Prescriber is enrolled in corresponding REMS program AND • If member is an adult (age ≥ 18 years), they have had an adequate trial and failure of therapy with 3 sedative hypnotic medications (examples include zolpidem and eszopiclone). Failure is defined as: lack of efficacy with 2 week trial, allergy, intolerable side effects or significant drug-drug interactions. <u>Initial and Continuation Prior Authorization Approval:</u> Initial prior authorization approval will be for 30 days. For continuation approval for one year, the following information must be provided: • Verification of Epworth Sleepiness Scale score reduction on follow-up OR • Verification of cataplexy episode count reduction on follow-up <u>Maximum Dosing:</u> 9 grams/day	
XYWAV (calcium, magnesium, potassium, sodium oxybates)	**Xywav** (calcium, magnesium, potassium, sodium oxybates) may be approved if the following criteria are met: • Member is ≥ 7 years of age AND • Member has a diagnosis of excessive daytime sleepiness with narcolepsy (confirmed by one of the following): o Hypocretin deficiency OR o Nocturnal sleep polysomnography showing rapid eye movement (REM) sleep latency less than or equal to 15 minutes, or a Multiple Sleep Latency Test (MSLT) showing a mean sleep latency less than or equal to 8 minutes and two or more sleep-onset REM periods AND • Baseline excessive daytime sleepiness is measured using the Epworth Sleepiness Scale or cataplexy episode count AND • Member has adequately trialed and failed therapy with 3 stimulants for narcolepsy (examples include methylphenidate and amphetamine salts) Failure is defined as: lack of efficacy with 2 week trial, contraindication to therapy, allergy, intolerable side effects, or significant drug-drug interactions AND • Member must not have recent (within 1 year) history of substance abuse AND	Initial: 30 days Continued: One year

Drug Product(s)	Criteria	PA Approval Length
	• Member is not taking opioids, benzodiazepines, sedative hypnotics (such as zolpidem, zaleplon, eszopiclone, chloral hydrate, etc.) or consuming alcohol while receiving Xywav (calcium, magnesium, potassium, sodium oxybates) therapy AND • Prescriber is enrolled in corresponding REMS program AND • If member is an adult (≥ 18 years of age), they have had an adequate trial and failure of therapy with 3 sedative hypnotic medications (examples include zolpidem and eszopiclone). Failure is defined as: lack of efficacy with 2 week trial, contraindication to therapy, allergy, intolerable side effects or significant drug-drug interactions. Initial and Continuation Prior Authorization Approval: Initial prior authorization approval will be for 30 days. For continuation approval for one year, the following information must be provided: • Verification of Epworth Sleepiness Scale score reduction on follow-up OR • Verification of cataplexy episode count reduction on follow-up Maximum Dosing: 9 grams/daily	
YCANTH (cantharidin)	**Ycanth** (cantharidin) may be approved if the following criteria are met: • For billing under the pharmacy benefit, medication is being administered in the member's home or in a long-term care facility (LTCF) by a healthcare professional AND • Member is ≥ 2 years of age AND • Member has a diagnosis of molluscum contagiosum AND • Requested product is being prescribed by or in consultation with a dermatologist AND • For members ≥ 18 years of age, the member has tried and failed an adequate trial with topical podofilox. Failure is defined as lack of efficacy, allergy, intolerable side effects, or significant drug-drug interaction, AND • Member has undergone a surgical intervention (such as cryotherapy, surgical scraping, laser therapy) with inadequate resolution OR provider has determined that member is not a good candidate for any of these procedures. Quantity limit: 6 single-use applicators/9 weeks	Five months
YORVIPATH (palopegteriparatide)	**Yorvipath** (palopegteriparatide) may be approved for members that meet the following criteria: • Member is ≥ 18 years of age AND • Member has been diagnosed with hypoparathyroidism for six or more months AND • Yorvipath (palopegteriparatide) is not being used for acute post-surgical hypoparathyroidism, due to lack of evidence AND • Member has had lack of efficacy with a stabilized dosing regimen that includes BOTH of the following: o High-dose active vitamin D metabolite/analog therapy (such as calcitriol >2 mcg/day) AND o Elemental calcium > 2,000 mg/day AND	Initial: 6 months Continued: One year

Drug Product(s)	Criteria	PA Approval Length

	• Member has sufficient 25-hydroxyvitamin D stores and magnesium concentrations at baseline before initiating therapy AND
	• Member meets one of the following two weeks before therapy initiation:
	  o Member has an albumin-corrected serum calcium concentration ≥ 7.8 mg/dL OR
	  o Member has an ionized serum calcium ≥ 4.4 mg/dL
	• AND
	• Prescriber acknowledges the following statement from the FDA-approved labeling: Yorvipath (palopegteriparatide) titration scheme has only been evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment AND
	• The medication is prescribed by or in consultation with an endocrinologist or nephrologist.
	
	Reauthorization: Member may receive reauthorization approval for 1 year if the following criteria are met:
	• Albumin-corrected serum calcium is within the normal range AND
	• There has been no increase in Yorvipath (palopegeriparatide) dose since Week 22 of therapy AND
	• Calcium and active 25-hydroxyvitamin D have been closely monitored during therapy AND
	• Member has achieved independence from conventional therapy (defined as requiring no active vitamin D and ≤600 mg/day of elemental calcium supplementation, including no use of as-needed doses) since Week 22 of therapy.
	
	Quantity Limit: 1 prefilled syringe/day
	
	Maximum dose: 30 mcg subcutaneously once daily	

YOSPRALA (aspirin/omeprazole)	**Yosprala** (aspirin/omeprazole) will be approved for members who meet the following criteria: • Member requires aspirin for secondary prevention of cardiovascular or cerebrovascular events AND • Member is at risk of developing aspirin associated gastric ulcers (member is ≥ 55 years of age or has documented history of gastric ulcers) AND • Member has failed treatment with three preferred proton pump inhibitors in the last 6 months (Failure is defined as: lack of efficacy of a seven-day trial, allergy, intolerable side effects, or significant drug-drug interaction).	One year
ZELSUMVI (berdazimer)	**Zelsuvmi** (berdazimer) may be approved if the following criteria are met: • Member is ≥ 1 year of age AND • Member has a diagnosis of molluscum contagiosum AND • Prior to treatment, a full skin examination has been performed to identify all lesions AND • The member does not have lesions involving the ocular mucosa or eyelids AND • Requested product is being prescribed by or in consultation with a dermatologist AND • For members ≥ 18 years of age, member has trialed and failed topical podofilox. Failure is defined as lack of efficacy after a 4-week trial, allergy, intolerable side effects, or significant drug-drug interaction AND	See criteria

Drug Product(s)	Criteria	PA Approval Length
	• Member has undergone a surgical intervention (such as cryotherapy, surgical scraping, laser therapy) with inadequate resolution OR provider has determined that member is not a good candidate for any of these procedures AND • Counseling has been provided about how to properly prepare and apply Zelsuvmi (berdazimer) AND • Member has been informed that molluscum contagiosum is usually self-limiting in immunocompetent individuals, and that a decision to forgo treatment may be appropriate for some cases and should be weighed against the severity of disease progression and the potential for adverse effects associated with therapeutic interventions. Quantity Limit: 1 kit/30 days Approval will be limited to one 12-week treatment course per year.	
ZILBRYSQ (zilucoplan)	**Zilbrysq** (zilucoplan) may be approved if the following criteria are met: • Member is ≥ 18 years of age AND • The requested medication is being prescribed for treatment of generalized myasthenia gravis that is anti-acetylcholine receptor (AChR) antibody positive AND • The member meets the criteria for Myasthenia Gravis Foundation of America (MGFA) clinical classification class II to IV AND • The requested medication is being prescribed by or in consultation with a neurologist AND • Provider will perform a myasthenia gravis functionality score (such as the MGADL or QMG) at baseline. Maximum Dose: 32.4mg/day Quantity Limit 28 single-dose prefilled syringes/28 days Reauthorization: Additional one year approval may be granted with provider attestation that a follow-up myasthenia gravis functionality assessment indicates stable symptoms or clinical improvement.	One year
ZOKINVY (lonafarnib)	**Zokinvy** (lonafarnib) may be approved if the following criteria are met: 1. Member is one year of age or older AND 2. Member has a body surface area of 0.39 m^2 or greater AND 3. Member has one of the following diagnoses: a. Hutchinson-Gilford Progeria Syndrome (HGPS) confirmed by genetic testing for the pathogenic variant in the LMNA gene that results in production of progerin b. Processing-deficient progeroid laminopathy confirmed by genetic testing for heterozygous LMNA mutation with progerin-like protein accumulation OR for homozygous or compound heterozygous ZMPSTE24 mutations AND 4. Member is not taking lovastatin, simvastatin, or atorvastatin AND 5. Member, parent, or legal guardian has been, or will be, counseled that Zokinvy (lonafarnib) may impact pubertal development and impair fertility AND	One year

Drug Product(s)	Criteria	PA Approval Length
	6. Zokinvy (lonafarnib) is being prescribed or in consultation with a specialist in the area of the patient's diagnosis (such as a cardiologist or geneticist). Maximum dose: 300 mg/day Quantity limit: 4 capsules/day	